PengsieX的个人主页 - 老虎社区

PengsieX

PengsieX

暂无个人介绍

IP属地：未知

30关注

31粉丝

2主题

0勋章

2022-01-22

Time for u turn / recovery

UBS’s Lovell Says Be Ready to Buy Dips as Stocks Are Nearly Oversold

2022-01-22

Right move to sell these. Maybe only PLTR can hold.

Why I Sold These 3 High-Growth Tech Stocks

2022-01-21

Explosion of revenue! Online shopping hits a new high!

Mastercard, Visa, and PayPal Earnings Are Coming. Here's What to Expect.

2022-01-21

Hopefully not too little too late

Intel Plans $20 Bln Chip Manufacturing Site in Ohio

2022-01-21

Back to gym for the sights and sounds!

Peloton Plans to Cut Jobs, Production Levels as Sales Slow

2022-01-20

Spending too much on new shows without the intention to continue when the ratings or response wasn't as good as expected

抱歉，原内容已删除

2022-01-18

Resilient to Omicron for now...

抱歉，原内容已删除

2022-01-18

Time for some positivity!

Earnings Season in Full Swing, Fed Blackout Period: What to Know This Week

2022-01-17

It must shine soon or it will lose investors

Is Palantir a 2022 Breakout Stock?

2022-01-15

Should focus on ROI for customers

Morgan Stanley Promotes Biggest Class of Managing Directors Since 2012

2021-12-28

It's gonna be a roller coaster in 2022. Brace yourselves

S&P 500 closes at record high on retail sales cheer

2021-12-27

Buzz lightyear

You Can't Buy SpaceX Yet But These Space Stocks Are Up For Grabs

2021-12-26

200 or 3000 dollar stock... If there's a recession one way or another you'll be affected too. Don't spend money on stock

2 Top Tech Stocks to Buy During a Recession

2021-12-25

Don't blindly follow Warren cos he has the major shareholding whereas you are just a tiny retail investor

3 Best Buffett Stocks to Buy for the Long Haul

2021-12-24

What about retail investors

Didi’s Early Investors Get Window to Exit After IPO Disaster

2021-12-24

There can only be one...

Is Amazon Stock A Buy Right Now As Epic Battle With Walmart Escalates

2021-12-23

Convenience could be a dangerous thing

U.S. authorizes Pfizer oral COVID-19 treatment, first for at-home use

2021-12-23

Hope no overdose incidents

U.S. authorizes Pfizer oral COVID-19 treatment, first for at-home use

2021-12-22

Jabs, pills... What's next

FDA Expected to Authorize Pfizer and Merck Covid Pills This Week

2021-12-21

Time for acquisitions again

Oracle to buy Cerner for $28 bln in healthcare sector push

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":3578047933589423,"uuid":"3578047933589423","gmtCreate":1614953909444,"gmtModify":1634954145210,"name":"PengsieX","pinyin":"pengsiex","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/ebe92821eba3b91a6431d698b66bbed5","hat":"https://static.tigerbbs.com/f84859c65fc2d7681e28f6b8e9b0535a","hatId":"1611920451684_head_frame","hatName":"goods_62_name","vip":1,"status":2,"fanSize":31,"headSize":30,"tweetSize":255,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":2,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":10,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"35ec162348d5460f88c959321e554969-3","templateUuid":"35ec162348d5460f88c959321e554969","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.02.23","exceedPercentage":"93.67%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-2","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"资深虎友","description":"加入老虎社区1000天","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.12.01","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"228c86a078844d74991fff2b7ab2428d-1","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资经理虎","description":"证券账户累计交易金额达到10万美元","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.10.18","exceedPercentage":"60.47%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":{"badgeId":"35ec162348d5460f88c959321e554969-2","templateUuid":"35ec162348d5460f88c959321e554969","name":"宗师交易员","description":"证券或期货账户累计交易次数达到100次","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":1,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"80.73%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},"individualDisplayBadges":null,"crmLevel":4,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":630638689,"gmtCreate":1642809607942,"gmtModify":1642809608348,"author":{"id":"3578047933589423","authorId":"3578047933589423","name":"PengsieX","avatar":"https://static.tigerbbs.com/ebe92821eba3b91a6431d698b66bbed5","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"Time for u turn / recovery&nbsp;","listText":"Time for u turn / recovery&nbsp;","text":"Time for u turn / recovery","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/630638689","repostId":"1159385618","repostType":4,"repost":{"id":"1159385618","pubTimestamp":1642784391,"share":"https://www.laohu8.com/m/news/1159385618?lang=&edition=full","pubTime":"2022-01-22 00:59","market":"us","language":"en","title":"UBS’s Lovell Says Be Ready to Buy Dips as Stocks Are Nearly Oversold","url":"https://stock-news.laohu8.com/highlight/detail?id=1159385618","media":"Bloomberg","summary":"Likes value, financials, energy now; eyes AI, data in techFirm expects three rate increases this yea","content":"<html><head></head><body><ul><li>Likes value, financials, energy now; eyes AI, data in tech</li><li>Firm expects three rate increases this year to cool inflation</li></ul><p>The S&amp;P 500 is down about 7% from a record earlier this year, and UBS Global Wealth Management’s Nadia Lovell is undaunted: Prepare to buy, she says.</p><p>“The market has had a choppy start to the year, but it does feel like most of the selling might be behind us,” the senior U.S. equity strategist at the firm told Bloomberg Television’s Surveillance Friday. “We are approaching key support levels on the S&amp;P 500, and that would suggest that the market is near oversold territory, so we are looking for some stability in the market going forward. Think about buying those dips.”</p><p>Lovell isn’t alone on seeing an opportunity. Some 74% of institutional investors are planning to increase their equity exposure in the near term, the results of the most recent survey by JPMorgan Chase &amp; Co. show. That’s the most since the bank’s strategists began conducting the poll in June 2021.</p><p>The UBS strategist is recommending investors focus on value stocks, particularly in financials and the energy sector. UBS is expecting the Federal Reserve to raise interest rates three times -- in March, June and September -- to calm inflation, and Lovell sees that as a reason to wait for a further pullback in most technology shares, which typically underperform when rates increase.</p><p>But there are some tech companies that she is keeping an eye on.</p><p>“We’ll use the opportunity of indiscriminate selling to build a position over the long term, particularly in areas like artificial intelligence, big data, cybersecurity,” Lovell said. “There’s an opportunity to build in high-quality names with sustainable business models.”</p></body></html>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>UBS’s Lovell Says Be Ready to Buy Dips as Stocks Are Nearly Oversold</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUBS’s Lovell Says Be Ready to Buy Dips as Stocks Are Nearly Oversold\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-22 00:59 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2022-01-21/ubs-s-lovell-says-be-ready-to-buy-dips-as-stocks-nearly-oversold?srnd=markets-vp><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Likes value, financials, energy now; eyes AI, data in techFirm expects three rate increases this year to cool inflationThe S&P 500 is down about 7% from a record earlier this year, and UBS Global ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2022-01-21/ubs-s-lovell-says-be-ready-to-buy-dips-as-stocks-nearly-oversold?srnd=markets-vp\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯",".SPX":"S&P 500 Index",".IXIC":"NASDAQ Composite"},"source_url":"https://www.bloomberg.com/news/articles/2022-01-21/ubs-s-lovell-says-be-ready-to-buy-dips-as-stocks-nearly-oversold?srnd=markets-vp","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1159385618","content_text":"Likes value, financials, energy now; eyes AI, data in techFirm expects three rate increases this year to cool inflationThe S&P 500 is down about 7% from a record earlier this year, and UBS Global Wealth Management’s Nadia Lovell is undaunted: Prepare to buy, she says.“The market has had a choppy start to the year, but it does feel like most of the selling might be behind us,” the senior U.S. equity strategist at the firm told Bloomberg Television’s Surveillance Friday. “We are approaching key support levels on the S&P 500, and that would suggest that the market is near oversold territory, so we are looking for some stability in the market going forward. Think about buying those dips.”Lovell isn’t alone on seeing an opportunity. Some 74% of institutional investors are planning to increase their equity exposure in the near term, the results of the most recent survey by JPMorgan Chase & Co. show. That’s the most since the bank’s strategists began conducting the poll in June 2021.The UBS strategist is recommending investors focus on value stocks, particularly in financials and the energy sector. UBS is expecting the Federal Reserve to raise interest rates three times -- in March, June and September -- to calm inflation, and Lovell sees that as a reason to wait for a further pullback in most technology shares, which typically underperform when rates increase.But there are some tech companies that she is keeping an eye on.“We’ll use the opportunity of indiscriminate selling to build a position over the long term, particularly in areas like artificial intelligence, big data, cybersecurity,” Lovell said. “There’s an opportunity to build in high-quality names with sustainable business models.”","news_type":1},"isVote":1,"tweetType":1,"viewCount":526,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":630638849,"gmtCreate":1642809531747,"gmtModify":1642809532128,"author":{"id":"3578047933589423","authorId":"3578047933589423","name":"PengsieX","avatar":"https://static.tigerbbs.com/ebe92821eba3b91a6431d698b66bbed5","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"Right move to sell these. Maybe only PLTR can hold.&nbsp;","listText":"Right move to sell these. Maybe only PLTR can hold.&nbsp;","text":"Right move to sell these. Maybe only PLTR can hold.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/630638849","repostId":"2205441860","repostType":4,"repost":{"id":"2205441860","pubTimestamp":1642808308,"share":"https://www.laohu8.com/m/news/2205441860?lang=&edition=full","pubTime":"2022-01-22 07:38","market":"us","language":"en","title":"Why I Sold These 3 High-Growth Tech Stocks","url":"https://stock-news.laohu8.com/highlight/detail?id=2205441860","media":"Motley Fool","summary":"I recently sold my shares of Snap, Palantir, and Bumble. Let's explore the reasons I pulled the trigger on the sales.","content":"<html><head></head><body><p>Rising inflation and higher interest rates have crushed many high-growth tech stocks over the past few months. The reasons are simple: Inflation reduces the value of a company&#39;s future revenue and earnings, while higher interest rates boost borrowing costs for unprofitable companies.</p><p>Like many investors, I reduced my exposure to that shift by selling some of my higher-growth tech stocks and rotating toward more conservative investments. Specifically, I took profits from my investments in <b>Snap</b> (NYSE:SNAP) and <b>Palantir</b> (NYSE:PLTR), but I took a net loss on <b>Bumble</b> (NASDAQ:BMBL).</p><p>Investors should do their own due diligence instead of following my example, but let me explain my logic for selling these three high-growth tech stocks.</p><p><img src=\"https://static.tigerbbs.com/869992e71713ee11433514b27cb91bce\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Image source: Getty Images.</p><h2>1. Snap</h2><p>Snap was once my favorite social media stock. It generated robust growth in daily active users and revenue, it remained a top app for teen users, and its profitability was gradually improving.</p><p>But over the past year, several red flags appeared. It vastly underestimated the impact of<b> Apple</b>&#39;s privacy update on iOS, set unrealistic growth targets at its investor day last February, and failed to outshine <b>ByteDance</b>&#39;s TikTok with Spotlight&#39;s short videos.</p><p>Snap&#39;s third-quarter numbers and fourth-quarter guidance last October strongly suggested it couldn&#39;t achieve its investor day target for 50% annual revenue growth over the next few years. But Snap didn&#39;t withdraw that guidance -- even after directly being questioned about it during its conference call -- and said it could retool its ads to overcome Apple&#39;s iOS changes.</p><p>Over the past three months, Snap&#39;s insiders still sold 22 times as many shares as they bought -- even as the stock price dropped more than 50%. That lack of confidence indicates its iOS headaches won&#39;t end anytime soon.</p><p>Snap might seem reasonably valued now at 10 times next year&#39;s sales, especially if it meets analysts&#39; estimates for 60% revenue growth in 2021 and 38% growth in 2022. Unfortunately, I think Snap could continue to struggle over the next few quarters and ultimately withdraw its 50% revenue growth guidance. When that happens, the stock will likely plummet to new lows.</p><h2>2. Palantir</h2><p>Palantir, the data analytics firm which serves the U.S. government and large enterprise customers, also has ambitious growth plans. It believes it can generate at least 30% annual revenue growth from 2021 to 2025.</p><p>At first glance, Palantir seems like a solid investment. The U.S. Army reportedly used its Gotham platform to hunt down Osama Bin Laden in 2011. That battle-hardened reputation enables it to promote its enterprise-facing Foundry platform to large companies. Its ability to gather data from disparate sources can help government agencies and companies make better data-driven decisions to streamline their operations.</p><p>But Palantir also has some glaring problems. It&#39;s deeply unprofitable but still trades at 15 times next year&#39;s sales, which leaves it highly exposed to rising inflation and higher interest rates. It&#39;s also constantly diluting its shares with big stock bonuses -- in the first nine months of 2021, its number of weighted-average shares jumped 165% year over year.</p><p>The growth of Gotham is also decelerating as the U.S. government quietly develops in-house alternatives. Enterprise customers could also gravitate toward other analytics services, such as <b>Alteryx</b> or <b>Splunk, </b>instead of its Foundry platform.</p><p>Instead of sticking with this speculative and unprofitable company, it might be smarter for investors to rotate back toward firmly profitable blue-chip tech stocks which will benefit from the same data-mining tailwinds.</p><h2>3. Bumble</h2><p>After defending Bumble for nearly a year, I finally realized that the online dating company&#39;s weaknesses outweighed its strengths. The growth of Bumble&#39;s namesake app, which lets women make the first move, is decelerating. Its secondary app, Badoo, continues to lose paid users.</p><p>Last quarter, Bumble&#39;s total number of paid users across both apps grew 20% year over year to 1.53 million, but that marked a deceleration from its 36% growth in the previous quarter. Meanwhile, <b>Match Group</b>&#39;s (NASDAQ:MTCH) total number of paying users, 64% of whom use Tinder, increased 16% year over year to 16.3 million in its latest quarter. The company actually accelerated from its 15% growth in the previous quarter.</p><p>Bumble also remains unprofitable, and it&#39;s shouldering <i>more than twice</i> as much debt as its total cash and equivalents. At the same time, it&#39;s pursuing scattershot strategies -- including opening a restaurant in New York City, selling branded apparel and products through an online store, and rebooting its BFF feature (for platonic friendships) as a vaguely defined metaverse platform.</p><p>Those plans probably won&#39;t widen Bumble&#39;s moat against Match&#39;s portfolio of over a dozen dating apps. After listening to its latest conference call, it became painfully clear that Bumble overestimated its own brand appeal while underestimating the competition.</p><p>Bumble expects its revenue to grow 31% to 32% this fiscal year, but that&#39;s only a bit faster than Match&#39;s projected revenue growth rate of 25%. Bumble&#39;s stock might seem reasonably valued at six times next year&#39;s sales, but it probably won&#39;t command a higher premium until it stabilizes its user growth and significantly narrows its net losses. Until that happens, Match will probably be the better overall investment.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why I Sold These 3 High-Growth Tech Stocks</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy I Sold These 3 High-Growth Tech Stocks\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-22 07:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/21/why-i-sold-these-3-high-growth-tech-stocks/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Rising inflation and higher interest rates have crushed many high-growth tech stocks over the past few months. The reasons are simple: Inflation reduces the value of a company's future revenue and ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/21/why-i-sold-these-3-high-growth-tech-stocks/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4553":"喜马拉雅资本持仓","BK4534":"瑞士信贷持仓","MTCH":"Match Group, Inc.","BK4507":"流媒体概念","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4566":"资本集团","BK4508":"社交媒体","AAPL":"苹果","BK4543":"AI","BK4559":"巴菲特持仓","BK4527":"明星科技股","PLTR":"Palantir Technologies Inc.","BK4077":"互动媒体与服务","BK4501":"段永平概念","BK4550":"红杉资本持仓","BK4551":"寇图资本持仓","BMBL":"Bumble Inc.","BK4547":"WSB热门概念","BK4505":"高瓴资本持仓","SNAP":"Snap Inc","BK4549":"软银资本持仓","BK4532":"文艺复兴科技持仓","BK4170":"电脑硬件、储存设备及电脑周边","BK4023":"应用软件","BK4554":"元宇宙及AR概念","BK4515":"5G概念"},"source_url":"https://www.fool.com/investing/2022/01/21/why-i-sold-these-3-high-growth-tech-stocks/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2205441860","content_text":"Rising inflation and higher interest rates have crushed many high-growth tech stocks over the past few months. The reasons are simple: Inflation reduces the value of a company's future revenue and earnings, while higher interest rates boost borrowing costs for unprofitable companies.Like many investors, I reduced my exposure to that shift by selling some of my higher-growth tech stocks and rotating toward more conservative investments. Specifically, I took profits from my investments in Snap (NYSE:SNAP) and Palantir (NYSE:PLTR), but I took a net loss on Bumble (NASDAQ:BMBL).Investors should do their own due diligence instead of following my example, but let me explain my logic for selling these three high-growth tech stocks.Image source: Getty Images.1. SnapSnap was once my favorite social media stock. It generated robust growth in daily active users and revenue, it remained a top app for teen users, and its profitability was gradually improving.But over the past year, several red flags appeared. It vastly underestimated the impact of Apple's privacy update on iOS, set unrealistic growth targets at its investor day last February, and failed to outshine ByteDance's TikTok with Spotlight's short videos.Snap's third-quarter numbers and fourth-quarter guidance last October strongly suggested it couldn't achieve its investor day target for 50% annual revenue growth over the next few years. But Snap didn't withdraw that guidance -- even after directly being questioned about it during its conference call -- and said it could retool its ads to overcome Apple's iOS changes.Over the past three months, Snap's insiders still sold 22 times as many shares as they bought -- even as the stock price dropped more than 50%. That lack of confidence indicates its iOS headaches won't end anytime soon.Snap might seem reasonably valued now at 10 times next year's sales, especially if it meets analysts' estimates for 60% revenue growth in 2021 and 38% growth in 2022. Unfortunately, I think Snap could continue to struggle over the next few quarters and ultimately withdraw its 50% revenue growth guidance. When that happens, the stock will likely plummet to new lows.2. PalantirPalantir, the data analytics firm which serves the U.S. government and large enterprise customers, also has ambitious growth plans. It believes it can generate at least 30% annual revenue growth from 2021 to 2025.At first glance, Palantir seems like a solid investment. The U.S. Army reportedly used its Gotham platform to hunt down Osama Bin Laden in 2011. That battle-hardened reputation enables it to promote its enterprise-facing Foundry platform to large companies. Its ability to gather data from disparate sources can help government agencies and companies make better data-driven decisions to streamline their operations.But Palantir also has some glaring problems. It's deeply unprofitable but still trades at 15 times next year's sales, which leaves it highly exposed to rising inflation and higher interest rates. It's also constantly diluting its shares with big stock bonuses -- in the first nine months of 2021, its number of weighted-average shares jumped 165% year over year.The growth of Gotham is also decelerating as the U.S. government quietly develops in-house alternatives. Enterprise customers could also gravitate toward other analytics services, such as Alteryx or Splunk, instead of its Foundry platform.Instead of sticking with this speculative and unprofitable company, it might be smarter for investors to rotate back toward firmly profitable blue-chip tech stocks which will benefit from the same data-mining tailwinds.3. BumbleAfter defending Bumble for nearly a year, I finally realized that the online dating company's weaknesses outweighed its strengths. The growth of Bumble's namesake app, which lets women make the first move, is decelerating. Its secondary app, Badoo, continues to lose paid users.Last quarter, Bumble's total number of paid users across both apps grew 20% year over year to 1.53 million, but that marked a deceleration from its 36% growth in the previous quarter. Meanwhile, Match Group's (NASDAQ:MTCH) total number of paying users, 64% of whom use Tinder, increased 16% year over year to 16.3 million in its latest quarter. The company actually accelerated from its 15% growth in the previous quarter.Bumble also remains unprofitable, and it's shouldering more than twice as much debt as its total cash and equivalents. At the same time, it's pursuing scattershot strategies -- including opening a restaurant in New York City, selling branded apparel and products through an online store, and rebooting its BFF feature (for platonic friendships) as a vaguely defined metaverse platform.Those plans probably won't widen Bumble's moat against Match's portfolio of over a dozen dating apps. After listening to its latest conference call, it became painfully clear that Bumble overestimated its own brand appeal while underestimating the competition.Bumble expects its revenue to grow 31% to 32% this fiscal year, but that's only a bit faster than Match's projected revenue growth rate of 25%. Bumble's stock might seem reasonably valued at six times next year's sales, but it probably won't command a higher premium until it stabilizes its user growth and significantly narrows its net losses. Until that happens, Match will probably be the better overall investment.","news_type":1},"isVote":1,"tweetType":1,"viewCount":489,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":630150643,"gmtCreate":1642749293300,"gmtModify":1642749293686,"author":{"id":"3578047933589423","authorId":"3578047933589423","name":"PengsieX","avatar":"https://static.tigerbbs.com/ebe92821eba3b91a6431d698b66bbed5","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"Explosion of revenue! Online shopping hits a new high!&nbsp;","listText":"Explosion of revenue! Online shopping hits a new high!&nbsp;","text":"Explosion of revenue! Online shopping hits a new high!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/630150643","repostId":"1132830350","repostType":4,"repost":{"id":"1132830350","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1642744904,"share":"https://www.laohu8.com/m/news/1132830350?lang=&edition=full","pubTime":"2022-01-21 14:01","market":"us","language":"en","title":"Mastercard, Visa, and PayPal Earnings Are Coming. Here's What to Expect.","url":"https://stock-news.laohu8.com/highlight/detail?id=1132830350","media":"Tiger Newspress","summary":"Mastercard, Visa, and PayPal are about to report earnings, so let's take a look at what investors ne","content":"<html><head></head><body><p>Mastercard, Visa, and PayPal are about to report earnings, so let&#39;s take a look at what investors need to know.</p><h3>Mastercard</h3><p>Mastercard is set to release its earnings data before the market opens on Thursday, January 27th.</p><p>Analysts expect the company to announce earnings of $2.19 per share for the quarter.</p><p>Analysts think disruption in the payments space could continue to weigh on Mastercard.</p><p>There&#39;s a lot of disruption in the fintech space right now, and there are fears that hefty margins enjoyed by credit card companies for many years may be in jeopardy.</p><p>Undoubtedly, Buy Now Pay Later (BNPL) is a hot trend in the fintech space, promising no interest on payment plans based on fixed installments. For consumers, it&#39;s a great deal versus the incredibly high interest on credit card debt, arguably one of the priciest debts to have aside from pay-day loan debt.</p><p>With digital retail kingpin Amazon previously remarking on high fees on Visa (V) cards, retailers could side with consumers as up-and-comers duke it out in the payments space in what could become a race to the bottom in terms of rates charged on consumer debts.</p><p>Analysts view the rise of BNPL firms and ongoing disruption in the payments space as a potentially long-lasting headwind that could continue to weigh on many incumbents.</p><p>While credit card issuers have created their own BNPL offerings, such moves are unlikely to stop the erosion of margins in credit cards that have helped firms like Mastercard and Visa grow earnings at an enviable pace over the years.</p><h3>Visa</h3><p>Visa is scheduled to be announcing its earnings results after the market closes on Thursday, January 27th.</p><p>This global payments processor is expected to post quarterly earnings of $1.69 per share in its upcoming report, which represents a year-over-year change of 19%.</p><p>Revenues are expected to be $6.76 billion, up 18.9% from the year-ago quarter.</p><p>Visa has launched multiple cryptocurrency initiatives in recent years as the company seeks to remain relevant in the changing payment industry. The company viewed cryptocurrency as a massive expansion from the fiat currency as more consumers recognized the value of the decentralized system. In addition, Visa also seeks to enhance its cross-border payment solutions as more fintech delivers more transparency and value to consumers.</p><p>The cryptocurrency market experienced extreme growth by the end of 2021, surpassing $3T of value in November, representing an increase of 375% since the start of the year. In addition, Bitcoin hit its all-time high of $68.7K on 10 November 2021, while Ether hit $4.4K on 11 November 2021.</p><p>Analysts expect the cryptocurrency market to perform well as a long-term digital asset with increased institutional adoption and federal government regulation. As a result, it made sense for Visa to perform a crucial bridging role between &#34;banks, crypto trading, and custody platforms,&#34; as more consumers embrace the decentralized currency. Moving forward, Analysts expect to see Visa flourish alongside the cryptocurrency market&#39;s macro growth trends.</p><p>In December 2021, Visa reported that it had acquired Currencycloud, a B2B cross-border payments solution, in a £700M deal. The company expects to further enhance its existing cross-border payments through the acquisition, on top of its current strategic partnership since 2019. Currencycloud currently supports 500 banking and technology clients in 180 countries, with over $5B in monthly cross-border transactions. Globally, around $1.9T of payment revenues are reported in 2020, with the number expected to rise to $2.5T by 2025, at a CAGR of 5.64%. It shows that global businesses are growing exponentially and that legacy payment platforms like Visa needs to innovate to stay competitive.</p><p>As a result, Visa and its consumers stand to gain from the enhanced cross-border payments as global B2B businesses and eCommerce becomes more mainstream.</p><h3>PayPal</h3><p>Early next month, PayPal will deliver 4Q21’s financials, and after lowering expectations last quarter, Deutsche Bank’s Bryan Keane expects the digital payments giant to deliver “steady growth.”</p><p>Boosted by ~24% year-over-year TPV growth, the analyst anticipates PYPL will generate revenue growth of ~12.9% and EPS of $1.12.</p><p>That said, Keane does not foresee any unexpected fireworks. “Given the latest quarterly trends in eComm, continued supply-chain issues, delta/omicron, and eBay headwinds, we see relatively limited upside again this quarter,” said the 5-star analyst.</p><p>Looking at PayPal’s monthly users trends, Keane’s expected results appear in the same ballpark as the quarter’s action. Unique Visitors (UVs) rose by 14% sequentially from 676.8 million to 769 million and came in 11% above the figure reported during the same period last year.</p><p><img src=\"https://static.tigerbbs.com/d650fa1f74de4036b93480e5e8873a41\" tg-width=\"554\" tg-height=\"218\" referrerpolicy=\"no-referrer\"/>Looking ahead to 1Q22, similar to 4Q21, given the “more difficult comps” yet offset by “moderating eBay headwinds,” Keane thinks PayPal will “potentially” guide to cc revenue growth of ~12-14%.</p><p>That, however, “should mark the trough as growth rates steady and start to re-accelerate.” In fact, by 4Q22, Keane anticipates revenue growth will increase to 20% year-over-year with EPS potentially seeing out 2022 up by 25%. This is due to both easier comps and the addition of “modest incremental momentum” from the Super App.</p><p>In September, the company launched the first version of the Super App, which mixes services such as BNPL and crypto with “new products” including high-yield savings, in-app shopping tools, deals, rewards and bill pay. Over the coming months, the app’s features will be further enhanced with the introduction of additional investment capabilities, new online and in-store shopping processes, and “better PYPL branded capabilities.” The company also recently announced it is looking at potentially adding its own stablecoin.</p><p>Keane reiterated a Buy rating while sticking to a $260 price target.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Mastercard, Visa, and PayPal Earnings Are Coming. Here's What to Expect.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMastercard, Visa, and PayPal Earnings Are Coming. Here's What to Expect.\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-01-21 14:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Mastercard, Visa, and PayPal are about to report earnings, so let&#39;s take a look at what investors need to know.</p><h3>Mastercard</h3><p>Mastercard is set to release its earnings data before the market opens on Thursday, January 27th.</p><p>Analysts expect the company to announce earnings of $2.19 per share for the quarter.</p><p>Analysts think disruption in the payments space could continue to weigh on Mastercard.</p><p>There&#39;s a lot of disruption in the fintech space right now, and there are fears that hefty margins enjoyed by credit card companies for many years may be in jeopardy.</p><p>Undoubtedly, Buy Now Pay Later (BNPL) is a hot trend in the fintech space, promising no interest on payment plans based on fixed installments. For consumers, it&#39;s a great deal versus the incredibly high interest on credit card debt, arguably one of the priciest debts to have aside from pay-day loan debt.</p><p>With digital retail kingpin Amazon previously remarking on high fees on Visa (V) cards, retailers could side with consumers as up-and-comers duke it out in the payments space in what could become a race to the bottom in terms of rates charged on consumer debts.</p><p>Analysts view the rise of BNPL firms and ongoing disruption in the payments space as a potentially long-lasting headwind that could continue to weigh on many incumbents.</p><p>While credit card issuers have created their own BNPL offerings, such moves are unlikely to stop the erosion of margins in credit cards that have helped firms like Mastercard and Visa grow earnings at an enviable pace over the years.</p><h3>Visa</h3><p>Visa is scheduled to be announcing its earnings results after the market closes on Thursday, January 27th.</p><p>This global payments processor is expected to post quarterly earnings of $1.69 per share in its upcoming report, which represents a year-over-year change of 19%.</p><p>Revenues are expected to be $6.76 billion, up 18.9% from the year-ago quarter.</p><p>Visa has launched multiple cryptocurrency initiatives in recent years as the company seeks to remain relevant in the changing payment industry. The company viewed cryptocurrency as a massive expansion from the fiat currency as more consumers recognized the value of the decentralized system. In addition, Visa also seeks to enhance its cross-border payment solutions as more fintech delivers more transparency and value to consumers.</p><p>The cryptocurrency market experienced extreme growth by the end of 2021, surpassing $3T of value in November, representing an increase of 375% since the start of the year. In addition, Bitcoin hit its all-time high of $68.7K on 10 November 2021, while Ether hit $4.4K on 11 November 2021.</p><p>Analysts expect the cryptocurrency market to perform well as a long-term digital asset with increased institutional adoption and federal government regulation. As a result, it made sense for Visa to perform a crucial bridging role between &#34;banks, crypto trading, and custody platforms,&#34; as more consumers embrace the decentralized currency. Moving forward, Analysts expect to see Visa flourish alongside the cryptocurrency market&#39;s macro growth trends.</p><p>In December 2021, Visa reported that it had acquired Currencycloud, a B2B cross-border payments solution, in a £700M deal. The company expects to further enhance its existing cross-border payments through the acquisition, on top of its current strategic partnership since 2019. Currencycloud currently supports 500 banking and technology clients in 180 countries, with over $5B in monthly cross-border transactions. Globally, around $1.9T of payment revenues are reported in 2020, with the number expected to rise to $2.5T by 2025, at a CAGR of 5.64%. It shows that global businesses are growing exponentially and that legacy payment platforms like Visa needs to innovate to stay competitive.</p><p>As a result, Visa and its consumers stand to gain from the enhanced cross-border payments as global B2B businesses and eCommerce becomes more mainstream.</p><h3>PayPal</h3><p>Early next month, PayPal will deliver 4Q21’s financials, and after lowering expectations last quarter, Deutsche Bank’s Bryan Keane expects the digital payments giant to deliver “steady growth.”</p><p>Boosted by ~24% year-over-year TPV growth, the analyst anticipates PYPL will generate revenue growth of ~12.9% and EPS of $1.12.</p><p>That said, Keane does not foresee any unexpected fireworks. “Given the latest quarterly trends in eComm, continued supply-chain issues, delta/omicron, and eBay headwinds, we see relatively limited upside again this quarter,” said the 5-star analyst.</p><p>Looking at PayPal’s monthly users trends, Keane’s expected results appear in the same ballpark as the quarter’s action. Unique Visitors (UVs) rose by 14% sequentially from 676.8 million to 769 million and came in 11% above the figure reported during the same period last year.</p><p><img src=\"https://static.tigerbbs.com/d650fa1f74de4036b93480e5e8873a41\" tg-width=\"554\" tg-height=\"218\" referrerpolicy=\"no-referrer\"/>Looking ahead to 1Q22, similar to 4Q21, given the “more difficult comps” yet offset by “moderating eBay headwinds,” Keane thinks PayPal will “potentially” guide to cc revenue growth of ~12-14%.</p><p>That, however, “should mark the trough as growth rates steady and start to re-accelerate.” In fact, by 4Q22, Keane anticipates revenue growth will increase to 20% year-over-year with EPS potentially seeing out 2022 up by 25%. This is due to both easier comps and the addition of “modest incremental momentum” from the Super App.</p><p>In September, the company launched the first version of the Super App, which mixes services such as BNPL and crypto with “new products” including high-yield savings, in-app shopping tools, deals, rewards and bill pay. Over the coming months, the app’s features will be further enhanced with the introduction of additional investment capabilities, new online and in-store shopping processes, and “better PYPL branded capabilities.” The company also recently announced it is looking at potentially adding its own stablecoin.</p><p>Keane reiterated a Buy rating while sticking to a $260 price target.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PYPL":"PayPal","MA":"万事达","V":"Visa"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1132830350","content_text":"Mastercard, Visa, and PayPal are about to report earnings, so let's take a look at what investors need to know.MastercardMastercard is set to release its earnings data before the market opens on Thursday, January 27th.Analysts expect the company to announce earnings of $2.19 per share for the quarter.Analysts think disruption in the payments space could continue to weigh on Mastercard.There's a lot of disruption in the fintech space right now, and there are fears that hefty margins enjoyed by credit card companies for many years may be in jeopardy.Undoubtedly, Buy Now Pay Later (BNPL) is a hot trend in the fintech space, promising no interest on payment plans based on fixed installments. For consumers, it's a great deal versus the incredibly high interest on credit card debt, arguably one of the priciest debts to have aside from pay-day loan debt.With digital retail kingpin Amazon previously remarking on high fees on Visa (V) cards, retailers could side with consumers as up-and-comers duke it out in the payments space in what could become a race to the bottom in terms of rates charged on consumer debts.Analysts view the rise of BNPL firms and ongoing disruption in the payments space as a potentially long-lasting headwind that could continue to weigh on many incumbents.While credit card issuers have created their own BNPL offerings, such moves are unlikely to stop the erosion of margins in credit cards that have helped firms like Mastercard and Visa grow earnings at an enviable pace over the years.VisaVisa is scheduled to be announcing its earnings results after the market closes on Thursday, January 27th.This global payments processor is expected to post quarterly earnings of $1.69 per share in its upcoming report, which represents a year-over-year change of 19%.Revenues are expected to be $6.76 billion, up 18.9% from the year-ago quarter.Visa has launched multiple cryptocurrency initiatives in recent years as the company seeks to remain relevant in the changing payment industry. The company viewed cryptocurrency as a massive expansion from the fiat currency as more consumers recognized the value of the decentralized system. In addition, Visa also seeks to enhance its cross-border payment solutions as more fintech delivers more transparency and value to consumers.The cryptocurrency market experienced extreme growth by the end of 2021, surpassing $3T of value in November, representing an increase of 375% since the start of the year. In addition, Bitcoin hit its all-time high of $68.7K on 10 November 2021, while Ether hit $4.4K on 11 November 2021.Analysts expect the cryptocurrency market to perform well as a long-term digital asset with increased institutional adoption and federal government regulation. As a result, it made sense for Visa to perform a crucial bridging role between \"banks, crypto trading, and custody platforms,\" as more consumers embrace the decentralized currency. Moving forward, Analysts expect to see Visa flourish alongside the cryptocurrency market's macro growth trends.In December 2021, Visa reported that it had acquired Currencycloud, a B2B cross-border payments solution, in a £700M deal. The company expects to further enhance its existing cross-border payments through the acquisition, on top of its current strategic partnership since 2019. Currencycloud currently supports 500 banking and technology clients in 180 countries, with over $5B in monthly cross-border transactions. Globally, around $1.9T of payment revenues are reported in 2020, with the number expected to rise to $2.5T by 2025, at a CAGR of 5.64%. It shows that global businesses are growing exponentially and that legacy payment platforms like Visa needs to innovate to stay competitive.As a result, Visa and its consumers stand to gain from the enhanced cross-border payments as global B2B businesses and eCommerce becomes more mainstream.PayPalEarly next month, PayPal will deliver 4Q21’s financials, and after lowering expectations last quarter, Deutsche Bank’s Bryan Keane expects the digital payments giant to deliver “steady growth.”Boosted by ~24% year-over-year TPV growth, the analyst anticipates PYPL will generate revenue growth of ~12.9% and EPS of $1.12.That said, Keane does not foresee any unexpected fireworks. “Given the latest quarterly trends in eComm, continued supply-chain issues, delta/omicron, and eBay headwinds, we see relatively limited upside again this quarter,” said the 5-star analyst.Looking at PayPal’s monthly users trends, Keane’s expected results appear in the same ballpark as the quarter’s action. Unique Visitors (UVs) rose by 14% sequentially from 676.8 million to 769 million and came in 11% above the figure reported during the same period last year.Looking ahead to 1Q22, similar to 4Q21, given the “more difficult comps” yet offset by “moderating eBay headwinds,” Keane thinks PayPal will “potentially” guide to cc revenue growth of ~12-14%.That, however, “should mark the trough as growth rates steady and start to re-accelerate.” In fact, by 4Q22, Keane anticipates revenue growth will increase to 20% year-over-year with EPS potentially seeing out 2022 up by 25%. This is due to both easier comps and the addition of “modest incremental momentum” from the Super App.In September, the company launched the first version of the Super App, which mixes services such as BNPL and crypto with “new products” including high-yield savings, in-app shopping tools, deals, rewards and bill pay. Over the coming months, the app’s features will be further enhanced with the introduction of additional investment capabilities, new online and in-store shopping processes, and “better PYPL branded capabilities.” The company also recently announced it is looking at potentially adding its own stablecoin.Keane reiterated a Buy rating while sticking to a $260 price target.","news_type":1},"isVote":1,"tweetType":1,"viewCount":558,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":630127771,"gmtCreate":1642749251180,"gmtModify":1642749251561,"author":{"id":"3578047933589423","authorId":"3578047933589423","name":"PengsieX","avatar":"https://static.tigerbbs.com/ebe92821eba3b91a6431d698b66bbed5","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"Hopefully not too little too late","listText":"Hopefully not too little too late","text":"Hopefully not too little too late","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/630127771","repostId":"2205014729","repostType":4,"repost":{"id":"2205014729","pubTimestamp":1642746990,"share":"https://www.laohu8.com/m/news/2205014729?lang=&edition=full","pubTime":"2022-01-21 14:36","market":"us","language":"en","title":"Intel Plans $20 Bln Chip Manufacturing Site in Ohio","url":"https://stock-news.laohu8.com/highlight/detail?id=2205014729","media":"Reuters","summary":"(Reuters) - Intel Corp on Friday is set to announce it will invest $20 billion in a massive new manu","content":"<html><head></head><body><p>(Reuters) - Intel Corp on Friday is set to announce it will invest $20 billion in a massive new manufacturing site near Columbus, Ohio to develop and manufacture advanced semiconductor chips, sources briefed on the matter told Reuters.</p><p>The planned investment includes 3,000 permanent jobs on the 1,000-acre site in New Albany, Ohio. Time magazine, which first reported the news, said Intel will build at least two semiconductor fabrication plants.</p><p>President Joe Biden is making remarks Friday on the U.S. government&#39;s efforts &#34;to increase the supply of semiconductors, make more in America, and rebuild our supply chains here at home,&#34; the White House said earlier.</p><p>Intel Chief Executive Pat Gelsinger is set to appear with Biden on Friday at the White House, sources told Reuters. The White House did not respond to a request for comment.</p><p>The initial $20 billion is the first step of what could be an eight-factory complex costing tens of billions of dollars.</p><p>Intel declined to comment on its plans but said in a statement that Gelsinger would disclose details Friday of &#34;Intel’s latest plans for investment in manufacturing leadership&#34; as it works &#34;to meet the surging demand for advanced semiconductors.&#34;</p><p>Chipmakers are scrambling to boost output after manufacturers around the world, from autos to consumer electronics, faced shortages of chips. Intel also is trying to win back its position as maker of the smallest and fastest chips from current leader TSMC, which is based in Taiwan.</p><p>Gelsinger last fall also said he planned to announce another U.S. campus site before the end of the year that would eventually hold eight chip factories.</p><p>He told the Washington Post the complex could cost $100 billion over a decade and eventually employ 10,000.</p><p>Gelsinger is driving Intel plans to expand, especially in Europe and the United States, as it seeks to heat up competition with global rivals and respond to a worldwide microchip shortage.</p><p>Intel and Italy are intensifying talks over investments expected to be worth around 8 billion euros ($9 billion) to build an advanced semiconductor packaging plant, Reuters reported late last year.</p><p>The Biden administration is making a big push to convince Congress to approve $52 billion in funding to dramatically increase chip production in the United States. The Senate in June voted 68-32 for the chips funding as part of a broader competitiveness bill, but it has been stalled in the House.</p><p>House Speaker Nancy Pelosi said Thursday she hopes to &#34;go to conference&#34; on the chips funding measure soon.</p><p>Still, Intel&#39;s plans for new factories will not alleviate the current demand crunch, because such complexes take years to build. Gelsinger previously said he expected the chip shortages to last into 2023.</p><p>In September, Intel broke ground on two factories in Arizona as part of its turnaround plan to become a major manufacturer of chips for outside customers. The $20 billion plants will bring the total number of Intel factories at its campus in the Phoenix suburb of Chandler to six.</p><p>Intel told Time it considered 38 sites before picking New Albany, Ohio in December. Ohio has agreed to invest $1 billion in infrastructure improvements to facilitate the factory, Time said. ($1 = 0.8829 euros)</p></body></html>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Intel Plans $20 Bln Chip Manufacturing Site in Ohio</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIntel Plans $20 Bln Chip Manufacturing Site in Ohio\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-21 14:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/1-intel-plans-20-bln-042141303.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Reuters) - Intel Corp on Friday is set to announce it will invest $20 billion in a massive new manufacturing site near Columbus, Ohio to develop and manufacture advanced semiconductor chips, sources ...</p>\n\n<a href=\"https://finance.yahoo.com/news/1-intel-plans-20-bln-042141303.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4512":"苹果概念","BK4141":"半导体产品","BK4554":"元宇宙及AR概念","INTC":"英特尔","BK4515":"5G概念","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4535":"淡马锡持仓","BK4534":"瑞士信贷持仓","BK4527":"明星科技股","BK4529":"IDC概念","BK4550":"红杉资本持仓"},"source_url":"https://finance.yahoo.com/news/1-intel-plans-20-bln-042141303.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2205014729","content_text":"(Reuters) - Intel Corp on Friday is set to announce it will invest $20 billion in a massive new manufacturing site near Columbus, Ohio to develop and manufacture advanced semiconductor chips, sources briefed on the matter told Reuters.The planned investment includes 3,000 permanent jobs on the 1,000-acre site in New Albany, Ohio. Time magazine, which first reported the news, said Intel will build at least two semiconductor fabrication plants.President Joe Biden is making remarks Friday on the U.S. government's efforts \"to increase the supply of semiconductors, make more in America, and rebuild our supply chains here at home,\" the White House said earlier.Intel Chief Executive Pat Gelsinger is set to appear with Biden on Friday at the White House, sources told Reuters. The White House did not respond to a request for comment.The initial $20 billion is the first step of what could be an eight-factory complex costing tens of billions of dollars.Intel declined to comment on its plans but said in a statement that Gelsinger would disclose details Friday of \"Intel’s latest plans for investment in manufacturing leadership\" as it works \"to meet the surging demand for advanced semiconductors.\"Chipmakers are scrambling to boost output after manufacturers around the world, from autos to consumer electronics, faced shortages of chips. Intel also is trying to win back its position as maker of the smallest and fastest chips from current leader TSMC, which is based in Taiwan.Gelsinger last fall also said he planned to announce another U.S. campus site before the end of the year that would eventually hold eight chip factories.He told the Washington Post the complex could cost $100 billion over a decade and eventually employ 10,000.Gelsinger is driving Intel plans to expand, especially in Europe and the United States, as it seeks to heat up competition with global rivals and respond to a worldwide microchip shortage.Intel and Italy are intensifying talks over investments expected to be worth around 8 billion euros ($9 billion) to build an advanced semiconductor packaging plant, Reuters reported late last year.The Biden administration is making a big push to convince Congress to approve $52 billion in funding to dramatically increase chip production in the United States. The Senate in June voted 68-32 for the chips funding as part of a broader competitiveness bill, but it has been stalled in the House.House Speaker Nancy Pelosi said Thursday she hopes to \"go to conference\" on the chips funding measure soon.Still, Intel's plans for new factories will not alleviate the current demand crunch, because such complexes take years to build. Gelsinger previously said he expected the chip shortages to last into 2023.In September, Intel broke ground on two factories in Arizona as part of its turnaround plan to become a major manufacturer of chips for outside customers. The $20 billion plants will bring the total number of Intel factories at its campus in the Phoenix suburb of Chandler to six.Intel told Time it considered 38 sites before picking New Albany, Ohio in December. Ohio has agreed to invest $1 billion in infrastructure improvements to facilitate the factory, Time said. ($1 = 0.8829 euros)","news_type":1},"isVote":1,"tweetType":1,"viewCount":655,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":630127563,"gmtCreate":1642749165033,"gmtModify":1642749165427,"author":{"id":"3578047933589423","authorId":"3578047933589423","name":"PengsieX","avatar":"https://static.tigerbbs.com/ebe92821eba3b91a6431d698b66bbed5","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"Back to gym for the sights and sounds!&nbsp;","listText":"Back to gym for the sights and sounds!&nbsp;","text":"Back to gym for the sights and sounds!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/630127563","repostId":"1155028154","repostType":4,"repost":{"id":"1155028154","pubTimestamp":1642748046,"share":"https://www.laohu8.com/m/news/1155028154?lang=&edition=full","pubTime":"2022-01-21 14:54","market":"us","language":"en","title":"Peloton Plans to Cut Jobs, Production Levels as Sales Slow","url":"https://stock-news.laohu8.com/highlight/detail?id=1155028154","media":"Bloomberg","summary":"Company posts revenue of $1.14 billion, just below estimatesCEO disputes reports of production halt,","content":"<html><head></head><body><ul><li>Company posts revenue of $1.14 billion, just below estimates</li><li>CEO disputes reports of production halt, but confirms layoffs</li></ul><p>Peloton Interactive Inc. vowed to slash expenses at the struggling fitness company, including labor and production costs, but disputed reports that it had idled its factories to save money.</p><p>In a memo to staff, Chief Executive Officer John Foley said Peloton was “right-sizing our production, and, as we evolve to more seasonal demand curves, we are resetting our production levels for sustainable growth.”</p><p>Peloton is reeling from a slowdown triggered by consumers emerging from pandemic lockdowns and returning to traditional gyms. It had been a Wall Street darling when customers were stuck at home and demand outstripped supply.</p><p>Now the company is considering jobs cuts to get itself back on track, Foley said.</p><p>“In the past, we’ve said layoffs would be the absolute last lever we would ever hope to pull,” he said. “However, we now need to evaluate our organization structure and size of our team, with the utmost care and compassion. And we are still in the process of considering all options as part of our efforts to make our business more flexible.”</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/13c79e9c9078241760fa4c4709c93219\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\"/><span>Peloton stationary bikes for sale at the company’s showroom in Dedham, Massachusetts.Photographer: Adam Glanzman/Bloomberg</span></p><p>Referring to reports that Peloton had temporarily shut down production, Foley said that leaks of confidential information “have led to a flurry of speculative articles in the press. The information the media has obtained is incomplete, out of context, and not reflective of Peloton’s strategy.”</p><p>He said the company had identified a leaker and was “moving forward with the appropriate legal action.”</p><p>Peloton also released a preliminary report of $1.14 billion in sales during the fiscal second quarter, which ended on Dec. 31. Analysts had estimated $1.16 billion. The company ended the period with 2.77 million connected fitness subscribers, just below the 2.81 million prediction.</p><p>In that report, Foley said Peloton was taking “significant corrective actions to improve our profitability outlook and optimize our costs across the company.” The effort “includes gross margin improvements, moving to a more variable cost structure, and identifying reductions in our operating expenses as we build a more focused Peloton moving forward.”</p><p>Foley said he would share more information on the cost-cutting plan when Peloton gives its formal earnings report on Feb. 8. “This work is still underway,” he said.</p><p>The early earnings release follows a report from CNBC Thursday that the company was temporarily halting manufacturing of bikes and Tread-branded treadmills. Production of Peloton’s main stationary bikes will be paused for two months, CNBC reported, citing internal documents. And the company will stop making its treadmill machine for six weeks, starting in February.</p><p>In the memo to staff, Foley disputed the report, saying that “rumors that we are halting all production of bikes and Treads are false.”</p><p>The CNBC story sent the shares down 24% to $24.22 in regular trading Thursday. Foley’s remarks after the close boosted the stock, with it gaining 9.2% as of 8 p.m. in New York.</p><p>Foley said Thursday that the company’s churn rate was 0.79%, signaling that “members are sticking with us.”</p><p>Peloton’s CEO said on the last earnings call that the company would be working to identify ways to cut costs. Peloton had spent millions of dollars on building up supply of its products to fulfill pandemic-fueled demand, only for interest to sputter as economies began to reopen.</p><p>The company didn’t provide updated fiscal-year guidance on Thursday. Peloton had said the previous quarter that it expects to generate revenue of $4.4 billion to $4.8 billion during fiscal 2022, which ends in June. That range was a reduction from earlier company projections of $5.4 billion.</p><p>When Peloton slashed its 2022 guidance in November, the shares suffered their biggest decline ever. The company also said that month that the second quarter was off to a “softer-than-anticipated start.”</p><p>“We anticipated fiscal 2022 would be a very challenging year to forecast,” management said in a letter to shareholders at the time. “We will be taking concrete steps to reexamine our expense base and adjust our operating costs.”</p></body></html>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Peloton Plans to Cut Jobs, Production Levels as Sales Slow</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPeloton Plans to Cut Jobs, Production Levels as Sales Slow\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-21 14:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2022-01-20/peloton-vows-to-slash-costs-as-it-posts-tepid-quarterly-results?srnd=premium-asia><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Company posts revenue of $1.14 billion, just below estimatesCEO disputes reports of production halt, but confirms layoffsPeloton Interactive Inc. vowed to slash expenses at the struggling fitness ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2022-01-20/peloton-vows-to-slash-costs-as-it-posts-tepid-quarterly-results?srnd=premium-asia\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PTON":"Peloton Interactive, Inc."},"source_url":"https://www.bloomberg.com/news/articles/2022-01-20/peloton-vows-to-slash-costs-as-it-posts-tepid-quarterly-results?srnd=premium-asia","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1155028154","content_text":"Company posts revenue of $1.14 billion, just below estimatesCEO disputes reports of production halt, but confirms layoffsPeloton Interactive Inc. vowed to slash expenses at the struggling fitness company, including labor and production costs, but disputed reports that it had idled its factories to save money.In a memo to staff, Chief Executive Officer John Foley said Peloton was “right-sizing our production, and, as we evolve to more seasonal demand curves, we are resetting our production levels for sustainable growth.”Peloton is reeling from a slowdown triggered by consumers emerging from pandemic lockdowns and returning to traditional gyms. It had been a Wall Street darling when customers were stuck at home and demand outstripped supply.Now the company is considering jobs cuts to get itself back on track, Foley said.“In the past, we’ve said layoffs would be the absolute last lever we would ever hope to pull,” he said. “However, we now need to evaluate our organization structure and size of our team, with the utmost care and compassion. And we are still in the process of considering all options as part of our efforts to make our business more flexible.”Peloton stationary bikes for sale at the company’s showroom in Dedham, Massachusetts.Photographer: Adam Glanzman/BloombergReferring to reports that Peloton had temporarily shut down production, Foley said that leaks of confidential information “have led to a flurry of speculative articles in the press. The information the media has obtained is incomplete, out of context, and not reflective of Peloton’s strategy.”He said the company had identified a leaker and was “moving forward with the appropriate legal action.”Peloton also released a preliminary report of $1.14 billion in sales during the fiscal second quarter, which ended on Dec. 31. Analysts had estimated $1.16 billion. The company ended the period with 2.77 million connected fitness subscribers, just below the 2.81 million prediction.In that report, Foley said Peloton was taking “significant corrective actions to improve our profitability outlook and optimize our costs across the company.” The effort “includes gross margin improvements, moving to a more variable cost structure, and identifying reductions in our operating expenses as we build a more focused Peloton moving forward.”Foley said he would share more information on the cost-cutting plan when Peloton gives its formal earnings report on Feb. 8. “This work is still underway,” he said.The early earnings release follows a report from CNBC Thursday that the company was temporarily halting manufacturing of bikes and Tread-branded treadmills. Production of Peloton’s main stationary bikes will be paused for two months, CNBC reported, citing internal documents. And the company will stop making its treadmill machine for six weeks, starting in February.In the memo to staff, Foley disputed the report, saying that “rumors that we are halting all production of bikes and Treads are false.”The CNBC story sent the shares down 24% to $24.22 in regular trading Thursday. Foley’s remarks after the close boosted the stock, with it gaining 9.2% as of 8 p.m. in New York.Foley said Thursday that the company’s churn rate was 0.79%, signaling that “members are sticking with us.”Peloton’s CEO said on the last earnings call that the company would be working to identify ways to cut costs. Peloton had spent millions of dollars on building up supply of its products to fulfill pandemic-fueled demand, only for interest to sputter as economies began to reopen.The company didn’t provide updated fiscal-year guidance on Thursday. Peloton had said the previous quarter that it expects to generate revenue of $4.4 billion to $4.8 billion during fiscal 2022, which ends in June. That range was a reduction from earlier company projections of $5.4 billion.When Peloton slashed its 2022 guidance in November, the shares suffered their biggest decline ever. The company also said that month that the second quarter was off to a “softer-than-anticipated start.”“We anticipated fiscal 2022 would be a very challenging year to forecast,” management said in a letter to shareholders at the time. “We will be taking concrete steps to reexamine our expense base and adjust our operating costs.”","news_type":1},"isVote":1,"tweetType":1,"viewCount":516,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":630960226,"gmtCreate":1642667643831,"gmtModify":1642667644226,"author":{"id":"3578047933589423","authorId":"3578047933589423","name":"PengsieX","avatar":"https://static.tigerbbs.com/ebe92821eba3b91a6431d698b66bbed5","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"Spending too much on new shows without the intention to continue when the ratings or response wasn't as good as expected","listText":"Spending too much on new shows without the intention to continue when the ratings or response wasn't as good as expected","text":"Spending too much on new shows without the intention to continue when the ratings or response wasn't as good as expected","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/630960226","repostId":"1105696017","repostType":4,"isVote":1,"tweetType":1,"viewCount":784,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"9000000000000591","authorId":"9000000000000591","name":"EvelynHoover","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0},"content":"我很同意你的看法。有时候我不太明白经理们在想什么","text":"我很同意你的看法。有时候我不太明白经理们在想什么","html":"我很同意你的看法。有时候我不太明白经理们在想什么"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":697672935,"gmtCreate":1642473421538,"gmtModify":1642473482560,"author":{"id":"3578047933589423","authorId":"3578047933589423","name":"PengsieX","avatar":"https://static.tigerbbs.com/ebe92821eba3b91a6431d698b66bbed5","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"Resilient to Omicron for now...&nbsp;","listText":"Resilient to Omicron for now...&nbsp;","text":"Resilient to Omicron for now...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/697672935","repostId":"1138317004","repostType":4,"isVote":1,"tweetType":1,"viewCount":505,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":697676267,"gmtCreate":1642473364440,"gmtModify":1642473480857,"author":{"id":"3578047933589423","authorId":"3578047933589423","name":"PengsieX","avatar":"https://static.tigerbbs.com/ebe92821eba3b91a6431d698b66bbed5","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"Time for some positivity!&nbsp;","listText":"Time for some positivity!&nbsp;","text":"Time for some positivity!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/697676267","repostId":"2204077133","repostType":4,"repost":{"id":"2204077133","pubTimestamp":1642462076,"share":"https://www.laohu8.com/m/news/2204077133?lang=&edition=full","pubTime":"2022-01-18 07:27","market":"us","language":"en","title":"Earnings Season in Full Swing, Fed Blackout Period: What to Know This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2204077133","media":"Yahoo Finance","summary":"Earnings season is heating up this week.Even with one fewer trading day, markets are closed in obser","content":"<html><head></head><body><p>Earnings season is heating up this week.</p><p>Even with <a href=\"https://laohu8.com/S/AONE.U\">one</a> fewer trading day, markets are closed in observance of Martin Luther King Jr. Day Monday, investors will come back from the holiday weekend to a prolific lineup of fourth quarter reports from market heavyweights such as Goldman Sachs (GS), Proctor &amp; Gamble (PG), Netflix (NFLX) and United Airlines (UAL). The period kicked off in earnest last week with lackluster results from major U.S. banks. JPMorgan (JPM), Wells Fargo (WFC), and Citigroup (C) were among the financial forms posting less-than-impressive results that dragged on Wall Street and tempered expectations for a strong start to the earnings season.</p><p>As fourth quarter earnings reports pick up speed, investors will shift their focus from monetary policy to look for signs of relief in company profits and other corporate metrics after economic uncertainty and worries around the Federal Reserve’s pace of interest rate hikes have weighed heavily on markets to start the new year.</p><p>The S&amp;P 500 is down 2.79% in 2022 so far, while the Dow has lost 1.84%. The Nasdaq has shed a whopping -5.93% year-to-date, with more than one third of companies in the index at least 50% from their 52-week highs, according to Bloomberg data.</p><p><img src=\"https://static.tigerbbs.com/cf5558c689efb2422aba2f457dd0ea41\" tg-width=\"4160\" tg-height=\"2773\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/>Earnings season kick into high gear this week. REUTERS/Brendan McDermidBrendan McDermid / reuters</p><p>“We’ll have to see if earnings season comes to the rescue once again,” Ed Clissold, chief U.S. strategist at Ned Davis, told Bloomberg earlier this week. “Still, earnings revisions over the past several weeks weren’t as strong as other pre-announcement periods last year, which leads us to believe that we may not get those fantastic beat rates.”</p><p>In the energy and industrials sector, which typically serves as a key driver in fourth quarter results, underlying fundamentals may lack the strength to power markets this earnings season, PNC chief investment officer Amanda Agati told Yahoo Finance Live.</p><p>“Investors need to be starting to set their expectations a bit lower,” she said. “Not necessarily bearish, but we do think the moderation in terms of growth not only for earnings season going forward, but also for economic growth is really going to be a dominant theme.&#34;</p><p>S&amp;P 500 earnings in aggregate were expected to grow 21.7% for the fourth-quarter of 2021, according to recent data from FactSet Research vice president and senior earnings analyst John Butters. That figure would mark a fourth consecutive quarter that earnings growth tops 20%.</p><p>Industry experts have previously predicted companies in the S&amp;P 500 will report record-high earnings per share in 2022. Butters has pointed out that the bottom-up EPS estimate for the S&amp;P 500 was $222.32 as of last month. If the forecast meets expectations, this would be the highest annual EPS number for the index since FactSet began tracking this metric in 1996.</p><p>FactSet reported that, on average, analysts have overestimated the final EPS number by 7.2%. Even taking the overestimation into account, the final EPS value of $206.32 for 2022 would still beat previous records.</p><p><img src=\"https://static.tigerbbs.com/0d2a8c99ee4ca3221a03b3c596293e3b\" tg-width=\"1804\" tg-height=\"1308\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/>The bottom-up EPS estimate for the S&amp;P 500 is $222.32, a figure that would mark the highest on record, according to FactSet data.FactSet Research vice president and senior earnings analyst john butters</p><p>Continued signs of Omicron’s economic impact and increasing indication by the Federal Reserve that it will intervene more aggressively to curb rising inflation, however, continue to dampen the outlook for 2022.</p><p>“Our expectation is that we&#39;re going to have a very solid and robust earnings season,” Schwab Asset Management CEO and CIO Omar Aguilar, though adding that the coming quarters may reflect the toll of Omicron more heavily than fourth quarter numbers.</p><p>“That being said, we expect the earnings to continue to decelerate — still very robust and in a good place as companies continue to drive to generate free cash flow and generate business,” but we will hear a lot about supply chain disruptions and the potential higher costs in these sectors that may have been transitioned to consumers.</p><p>&#34;I think what investors are really focused on is what are these CEOs going to say about two primary things, number one being inflation,&#34; TD Ameritrade Chief Market Strategist JJ Kinahan told Yahoo Finance Life.</p><p>&#34;For the financials, it&#39;ll probably be more wage inflation and their ability to retain workers and pay up... and then on the other end of that, for the non-financials, perhaps it&#39;s more of whether they can go through supply chain issues, because of COVID or because of the cost of inflation, to deliver goods to their end customers.&#34;</p><p>Meanwhile in Washington, Fed policymakers will enter a blackout period this week ahead of the Federal Open Market Committee’s (FOMC) next meeting on Jan. 26. The central bank has been top of mind for investors bracing for interest rate increases and tighter financial conditions that could come as soon as March.</p><p>In confirmation hearings last week, Fed officials have doubled down on earlier assertions that the central bank is prepared to mitigate inflation through higher interest rates.</p><p>Federal Reserve Chair Jerome Powell told Congress Tuesday that if the pace of price increases does not settle, policymakers will get more aggressive with raising short-term borrowing costs. In a separate hearing on Thursday, Fed governor and vice chair nominee Lael Brainard pledged to use that &#34;powerful tool&#34; — the central bank&#39;s benchmark for short-term interest rates called the federal funds rate — to bring inflation down over time.</p><h2>Economic calendar</h2><ul><li><p><b>Monday:</b> <i>Markets closed in observance of Martin Luther King Jr. Day; No economic reports scheduled for release</i></p></li><li><p><b>Tuesday:</b> Empire Manufacturing, January (25 expected, 31.9 prior); NAHB Housing Market Index, January (84 expected, 84 prior); Net Long-Term TIC Flows, November ($7,100,000,000 prior); Total Net TIC Flows, November ($143,000,000,000 prior)</p></li><li><p><b>Wednesday:</b> MBA Mortgage Applications, week ended January 14 (1.4% during prior week); Building Permits, December (1,700,000 expected, 1,712,000 during prior month, upwardly revised to 1,717,000); Building Permits, month-over-month, December (-1.0% expected, 3.6% during prior month, upwardly revised to 3.9%); Housing Starts, December (1,650,000 expected, 1,679,000 during prior month); Housing Starts, month over month, December (-1.7% expected, 11.8% during prior month)</p></li><li><p><b>Thursday:</b> Initial Jobless Claims, week ended January 15 (220,000 expected, 230,000 during prior week) Continuing Claims, week ended January 15 (1,521,000 expected, 1,559,000 prior week); Philadelphia Fed Business Outlook, January (19.8 expected, 15.4 prior); Existing Home Sales, December (6,410,000 expected, 6,460,000 during prior month); Existing Home Sales, month over month, December (-0.8% expected, 1.9% during prior month);</p></li><li><p><b>Friday: </b>Leading Index, December (0.8% expected, 1.1% prior)</p></li></ul><p><b>Earnings:</b></p><ul><li><p><b>Monday:</b> N<i>Markets closed in observance of Martin Luther King Jr. Day; o reports scheduled for release</i></p></li><li><p><b>Tuesday:</b> Goldman Sachs (GS) before market open, PNC Bank (PNC) before market open, Charles Schwab (SCHW), Bank of New York Mellon (BK) and Truist Financial (TFC) before market open; Interactive Brokers (IBKR), Hunt Transport (JBHT) after market close, Citrix Systems (CTXS)</p></li><li><p><b>Wednesday:</b> Bank of America (BAC) before market open, Procter &amp; Gamble (PG) before market open, United Health (UNH) before market open, <a href=\"https://laohu8.com/S/MSTLW\">Morgan Stanley</a> (MS) before market open, United Airlines (UAL) after market close, Discover Financial (DFS) after market close, State Street (STT) before market open, Comerica (CMA) before market open</p></li><li><p><b>Thursday:</b> Travelers (TRV) and American Airlines (AAL) and Northern Trust (NTRS) before market open; Netflix (NFLX) at market close</p></li><li><p><b>Friday:</b> Schlumberger (SLB), <a href=\"https://laohu8.com/S/GOM\">Ally Financial</a> (ALLY)</p></li></ul></body></html>","source":"yahoofinance_au","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Earnings Season in Full Swing, Fed Blackout Period: What to Know This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEarnings Season in Full Swing, Fed Blackout Period: What to Know This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-18 07:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/earnings-season-gains-momentum-fed-blackout-period-what-to-know-this-week-163248002.html><strong>Yahoo Finance</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Earnings season is heating up this week.Even with one fewer trading day, markets are closed in observance of Martin Luther King Jr. Day Monday, investors will come back from the holiday weekend to a ...</p>\n\n<a href=\"https://finance.yahoo.com/news/earnings-season-gains-momentum-fed-blackout-period-what-to-know-this-week-163248002.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯",".SPX":"S&P 500 Index",".IXIC":"NASDAQ Composite"},"source_url":"https://finance.yahoo.com/news/earnings-season-gains-momentum-fed-blackout-period-what-to-know-this-week-163248002.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2204077133","content_text":"Earnings season is heating up this week.Even with one fewer trading day, markets are closed in observance of Martin Luther King Jr. Day Monday, investors will come back from the holiday weekend to a prolific lineup of fourth quarter reports from market heavyweights such as Goldman Sachs (GS), Proctor & Gamble (PG), Netflix (NFLX) and United Airlines (UAL). The period kicked off in earnest last week with lackluster results from major U.S. banks. JPMorgan (JPM), Wells Fargo (WFC), and Citigroup (C) were among the financial forms posting less-than-impressive results that dragged on Wall Street and tempered expectations for a strong start to the earnings season.As fourth quarter earnings reports pick up speed, investors will shift their focus from monetary policy to look for signs of relief in company profits and other corporate metrics after economic uncertainty and worries around the Federal Reserve’s pace of interest rate hikes have weighed heavily on markets to start the new year.The S&P 500 is down 2.79% in 2022 so far, while the Dow has lost 1.84%. The Nasdaq has shed a whopping -5.93% year-to-date, with more than one third of companies in the index at least 50% from their 52-week highs, according to Bloomberg data.Earnings season kick into high gear this week. REUTERS/Brendan McDermidBrendan McDermid / reuters“We’ll have to see if earnings season comes to the rescue once again,” Ed Clissold, chief U.S. strategist at Ned Davis, told Bloomberg earlier this week. “Still, earnings revisions over the past several weeks weren’t as strong as other pre-announcement periods last year, which leads us to believe that we may not get those fantastic beat rates.”In the energy and industrials sector, which typically serves as a key driver in fourth quarter results, underlying fundamentals may lack the strength to power markets this earnings season, PNC chief investment officer Amanda Agati told Yahoo Finance Live.“Investors need to be starting to set their expectations a bit lower,” she said. “Not necessarily bearish, but we do think the moderation in terms of growth not only for earnings season going forward, but also for economic growth is really going to be a dominant theme.\"S&P 500 earnings in aggregate were expected to grow 21.7% for the fourth-quarter of 2021, according to recent data from FactSet Research vice president and senior earnings analyst John Butters. That figure would mark a fourth consecutive quarter that earnings growth tops 20%.Industry experts have previously predicted companies in the S&P 500 will report record-high earnings per share in 2022. Butters has pointed out that the bottom-up EPS estimate for the S&P 500 was $222.32 as of last month. If the forecast meets expectations, this would be the highest annual EPS number for the index since FactSet began tracking this metric in 1996.FactSet reported that, on average, analysts have overestimated the final EPS number by 7.2%. Even taking the overestimation into account, the final EPS value of $206.32 for 2022 would still beat previous records.The bottom-up EPS estimate for the S&P 500 is $222.32, a figure that would mark the highest on record, according to FactSet data.FactSet Research vice president and senior earnings analyst john buttersContinued signs of Omicron’s economic impact and increasing indication by the Federal Reserve that it will intervene more aggressively to curb rising inflation, however, continue to dampen the outlook for 2022.“Our expectation is that we're going to have a very solid and robust earnings season,” Schwab Asset Management CEO and CIO Omar Aguilar, though adding that the coming quarters may reflect the toll of Omicron more heavily than fourth quarter numbers.“That being said, we expect the earnings to continue to decelerate — still very robust and in a good place as companies continue to drive to generate free cash flow and generate business,” but we will hear a lot about supply chain disruptions and the potential higher costs in these sectors that may have been transitioned to consumers.\"I think what investors are really focused on is what are these CEOs going to say about two primary things, number one being inflation,\" TD Ameritrade Chief Market Strategist JJ Kinahan told Yahoo Finance Life.\"For the financials, it'll probably be more wage inflation and their ability to retain workers and pay up... and then on the other end of that, for the non-financials, perhaps it's more of whether they can go through supply chain issues, because of COVID or because of the cost of inflation, to deliver goods to their end customers.\"Meanwhile in Washington, Fed policymakers will enter a blackout period this week ahead of the Federal Open Market Committee’s (FOMC) next meeting on Jan. 26. The central bank has been top of mind for investors bracing for interest rate increases and tighter financial conditions that could come as soon as March.In confirmation hearings last week, Fed officials have doubled down on earlier assertions that the central bank is prepared to mitigate inflation through higher interest rates.Federal Reserve Chair Jerome Powell told Congress Tuesday that if the pace of price increases does not settle, policymakers will get more aggressive with raising short-term borrowing costs. In a separate hearing on Thursday, Fed governor and vice chair nominee Lael Brainard pledged to use that \"powerful tool\" — the central bank's benchmark for short-term interest rates called the federal funds rate — to bring inflation down over time.Economic calendarMonday: Markets closed in observance of Martin Luther King Jr. Day; No economic reports scheduled for releaseTuesday: Empire Manufacturing, January (25 expected, 31.9 prior); NAHB Housing Market Index, January (84 expected, 84 prior); Net Long-Term TIC Flows, November ($7,100,000,000 prior); Total Net TIC Flows, November ($143,000,000,000 prior)Wednesday: MBA Mortgage Applications, week ended January 14 (1.4% during prior week); Building Permits, December (1,700,000 expected, 1,712,000 during prior month, upwardly revised to 1,717,000); Building Permits, month-over-month, December (-1.0% expected, 3.6% during prior month, upwardly revised to 3.9%); Housing Starts, December (1,650,000 expected, 1,679,000 during prior month); Housing Starts, month over month, December (-1.7% expected, 11.8% during prior month)Thursday: Initial Jobless Claims, week ended January 15 (220,000 expected, 230,000 during prior week) Continuing Claims, week ended January 15 (1,521,000 expected, 1,559,000 prior week); Philadelphia Fed Business Outlook, January (19.8 expected, 15.4 prior); Existing Home Sales, December (6,410,000 expected, 6,460,000 during prior month); Existing Home Sales, month over month, December (-0.8% expected, 1.9% during prior month);Friday: Leading Index, December (0.8% expected, 1.1% prior)Earnings:Monday: NMarkets closed in observance of Martin Luther King Jr. Day; o reports scheduled for releaseTuesday: Goldman Sachs (GS) before market open, PNC Bank (PNC) before market open, Charles Schwab (SCHW), Bank of New York Mellon (BK) and Truist Financial (TFC) before market open; Interactive Brokers (IBKR), Hunt Transport (JBHT) after market close, Citrix Systems (CTXS)Wednesday: Bank of America (BAC) before market open, Procter & Gamble (PG) before market open, United Health (UNH) before market open, Morgan Stanley (MS) before market open, United Airlines (UAL) after market close, Discover Financial (DFS) after market close, State Street (STT) before market open, Comerica (CMA) before market openThursday: Travelers (TRV) and American Airlines (AAL) and Northern Trust (NTRS) before market open; Netflix (NFLX) at market closeFriday: Schlumberger (SLB), Ally Financial (ALLY)","news_type":1},"isVote":1,"tweetType":1,"viewCount":809,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":697817806,"gmtCreate":1642401056376,"gmtModify":1642401056783,"author":{"id":"3578047933589423","authorId":"3578047933589423","name":"PengsieX","avatar":"https://static.tigerbbs.com/ebe92821eba3b91a6431d698b66bbed5","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"It must shine soon or it will lose investors","listText":"It must shine soon or it will lose investors","text":"It must shine soon or it will lose investors","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/697817806","repostId":"2203139742","repostType":4,"repost":{"id":"2203139742","pubTimestamp":1642392014,"share":"https://www.laohu8.com/m/news/2203139742?lang=&edition=full","pubTime":"2022-01-17 12:00","market":"us","language":"en","title":"Is Palantir a 2022 Breakout Stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=2203139742","media":"Motley Fool","summary":"Its commercial applications are starting to shine.","content":"<html><head></head><body><p>While starting off as a data analytics company that catered to the U.S. government, <b>Palantir </b>(NYSE:PLTR) has pivoted to provide its services to the civilian market. Some people fear the government has access to too much personal data, and Palantir processes a portion of the information -- making the stock controversial for some.</p><p>As Palantir shifts toward commercial customers, can it break free from its government-affiliated stigma?</p><h2>Powering businesses to process data and give the best insights</h2><p>Palantir has three main offerings: Foundry, Gotham, and Apollo. Foundry is a data management platform that allows businesses to interpret information feeds. Tools like artificial intelligence (AI) and machine learning improve processing and can identify supply chain bottlenecks -- something all businesses could use with today&#39;s issues. With Foundry, code writing isn&#39;t necessary to analyze the data, making implementation easier across all business types.</p><p>Gotham is often used by governments to process real-time information and then present critical data cleanly so those making decisions have the best chance of succeeding. Former U.S. Secretary of Defense James Mattis said Gotham &#34;came up with ground breaking technologies that help us make better decisions in combat zones. You are giving us advantages right now that we need.&#34; Gotham can be used in military applications, but it also works with disaster response and law enforcement.</p><p>The Apollo software allows Foundry to run across multiple networks, whether on-premise data centers or cloud networks. Companies can also use multiple cloud providers, so <b>Amazon </b>or <b>Microsoft </b>cannot lock a company into unreasonable contracts. This gives Palantir an edge against typical software-as-a-service (SaaS) companies, as most require sticking with <a href=\"https://laohu8.com/S/AONE.U\">one</a> provider, be it on-premise or cloud.</p><h2>Strong growth, but with a caveat</h2><p>Examining Palantir&#39;s earnings performance from quarter to quarter can be misleading. Palantir&#39;s contracts are often massive -- it closed 54 deals of at least $1 million and 18 worth $10 million or more during the third quarter alone -- and can lead to odd comparisons. Still, Palantir had a strong third quarter and did well in 2021.</p><p>Q3 revenue increased 36% to $392 million, driving its remaining deal value to $3.6 billion, a 50% increase since Q3 2020. Showcasing its expansion into civilian enterprises, its commercial customer count grew 135% in just nine months. While it is too soon to tell, Palantir&#39;s business model expansion appears to be working.</p><p>Palantir isn&#39;t profitable yet, mostly caused by its massive stock-based compensation bill. During Q3, it shelled out $184 million in stock to its employees while bringing in $392 million. This led to an abysmal net loss margin of 26%. Once this expense is pulled out -- investors should be careful doing this when stock-based compensation is this high -- the net margin is 21%. Because this expense isn&#39;t cash, Palantir is free-cash-flow positive and sports an impressive 30% margin.</p><p>Supercharging growth with stock compensation is a great strategy when capturing market share, as it allows management to hire talent by compensating them generously with stock -- a cheap currency that can be created by the company. However, businesses must balance this expense; shareholders won&#39;t tolerate this strategy forever because existing shares are diluted each time a new one is created.</p><h2>Palantir&#39;s future</h2><p>Like many high-growth unprofitable tech stocks, Palantir has seen its valuation reduced over the last month.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/3f0e8dd22c3b64f2640b3d2c4647346d\" tg-width=\"720\" tg-height=\"433\" width=\"100%\" height=\"auto\"/><span>PLTR PS Ratio data by YCharts.</span></p><p>Still, a 23 price-to-sales multiple is expensive to pay for a stock growing at 36%. Examining Palantir with a rule of 40 lens -- often used to judge if a company is growing quickly enough to warrant losing money -- is calculated by adding its revenue growth to a profit margin of some type and seeing if it is above 40%. With a 36% revenue growth and a negative 26% net margin, Palantir fails this test with a paltry 10% score.</p><p>The company is seizing an exciting new market segment in cryptocurrency exchanges. With Foundry, platforms can detect money laundering schemes and reduce fraud. While the crypto market opportunity is still young, it could have a significant use-case for many entities -- including the government.</p><p>One Palantir competitor is <b>Alteryx </b>(NYSE:AYX). Alteryx offers many data analytics tools, but its stock has been hammered over the last year because of its lackluster earnings due to its cloud migration. As Alteryx completes the cloud transition, the battle between the two could heat up. However, there is plenty of room for multiple winners in the data analytics space.</p><p>Palantir has momentum going for it in 2022. I expect it to continue growing its revenue and customers rapidly. Still, its stock-based compensation will prevent it from becoming profitable for years. Additionally, Palantir is often mentioned on Reddit boards and could cause large price movements, depending on what the community is attempting to do. However, I believe Palantir can still be a great long-term investment.</p><p>While I don&#39;t know how 2022 will treat Palantir, its long-term prospects are bright.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Palantir a 2022 Breakout Stock?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Palantir a 2022 Breakout Stock?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-17 12:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/15/is-palantir-a-2022-breakout-stock/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>While starting off as a data analytics company that catered to the U.S. government, Palantir (NYSE:PLTR) has pivoted to provide its services to the civilian market. Some people fear the government has...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/15/is-palantir-a-2022-breakout-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4551":"寇图资本持仓","AYX":"Alteryx Inc.","BK4547":"WSB热门概念","BK4543":"AI","PLTR":"Palantir Technologies Inc.","BK4528":"SaaS概念","AI":"C3.ai, Inc.","BK4023":"应用软件"},"source_url":"https://www.fool.com/investing/2022/01/15/is-palantir-a-2022-breakout-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2203139742","content_text":"While starting off as a data analytics company that catered to the U.S. government, Palantir (NYSE:PLTR) has pivoted to provide its services to the civilian market. Some people fear the government has access to too much personal data, and Palantir processes a portion of the information -- making the stock controversial for some.As Palantir shifts toward commercial customers, can it break free from its government-affiliated stigma?Powering businesses to process data and give the best insightsPalantir has three main offerings: Foundry, Gotham, and Apollo. Foundry is a data management platform that allows businesses to interpret information feeds. Tools like artificial intelligence (AI) and machine learning improve processing and can identify supply chain bottlenecks -- something all businesses could use with today's issues. With Foundry, code writing isn't necessary to analyze the data, making implementation easier across all business types.Gotham is often used by governments to process real-time information and then present critical data cleanly so those making decisions have the best chance of succeeding. Former U.S. Secretary of Defense James Mattis said Gotham \"came up with ground breaking technologies that help us make better decisions in combat zones. You are giving us advantages right now that we need.\" Gotham can be used in military applications, but it also works with disaster response and law enforcement.The Apollo software allows Foundry to run across multiple networks, whether on-premise data centers or cloud networks. Companies can also use multiple cloud providers, so Amazon or Microsoft cannot lock a company into unreasonable contracts. This gives Palantir an edge against typical software-as-a-service (SaaS) companies, as most require sticking with one provider, be it on-premise or cloud.Strong growth, but with a caveatExamining Palantir's earnings performance from quarter to quarter can be misleading. Palantir's contracts are often massive -- it closed 54 deals of at least $1 million and 18 worth $10 million or more during the third quarter alone -- and can lead to odd comparisons. Still, Palantir had a strong third quarter and did well in 2021.Q3 revenue increased 36% to $392 million, driving its remaining deal value to $3.6 billion, a 50% increase since Q3 2020. Showcasing its expansion into civilian enterprises, its commercial customer count grew 135% in just nine months. While it is too soon to tell, Palantir's business model expansion appears to be working.Palantir isn't profitable yet, mostly caused by its massive stock-based compensation bill. During Q3, it shelled out $184 million in stock to its employees while bringing in $392 million. This led to an abysmal net loss margin of 26%. Once this expense is pulled out -- investors should be careful doing this when stock-based compensation is this high -- the net margin is 21%. Because this expense isn't cash, Palantir is free-cash-flow positive and sports an impressive 30% margin.Supercharging growth with stock compensation is a great strategy when capturing market share, as it allows management to hire talent by compensating them generously with stock -- a cheap currency that can be created by the company. However, businesses must balance this expense; shareholders won't tolerate this strategy forever because existing shares are diluted each time a new one is created.Palantir's futureLike many high-growth unprofitable tech stocks, Palantir has seen its valuation reduced over the last month.PLTR PS Ratio data by YCharts.Still, a 23 price-to-sales multiple is expensive to pay for a stock growing at 36%. Examining Palantir with a rule of 40 lens -- often used to judge if a company is growing quickly enough to warrant losing money -- is calculated by adding its revenue growth to a profit margin of some type and seeing if it is above 40%. With a 36% revenue growth and a negative 26% net margin, Palantir fails this test with a paltry 10% score.The company is seizing an exciting new market segment in cryptocurrency exchanges. With Foundry, platforms can detect money laundering schemes and reduce fraud. While the crypto market opportunity is still young, it could have a significant use-case for many entities -- including the government.One Palantir competitor is Alteryx (NYSE:AYX). Alteryx offers many data analytics tools, but its stock has been hammered over the last year because of its lackluster earnings due to its cloud migration. As Alteryx completes the cloud transition, the battle between the two could heat up. However, there is plenty of room for multiple winners in the data analytics space.Palantir has momentum going for it in 2022. I expect it to continue growing its revenue and customers rapidly. Still, its stock-based compensation will prevent it from becoming profitable for years. Additionally, Palantir is often mentioned on Reddit boards and could cause large price movements, depending on what the community is attempting to do. However, I believe Palantir can still be a great long-term investment.While I don't know how 2022 will treat Palantir, its long-term prospects are bright.","news_type":1},"isVote":1,"tweetType":1,"viewCount":502,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":697944150,"gmtCreate":1642242073289,"gmtModify":1642242073675,"author":{"id":"3578047933589423","authorId":"3578047933589423","name":"PengsieX","avatar":"https://static.tigerbbs.com/ebe92821eba3b91a6431d698b66bbed5","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"Should focus on ROI for customers&nbsp;","listText":"Should focus on ROI for customers&nbsp;","text":"Should focus on ROI for customers","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/697944150","repostId":"1167122618","repostType":4,"repost":{"id":"1167122618","pubTimestamp":1642212214,"share":"https://www.laohu8.com/m/news/1167122618?lang=&edition=full","pubTime":"2022-01-15 10:03","market":"us","language":"en","title":"Morgan Stanley Promotes Biggest Class of Managing Directors Since 2012","url":"https://stock-news.laohu8.com/highlight/detail?id=1167122618","media":"Seeking Alpha","summary":"While efforts to hire and retain workers pick up across Wall Street, Morgan Stanley(NYSE:MS)names 19","content":"<html><head></head><body><ul><li>While efforts to hire and retain workers pick up across Wall Street, Morgan Stanley(NYSE:MS)names 199 employees as new managing directors, a person with knowledge on the matter told Bloomberg.</li><li>This is up from 171 last year and 130 in 2020, Bloomberg reports. The U.S. region counts for 64% of the promotions, with 23% in Europe, the Middle East and Africa, and 14% in Asia.</li><li>A third of the new managing directors are women, the person told Bloomberg. This means 23% of the bank&#39;s managing directors are female, a new record, Bloomberg notes.</li><li>Recall Goldman Sachs(NYSE:GS)recently said it plans to boost hiring in Latin America after a record year.</li><li>Previously, (Jan. 4, 2021) Morgan Stanley inked a lease for BlackRock&#39;sheadquarters in New York City.</li></ul></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Morgan Stanley Promotes Biggest Class of Managing Directors Since 2012</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMorgan Stanley Promotes Biggest Class of Managing Directors Since 2012\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-15 10:03 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3788415-morgan-stanley-promotes-most-staff-to-managing-directors-since-2012-bloomberg><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>While efforts to hire and retain workers pick up across Wall Street, Morgan Stanley(NYSE:MS)names 199 employees as new managing directors, a person with knowledge on the matter told Bloomberg.This is ...</p>\n\n<a href=\"https://seekingalpha.com/news/3788415-morgan-stanley-promotes-most-staff-to-managing-directors-since-2012-bloomberg\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MS":"摩根士丹利"},"source_url":"https://seekingalpha.com/news/3788415-morgan-stanley-promotes-most-staff-to-managing-directors-since-2012-bloomberg","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1167122618","content_text":"While efforts to hire and retain workers pick up across Wall Street, Morgan Stanley(NYSE:MS)names 199 employees as new managing directors, a person with knowledge on the matter told Bloomberg.This is up from 171 last year and 130 in 2020, Bloomberg reports. The U.S. region counts for 64% of the promotions, with 23% in Europe, the Middle East and Africa, and 14% in Asia.A third of the new managing directors are women, the person told Bloomberg. This means 23% of the bank's managing directors are female, a new record, Bloomberg notes.Recall Goldman Sachs(NYSE:GS)recently said it plans to boost hiring in Latin America after a record year.Previously, (Jan. 4, 2021) Morgan Stanley inked a lease for BlackRock'sheadquarters in New York City.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1050,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":696197549,"gmtCreate":1640647570099,"gmtModify":1640647570490,"author":{"id":"3578047933589423","authorId":"3578047933589423","name":"PengsieX","avatar":"https://static.tigerbbs.com/ebe92821eba3b91a6431d698b66bbed5","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"It's gonna be a roller coaster in 2022. Brace yourselves","listText":"It's gonna be a roller coaster in 2022. Brace yourselves","text":"It's gonna be a roller coaster in 2022. Brace yourselves","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/696197549","repostId":"1127544468","repostType":4,"repost":{"id":"1127544468","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1640646504,"share":"https://www.laohu8.com/m/news/1127544468?lang=&edition=full","pubTime":"2021-12-28 07:08","market":"us","language":"en","title":"S&P 500 closes at record high on retail sales cheer","url":"https://stock-news.laohu8.com/highlight/detail?id=1127544468","media":"Reuters","summary":"Dec 27  - The S&P 500 indexended at a record high on Monday, its fourth straight session of gains, as strong U.S. retail sales underscored economic strength and eased worries from Omicron-driven flight cancellations that hit travel stocks.U.S. retail sales increased 8.5% year-over-year this holiday season, powered by an ecommerce boom, according to a Mastercard Inc report, giving the S&P 500 retailing indexa boost.Travel-related stocks, typically sensitive to coronavirus news, declined after U.S","content":"<p>Dec 27 (Reuters) - The S&amp;P 500 index(.SPX)ended at a record high on Monday, its fourth straight session of gains, as strong U.S. retail sales underscored economic strength and eased worries from Omicron-driven flight cancellations that hit travel stocks.</p>\n<p>U.S. retail sales increased 8.5% year-over-year this holiday season, powered by an ecommerce boom, according to a Mastercard Inc report, giving the S&amp;P 500 retailing index(.SPXRT)a boost.</p>\n<p>Travel-related stocks, typically sensitive to coronavirus news, declined after U.S. airlines canceled about 800 more flights on Monday after nixing thousands during the Christmas weekend, as Omicron cases soared.</p>\n<p>The S&amp;P 1500 airlines index&nbsp;shed 0.57%. Cruise operators <a href=\"https://laohu8.com/S/NCLH\">Norwegian Cruise Line</a> Holdings, <a href=\"https://laohu8.com/S/RGLD\">Royal</a> Caribbean(RCL.N)and <a href=\"https://laohu8.com/S/CCL\">Carnival</a> Corp(CCL.N)fell 2.55%, 1.35% and 1.18% respectively, among the biggest decliners on the benchmark S&amp;P 500.</p>\n<p>\"The market is in this interesting place where we have a strong consumer, with spending up 8% year over year. Personal consumption makes up 70% of our GDP, and that remains flush,\" said Sylvia Jablonski Kampaktsis, chief investment officer and co-founder at Defiance ETFs in <a href=\"https://laohu8.com/S/NWY\">New York</a>.</p>\n<p>\"Omicron reminds us that we still exist in this corona ecosystem. And it'll probably be <a href=\"https://laohu8.com/S/AONE.U\">one</a> of many things that we will continue talking about with this virus but the doomsday COVID scenario of 2020 feels like it's far behind us.\"</p>\n<p>All 11 main S&amp;P 500 sector indexes advanced, with energy(.SPNY)and tech(.SPLRCT)leading percentage gains.</p>\n<p>The Dow Jones Industrial Average(.DJI)rose 351.82 points, or 0.98%, to 36,302.38, the S&amp;P 500(.SPX)gained 65.4 points, or 1.38%, to 4,791.19 and the <a href=\"https://laohu8.com/S/NDAQ\">Nasdaq</a> Composite(.IXIC)added 217.89 points, or 1.39%, to 15,871.26.</p>\n<p>The S&amp;P 500 has climbed 4.9% during its recent run of gains, its biggest percentage gain over a four-day period since early November 2020.</p>\n<p>The Nasdaq Composite(.IXIC)got a boost from megacap companies, including Tesla Inc(TSLA.O), <a href=\"https://laohu8.com/S/MSFT\">Microsoft</a> Corp(MSFT.O), <a href=\"https://laohu8.com/S/AAPL\">Apple</a> Inc(AAPL.O)and <a href=\"https://laohu8.com/S/CASH\">Meta</a> Platform(FB.O).</p>\n<p>Main U.S. stock indexes are on track for a third straight yearly gain, with the benchmark S&amp;P 500(.SPX)poised for its best three-year performance since 1999.</p>\n<p>Volume on U.S. exchanges was 7.76 billion shares, compared with the 11.74 billion average for the full session over the last 20 trading days.</p>\n<p>Advancing issues outnumbered decliners on the NYSE by a 2.29-to-1 ratio; on Nasdaq, a 1.09-to-1 ratio favored advancers.</p>\n<p>The S&amp;P 500 posted 58 new 52-week highs and no new lows; the Nasdaq Composite recorded 101 new highs and 145 new lows.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>S&P 500 closes at record high on retail sales cheer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nS&P 500 closes at record high on retail sales cheer\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-12-28 07:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Dec 27 (Reuters) - The S&amp;P 500 index(.SPX)ended at a record high on Monday, its fourth straight session of gains, as strong U.S. retail sales underscored economic strength and eased worries from Omicron-driven flight cancellations that hit travel stocks.</p>\n<p>U.S. retail sales increased 8.5% year-over-year this holiday season, powered by an ecommerce boom, according to a Mastercard Inc report, giving the S&amp;P 500 retailing index(.SPXRT)a boost.</p>\n<p>Travel-related stocks, typically sensitive to coronavirus news, declined after U.S. airlines canceled about 800 more flights on Monday after nixing thousands during the Christmas weekend, as Omicron cases soared.</p>\n<p>The S&amp;P 1500 airlines index&nbsp;shed 0.57%. Cruise operators <a href=\"https://laohu8.com/S/NCLH\">Norwegian Cruise Line</a> Holdings, <a href=\"https://laohu8.com/S/RGLD\">Royal</a> Caribbean(RCL.N)and <a href=\"https://laohu8.com/S/CCL\">Carnival</a> Corp(CCL.N)fell 2.55%, 1.35% and 1.18% respectively, among the biggest decliners on the benchmark S&amp;P 500.</p>\n<p>\"The market is in this interesting place where we have a strong consumer, with spending up 8% year over year. Personal consumption makes up 70% of our GDP, and that remains flush,\" said Sylvia Jablonski Kampaktsis, chief investment officer and co-founder at Defiance ETFs in <a href=\"https://laohu8.com/S/NWY\">New York</a>.</p>\n<p>\"Omicron reminds us that we still exist in this corona ecosystem. And it'll probably be <a href=\"https://laohu8.com/S/AONE.U\">one</a> of many things that we will continue talking about with this virus but the doomsday COVID scenario of 2020 feels like it's far behind us.\"</p>\n<p>All 11 main S&amp;P 500 sector indexes advanced, with energy(.SPNY)and tech(.SPLRCT)leading percentage gains.</p>\n<p>The Dow Jones Industrial Average(.DJI)rose 351.82 points, or 0.98%, to 36,302.38, the S&amp;P 500(.SPX)gained 65.4 points, or 1.38%, to 4,791.19 and the <a href=\"https://laohu8.com/S/NDAQ\">Nasdaq</a> Composite(.IXIC)added 217.89 points, or 1.39%, to 15,871.26.</p>\n<p>The S&amp;P 500 has climbed 4.9% during its recent run of gains, its biggest percentage gain over a four-day period since early November 2020.</p>\n<p>The Nasdaq Composite(.IXIC)got a boost from megacap companies, including Tesla Inc(TSLA.O), <a href=\"https://laohu8.com/S/MSFT\">Microsoft</a> Corp(MSFT.O), <a href=\"https://laohu8.com/S/AAPL\">Apple</a> Inc(AAPL.O)and <a href=\"https://laohu8.com/S/CASH\">Meta</a> Platform(FB.O).</p>\n<p>Main U.S. stock indexes are on track for a third straight yearly gain, with the benchmark S&amp;P 500(.SPX)poised for its best three-year performance since 1999.</p>\n<p>Volume on U.S. exchanges was 7.76 billion shares, compared with the 11.74 billion average for the full session over the last 20 trading days.</p>\n<p>Advancing issues outnumbered decliners on the NYSE by a 2.29-to-1 ratio; on Nasdaq, a 1.09-to-1 ratio favored advancers.</p>\n<p>The S&amp;P 500 posted 58 new 52-week highs and no new lows; the Nasdaq Composite recorded 101 new highs and 145 new lows.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"161125":"标普500","513500":"标普500ETF","OEX":"标普100","SPXU":"三倍做空标普500ETF",".SPX":"S&P 500 Index","BK4559":"巴菲特持仓","BK4534":"瑞士信贷持仓","OEF":"标普100指数ETF-iShares","IVV":"标普500指数ETF","BK4550":"红杉资本持仓","BK4504":"桥水持仓","SPY":"标普500ETF","UPRO":"三倍做多标普500ETF","SH":"标普500反向ETF","SDS":"两倍做空标普500ETF","SSO":"两倍做多标普500ETF"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1127544468","content_text":"Dec 27 (Reuters) - The S&P 500 index(.SPX)ended at a record high on Monday, its fourth straight session of gains, as strong U.S. retail sales underscored economic strength and eased worries from Omicron-driven flight cancellations that hit travel stocks.\nU.S. retail sales increased 8.5% year-over-year this holiday season, powered by an ecommerce boom, according to a Mastercard Inc report, giving the S&P 500 retailing index(.SPXRT)a boost.\nTravel-related stocks, typically sensitive to coronavirus news, declined after U.S. airlines canceled about 800 more flights on Monday after nixing thousands during the Christmas weekend, as Omicron cases soared.\nThe S&P 1500 airlines index shed 0.57%. Cruise operators Norwegian Cruise Line Holdings, Royal Caribbean(RCL.N)and Carnival Corp(CCL.N)fell 2.55%, 1.35% and 1.18% respectively, among the biggest decliners on the benchmark S&P 500.\n\"The market is in this interesting place where we have a strong consumer, with spending up 8% year over year. Personal consumption makes up 70% of our GDP, and that remains flush,\" said Sylvia Jablonski Kampaktsis, chief investment officer and co-founder at Defiance ETFs in New York.\n\"Omicron reminds us that we still exist in this corona ecosystem. And it'll probably be one of many things that we will continue talking about with this virus but the doomsday COVID scenario of 2020 feels like it's far behind us.\"\nAll 11 main S&P 500 sector indexes advanced, with energy(.SPNY)and tech(.SPLRCT)leading percentage gains.\nThe Dow Jones Industrial Average(.DJI)rose 351.82 points, or 0.98%, to 36,302.38, the S&P 500(.SPX)gained 65.4 points, or 1.38%, to 4,791.19 and the Nasdaq Composite(.IXIC)added 217.89 points, or 1.39%, to 15,871.26.\nThe S&P 500 has climbed 4.9% during its recent run of gains, its biggest percentage gain over a four-day period since early November 2020.\nThe Nasdaq Composite(.IXIC)got a boost from megacap companies, including Tesla Inc(TSLA.O), Microsoft Corp(MSFT.O), Apple Inc(AAPL.O)and Meta Platform(FB.O).\nMain U.S. stock indexes are on track for a third straight yearly gain, with the benchmark S&P 500(.SPX)poised for its best three-year performance since 1999.\nVolume on U.S. exchanges was 7.76 billion shares, compared with the 11.74 billion average for the full session over the last 20 trading days.\nAdvancing issues outnumbered decliners on the NYSE by a 2.29-to-1 ratio; on Nasdaq, a 1.09-to-1 ratio favored advancers.\nThe S&P 500 posted 58 new 52-week highs and no new lows; the Nasdaq Composite recorded 101 new highs and 145 new lows.","news_type":1},"isVote":1,"tweetType":1,"viewCount":131,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":696092824,"gmtCreate":1640570361049,"gmtModify":1640570924779,"author":{"id":"3578047933589423","authorId":"3578047933589423","name":"PengsieX","avatar":"https://static.tigerbbs.com/ebe92821eba3b91a6431d698b66bbed5","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"Buzz lightyear&nbsp;","listText":"Buzz lightyear&nbsp;","text":"Buzz lightyear","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/696092824","repostId":"1128895961","repostType":4,"repost":{"id":"1128895961","pubTimestamp":1640565848,"share":"https://www.laohu8.com/m/news/1128895961?lang=&edition=full","pubTime":"2021-12-27 08:44","market":"us","language":"en","title":"You Can't Buy SpaceX Yet But These Space Stocks Are Up For Grabs","url":"https://stock-news.laohu8.com/highlight/detail?id=1128895961","media":"Investors","summary":"SpaceX continues to mark new milestones as a private company, and that has spurred investors' appeti","content":"<p>SpaceX continues to mark new milestones as a private company, and that has spurred investors' appetites for publicly traded space stocks, which have multiplied rapidly in recent years.</p>\n<p>The proliferation of new space stocks has come as&nbsp;SPACshave taken over. Special purpose acquisition companies also known as \"blank check companies\" offer a way for private companies to go public without an IPO. Instead of selling stock, the private enterprise merges with a shell company that's already public. SPACs have become popular after years of being shunned by the financial community.</p>\n<p>Astra Space went publicon July 1 via&nbsp;<b>Holicity</b>(HOL),Momentus went public&nbsp;via&nbsp;<b>Stable RoadCapital</b>(SRAC) and&nbsp;<b>Vector Acquisition</b>(VACQ) took&nbsp;Rocket Lab public&nbsp;in August in a deal that values the space company at $4.1 billion.<b>Redwire Space</b>(RDW) is merged with&nbsp;<b>Genesis Park</b>(GNPK) to go public in September. Satellite imaging company&nbsp;<b>Planet</b>(PL) went public via SPAC on Dec. 8.</p>\n<p><b>Virgin Galactic's</b>(SPCE) sister company, Virgin Orbit, is going public via a&nbsp;blank-check mergerwith<b>NextGen Acquisition II</b>(NGCA).</p>\n<p>\"After a wave of recent space de-SPACings, investors are now turning their focus toward execution, profitability and return on investment,\" Morgan Stanely analysts wrote in a note dated Dec. 8. \"The challenge facing investors is separating wheat from chaff and identifying companies that have not only discriminating technology, but also sustainable business models.\"</p>\n<p>Meanwhile, in the legacy space industry,<b>Boeing</b>(BA) is building its own space taxis as well as the most powerful rocket ever. NASA also is working with other established space stocks like&nbsp;<b>Lockheed Martin</b>(LMT) along with upstart space companies to return astronauts to the moon and Mars.</p>\n<p>Here's a look at key publicly traded space stocks as of Dec. 25:</p>\n<p><b>Space Stocks ETFs</b></p>\n<p>One option investors have is investing in an ETF. Procure Space ETF (UFO), a space-related exchange traded fund, launched back in April 2019. The fund includes holdings in space stocks like Boeing,<b>Maxar</b>(MAXR),<b>Iridium Communications</b>(IRDM),<b>Intelsat</b>(I) and<b>Airbus</b>(EADSY).</p>\n<p>Cathie Wood's Ark Investment Management launched the ARK Space Exploration ETF (ARKX) earlier this year. The space-focused ETF includes Boeing and&nbsp;<b>Amazon</b>(AMZN). But it has exited its stake in Virgin Galactic.</p>\n<p><b>Virgin Galactic</b></p>\n<p>On Oct. 28, 2019, Virgin Galactic stock became the first publicly traded commercial space tourism company after a reverse merger with Social Capital Hedosophia Holdings.</p>\n<p>The company, which counts Boeing as an investor, successfully conducted its&nbsp;first fully crewed flight&nbsp;on July 11, sending founder Richard Branson into space. The flight not only means the company's billionaire founder beat Blue Origin's Jeff Bezos to space, but it's also crucial to the start of commercial service in 2022.</p>\n<p>But the Federal Aviation Administration grounded the company's space plane in September and opened a probe into the flight for veering off its projected flight path during descent.&nbsp; The FAA lifted the grounding on Sept. 29.&nbsp;On Oct. 14, the space company announced it woulddelay the start of commercial flights&nbsp;until the fourth quarter of 2022.</p>\n<p>In addition to space tourism, Wall Street has noted Virgin Galactic's potential in hypersonic intercontinental travel.</p>\n<p>In August 2020, Virgin Galactic signed a memorandum of understanding with Rolls-Royce to collaborate in designing and developing engine propulsion technology for Mach 3 commercial aircraft. Virgin Galactic entered into a Space Act Agreement with NASA in May to work on developing a sustainable high-Mach supersonic vehicle. The U.S. space agency has been working on high-Mach flight with its Supersonic X-59 test plane built by Lockheed.</p>\n<p><b>Boeing</b></p>\n<p>One of the original space stocks, Boeing built the first stage of the Saturn V rocket that helped propel Apollo 11 astronauts to the moon in 1969. Now it's building theSpace Launch System rocket&nbsp;at the same facility as the Saturn V rocket in New Orleans.</p>\n<p>The SLS is designed to be the most powerful rocket ever, taking astronauts and probes into deep space. But delays and costs overruns have plagued the NASA rocket.&nbsp;In January,&nbsp;NASA cut short a test of the core stage&nbsp;but was able to&nbsp;successfully complete the key hot fire test&nbsp;for the full duration in March. The rocket keeps facing delays due to Covid-19 and won't fly until 2022.</p>\n<p>Boeing also developed the Starliner capsule to ferry astronauts to and from the ISS. But the capsule failed to reach the correct orbit during the&nbsp;test flight&nbsp;in December 2019 and a potentially \"catastrophic\" software issue was discovered. Boeing planned to redo the test flight on July 30 but the launch has been delayed until 2022 as the company looks for the cause of a technical issue that emerged.</p>\n<p>In October, NASA moved astronauts from a Starliner mission to a SpaceX Crew Dragon mission amid the delays.</p>\n<p>Boeing also builds satellites and manages the ISS for NASA.</p>\n<p><b>Lockheed Martin</b></p>\n<p>Lockheed also has a long history as one of the top space stocks. It built&nbsp;the solid propellant launch escape motor and the pitch control motor for the Apollo 11 spacecraft.</p>\n<p>Now Lockheed is&nbsp;developing the deep-space Orion spacecraft for the SLS rocket&nbsp;to carry astronauts into deep space, including to lunar orbit.</p>\n<p>Lockheed also makes satellites and space probes for NASA. More recently, Lockheed built components for the Mars Perseverance rover, which landed in February, and the Mars InSight lander, which landed in November 2018.</p>\n<p>In addition, its joint venture with Boeing, United Launch Alliance, makes rockets that provide launch services.</p>\n<p>In December 2020, Lockheed announced it would buy&nbsp;engine maker Aerojet Rocketdynein an estimated $4.4 billion deal to boost its hypersonic weapons and space capabilities.</p>\n<p>Aerojet's engines were used in the Apollo 11 mission and were on the Space Shuttle. The company is also providing the engines for Boeing's SLS rocket, ULA's Vulcan rocket upper stage and&nbsp;Northrop's OmegA rocket third stage.</p>\n<p><b>Northrop Grumman</b></p>\n<p><b>Northrop Grumman</b>(NOC) expanded its scope as one of the leading space stocks after it bought rocket maker Orbital ATK in 2018.</p>\n<p>The company is working on the&nbsp;OmegA heavy-lift rocket and received Air Force funding last year to help end the U.S. reliance on Russian engines used in the Atlas 5 rocket by ULA.</p>\n<p>Northrop makes satellites as well and is developing the James Webb Space Telescope for NASA. But the deep-space telescope is behind schedule with Covid-19 further dragging on timing. NASA expects the telescope to launch on Dec. 25.</p>\n<p>Northrop and Lockheed teamed up with Blue Origin on a lunar lander program for NASA. Butthey lost out to SpaceX.</p>\n<p><b>Maxar</b></p>\n<p>Smaller space stocks are leaving their mark on the new space race too.&nbsp;Maxar will build the first components ofNASA's Lunar Gatewayspace station.</p>\n<p>It also builds communication and Earth observations satellites as well as robotic systems for use in space.</p>\n<p>In addition, Maxar provides access to satellite imagery and map data.</p>\n<p><b>SpaceX</b></p>\n<p>Investors' hopes for SpaceX have made it one of the most valuable pre-IPO companies in the world. An insider share sale in early October put its worth at$100 billion,&nbsp;according to a CNBC report. But Musk has no plans for it to go public...yet.</p>\n<p>An IPO of the&nbsp;SpaceX Starlink satellite business&nbsp;reportedly could be in the works, perhaps in the next several years. SpaceX has launched more than 1,700 Starlink satellites for delivering space-based broadband connections, and beta testing is ongoing. In May, the company said more than 500,000 people have ordered or made a deposit for service.</p>\n<p>SpaceX's Falcon 9 rocket routinely carries payloads into space for NASA, the Pentagon as well as other governments and companies, while its Falcon Heavy has launched commercial and government payloads.</p>\n<p>SpaceX is now sending astronauts to the space station on regular trips via the Crew Dragon capsule. SpaceX is also developing the Starship for deep-space missions and space tourism.</p>\n<p>In April, NASA awarded SpaceX $2.9 billion to further develop the Starship to land astronauts on the moon. Blue Origin and Dynetics have filed protests. In May, SpaceX launched and landed an uncrewed prototype safely, after prior high-altitude flights ended in explosions.</p>\n<p><b>Blue Origin</b></p>\n<p>Jeff Bezos' Blue Origin is developing the New Glenn and New Shepard rockets as well as engines and the Blue Moon lunar lander. In addition to carrying payloads, Blue Origin also plans to take tourists into space and is developing its own constellation of satellites for internet service.</p>\n<p>Bezos and his brother flew on New Shepard's first crewed flight on July 20. Blue Origin said that it has nearly $100 million in commercial sales for flights on its rocket. Two more commercial flights are expected this year. Star Trek actor William Shatner flew on Blue Origin's successful Oct. 13 mission. At 90, he became the oldest person in space.</p>\n<p>Bezos said he's not sure how many flights will happen in 2022 but that \"demand is very, very high.\"</p>","source":"lsy1610449120050","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>You Can't Buy SpaceX Yet But These Space Stocks Are Up For Grabs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nYou Can't Buy SpaceX Yet But These Space Stocks Are Up For Grabs\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-27 08:44 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.investors.com/news/space-stocks-upstart-space-companies-moon-mars/?src=A00220><strong>Investors</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>SpaceX continues to mark new milestones as a private company, and that has spurred investors' appetites for publicly traded space stocks, which have multiplied rapidly in recent years.\nThe ...</p>\n\n<a href=\"https://www.investors.com/news/space-stocks-upstart-space-companies-moon-mars/?src=A00220\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ASTR":"Astra Space","BA":"波音","NOC":"诺斯罗普格鲁曼","RDW":"Redwire Corp.","MNTS":"Momentus Inc.","VAQC":"Vector Acquisition Corporation II","LMT":"洛克希德马丁","PL":"Planet  Labs Pbc","SPCE":"维珍银河"},"source_url":"https://www.investors.com/news/space-stocks-upstart-space-companies-moon-mars/?src=A00220","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1128895961","content_text":"SpaceX continues to mark new milestones as a private company, and that has spurred investors' appetites for publicly traded space stocks, which have multiplied rapidly in recent years.\nThe proliferation of new space stocks has come as SPACshave taken over. Special purpose acquisition companies also known as \"blank check companies\" offer a way for private companies to go public without an IPO. Instead of selling stock, the private enterprise merges with a shell company that's already public. SPACs have become popular after years of being shunned by the financial community.\nAstra Space went publicon July 1 via Holicity(HOL),Momentus went public via Stable RoadCapital(SRAC) and Vector Acquisition(VACQ) took Rocket Lab public in August in a deal that values the space company at $4.1 billion.Redwire Space(RDW) is merged with Genesis Park(GNPK) to go public in September. Satellite imaging company Planet(PL) went public via SPAC on Dec. 8.\nVirgin Galactic's(SPCE) sister company, Virgin Orbit, is going public via a blank-check mergerwithNextGen Acquisition II(NGCA).\n\"After a wave of recent space de-SPACings, investors are now turning their focus toward execution, profitability and return on investment,\" Morgan Stanely analysts wrote in a note dated Dec. 8. \"The challenge facing investors is separating wheat from chaff and identifying companies that have not only discriminating technology, but also sustainable business models.\"\nMeanwhile, in the legacy space industry,Boeing(BA) is building its own space taxis as well as the most powerful rocket ever. NASA also is working with other established space stocks like Lockheed Martin(LMT) along with upstart space companies to return astronauts to the moon and Mars.\nHere's a look at key publicly traded space stocks as of Dec. 25:\nSpace Stocks ETFs\nOne option investors have is investing in an ETF. Procure Space ETF (UFO), a space-related exchange traded fund, launched back in April 2019. The fund includes holdings in space stocks like Boeing,Maxar(MAXR),Iridium Communications(IRDM),Intelsat(I) andAirbus(EADSY).\nCathie Wood's Ark Investment Management launched the ARK Space Exploration ETF (ARKX) earlier this year. The space-focused ETF includes Boeing and Amazon(AMZN). But it has exited its stake in Virgin Galactic.\nVirgin Galactic\nOn Oct. 28, 2019, Virgin Galactic stock became the first publicly traded commercial space tourism company after a reverse merger with Social Capital Hedosophia Holdings.\nThe company, which counts Boeing as an investor, successfully conducted its first fully crewed flight on July 11, sending founder Richard Branson into space. The flight not only means the company's billionaire founder beat Blue Origin's Jeff Bezos to space, but it's also crucial to the start of commercial service in 2022.\nBut the Federal Aviation Administration grounded the company's space plane in September and opened a probe into the flight for veering off its projected flight path during descent.  The FAA lifted the grounding on Sept. 29. On Oct. 14, the space company announced it woulddelay the start of commercial flights until the fourth quarter of 2022.\nIn addition to space tourism, Wall Street has noted Virgin Galactic's potential in hypersonic intercontinental travel.\nIn August 2020, Virgin Galactic signed a memorandum of understanding with Rolls-Royce to collaborate in designing and developing engine propulsion technology for Mach 3 commercial aircraft. Virgin Galactic entered into a Space Act Agreement with NASA in May to work on developing a sustainable high-Mach supersonic vehicle. The U.S. space agency has been working on high-Mach flight with its Supersonic X-59 test plane built by Lockheed.\nBoeing\nOne of the original space stocks, Boeing built the first stage of the Saturn V rocket that helped propel Apollo 11 astronauts to the moon in 1969. Now it's building theSpace Launch System rocket at the same facility as the Saturn V rocket in New Orleans.\nThe SLS is designed to be the most powerful rocket ever, taking astronauts and probes into deep space. But delays and costs overruns have plagued the NASA rocket. In January, NASA cut short a test of the core stage but was able to successfully complete the key hot fire test for the full duration in March. The rocket keeps facing delays due to Covid-19 and won't fly until 2022.\nBoeing also developed the Starliner capsule to ferry astronauts to and from the ISS. But the capsule failed to reach the correct orbit during the test flight in December 2019 and a potentially \"catastrophic\" software issue was discovered. Boeing planned to redo the test flight on July 30 but the launch has been delayed until 2022 as the company looks for the cause of a technical issue that emerged.\nIn October, NASA moved astronauts from a Starliner mission to a SpaceX Crew Dragon mission amid the delays.\nBoeing also builds satellites and manages the ISS for NASA.\nLockheed Martin\nLockheed also has a long history as one of the top space stocks. It built the solid propellant launch escape motor and the pitch control motor for the Apollo 11 spacecraft.\nNow Lockheed is developing the deep-space Orion spacecraft for the SLS rocket to carry astronauts into deep space, including to lunar orbit.\nLockheed also makes satellites and space probes for NASA. More recently, Lockheed built components for the Mars Perseverance rover, which landed in February, and the Mars InSight lander, which landed in November 2018.\nIn addition, its joint venture with Boeing, United Launch Alliance, makes rockets that provide launch services.\nIn December 2020, Lockheed announced it would buy engine maker Aerojet Rocketdynein an estimated $4.4 billion deal to boost its hypersonic weapons and space capabilities.\nAerojet's engines were used in the Apollo 11 mission and were on the Space Shuttle. The company is also providing the engines for Boeing's SLS rocket, ULA's Vulcan rocket upper stage and Northrop's OmegA rocket third stage.\nNorthrop Grumman\nNorthrop Grumman(NOC) expanded its scope as one of the leading space stocks after it bought rocket maker Orbital ATK in 2018.\nThe company is working on the OmegA heavy-lift rocket and received Air Force funding last year to help end the U.S. reliance on Russian engines used in the Atlas 5 rocket by ULA.\nNorthrop makes satellites as well and is developing the James Webb Space Telescope for NASA. But the deep-space telescope is behind schedule with Covid-19 further dragging on timing. NASA expects the telescope to launch on Dec. 25.\nNorthrop and Lockheed teamed up with Blue Origin on a lunar lander program for NASA. Butthey lost out to SpaceX.\nMaxar\nSmaller space stocks are leaving their mark on the new space race too. Maxar will build the first components ofNASA's Lunar Gatewayspace station.\nIt also builds communication and Earth observations satellites as well as robotic systems for use in space.\nIn addition, Maxar provides access to satellite imagery and map data.\nSpaceX\nInvestors' hopes for SpaceX have made it one of the most valuable pre-IPO companies in the world. An insider share sale in early October put its worth at$100 billion, according to a CNBC report. But Musk has no plans for it to go public...yet.\nAn IPO of the SpaceX Starlink satellite business reportedly could be in the works, perhaps in the next several years. SpaceX has launched more than 1,700 Starlink satellites for delivering space-based broadband connections, and beta testing is ongoing. In May, the company said more than 500,000 people have ordered or made a deposit for service.\nSpaceX's Falcon 9 rocket routinely carries payloads into space for NASA, the Pentagon as well as other governments and companies, while its Falcon Heavy has launched commercial and government payloads.\nSpaceX is now sending astronauts to the space station on regular trips via the Crew Dragon capsule. SpaceX is also developing the Starship for deep-space missions and space tourism.\nIn April, NASA awarded SpaceX $2.9 billion to further develop the Starship to land astronauts on the moon. Blue Origin and Dynetics have filed protests. In May, SpaceX launched and landed an uncrewed prototype safely, after prior high-altitude flights ended in explosions.\nBlue Origin\nJeff Bezos' Blue Origin is developing the New Glenn and New Shepard rockets as well as engines and the Blue Moon lunar lander. In addition to carrying payloads, Blue Origin also plans to take tourists into space and is developing its own constellation of satellites for internet service.\nBezos and his brother flew on New Shepard's first crewed flight on July 20. Blue Origin said that it has nearly $100 million in commercial sales for flights on its rocket. Two more commercial flights are expected this year. Star Trek actor William Shatner flew on Blue Origin's successful Oct. 13 mission. At 90, he became the oldest person in space.\nBezos said he's not sure how many flights will happen in 2022 but that \"demand is very, very high.\"","news_type":1},"isVote":1,"tweetType":1,"viewCount":111,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698456473,"gmtCreate":1640506984623,"gmtModify":1640506984989,"author":{"id":"3578047933589423","authorId":"3578047933589423","name":"PengsieX","avatar":"https://static.tigerbbs.com/ebe92821eba3b91a6431d698b66bbed5","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"200 or 3000 dollar stock... If there's a recession one way or another you'll be affected too. Don't spend money on stock","listText":"200 or 3000 dollar stock... If there's a recession one way or another you'll be affected too. Don't spend money on stock","text":"200 or 3000 dollar stock... If there's a recession one way or another you'll be affected too. Don't spend money on stock","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/698456473","repostId":"2193781141","repostType":4,"repost":{"id":"2193781141","pubTimestamp":1640485676,"share":"https://www.laohu8.com/m/news/2193781141?lang=&edition=full","pubTime":"2021-12-26 10:27","market":"us","language":"en","title":"2 Top Tech Stocks to Buy During a Recession","url":"https://stock-news.laohu8.com/highlight/detail?id=2193781141","media":"Motley Fool","summary":"Market crashes are inevitable, but they're the perfect time to buy great businesses at a discount.","content":"<p>We're days away from the end of 2021, and the <b>S&amp;P 500</b> has put on a master class in outperforming expectations. Even with its pullback in recent days, the broad market index has gained nearly 30% this year, more than double its long-term historical average.</p>\n<p>Yet that just means we're another day closer to the inevitable market correction. Just as night follows day, a stock market crash is inevitable because market declines are a natural part of the normal business and investment cycle. No <a href=\"https://laohu8.com/S/AONE.U\">one</a> can forecast exactly when it will strike, but smart investors realize it's best to prepare for the eventuality.</p>\n<p>For as long as people have been investing, stretching even as far back to the Dutch tulip mania in the 1600s, busts have followed booms. And what a boom we've enjoyed! Since the bottom of the Great Recession, the S&amp;P 500 has quadrupled in value.</p>\n<p>2020's pandemic-driven 34% drop in the stock indexes within the span of just a few weeks was the worst on record. But savvy investors don't have to worry. These events are not a problem when you're invested in the right companies. Being prepared for the worst and hoping for the best means when the next stock market crash or correction occurs, you'll want to have your money invested in stocks that will help lead the way forward. Here are two tech stocks you'll want to buy.</p>\n<h2>1. Apple</h2>\n<p>The burden that inflation is imposing on consumers also poses a threat to some of the biggest, best-run businesses, like <b>Apple</b> (NASDAQ:AAPL), which is currently benefiting from the smartphone upgrade cycle and the rollout of 5G network infrastructure. Any attempt by the Federal Reserve to raise interest rates to contain runaway inflation could cause an economic slowdown by making money more expensive to borrow. Stock valuations would also turn lower.</p>\n<p>That's not necessarily bad news for investors who might find Apple's $2.8 trillion valuation a bit rich to buy into at the moment. The stock trades at 30 times trailing earnings, or about double its typical multiple. A correction would bring Apple back into the realm of the attainable, even as its business continues jogging forward.</p>\n<p>Sales of the iPhone 13 are outpacing those of the iPhone 12 at the same time, but Apple reportedly warned suppliers that demand is waning as the calendar year progresses. It's not necessarily for a lack of consumer desire, but rather the global supply chain constraints that have made it difficult to find the product. Apple previously cut its iPhone production target by 10 million units from its original goal of 90 million.</p>\n<p>Analysts think many consumers may choose to forgo the iPhone 13 and wait for the next upgrade. Coupled with a market crash, that could put Apple stock at a very attractive entry point with pent-up demand for the next iteration of the iPhone.</p>\n<h2>2. Amazon</h2>\n<p>Few companies are as essential to the working of the U.S. economy as <b>Amazon</b>&nbsp;(NASDAQ:AMZN). It will account for 41.4% of all online spending in the U.S. this year, according to eMarketer estimates. At the same time, Amazon Web Services (AWS), its cloud infrastructure business, is on track to generate over $60 billion in annual revenue in 2021 based on its year-to-date performance. The company is responsible for thousands of web-based businesses and the federal government's ability to remain online, making Amazon crucial to a well-functioning economy.</p>\n<p>That won't change if the stock market collapses. Its share of U.S. retail e-commerce sales will be more than 50% larger than the shares of the next nine e-commerce companies combined. Amazon's piece of the online market is nearly six times more than <b>Walmart</b>'s second-place share at just 7.2%, and 10 times greater than third-place <b><a href=\"https://laohu8.com/S/EBAY\">eBay</a></b>. E-commerce data tracker Edge by Ascential expects Amazon will see $26.7 billion just in online grocery sales five from now years, or nearly double its current amount.</p>\n<p>Amid rising prices and supply chain woes, Amazon has become a lifeline for many, and that will continue long after any financial restructuring. The stock gained 76% during the first year of the pandemic and took a breather during the reopening of the economy. Amazon shares have been relatively flat all year long. A correction would allow investors to buy a tech stock at a more reasonable valuation even as its crucial role only gets reinforced.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Top Tech Stocks to Buy During a Recession</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Top Tech Stocks to Buy During a Recession\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-26 10:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/24/2-top-tech-stocks-to-buy-during-a-recession/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>We're days away from the end of 2021, and the S&P 500 has put on a master class in outperforming expectations. Even with its pullback in recent days, the broad market index has gained nearly 30% ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/24/2-top-tech-stocks-to-buy-during-a-recession/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4524":"宅经济概念","BK4535":"淡马锡持仓","BK4538":"云计算","BK4527":"明星科技股","BK4559":"巴菲特持仓","BK4501":"段永平概念","AAPL":"苹果","BK4550":"红杉资本持仓","BK4503":"景林资产持仓","BK4122":"互联网与直销零售","BK4551":"寇图资本持仓","BK4561":"索罗斯持仓","BK4505":"高瓴资本持仓","BK4548":"巴美列捷福持仓","BK4170":"电脑硬件、储存设备及电脑周边","AMZN":"亚马逊","BK4554":"元宇宙及AR概念","BK4532":"文艺复兴科技持仓","BK4515":"5G概念","BK4553":"喜马拉雅资本持仓","BK4507":"流媒体概念","BK4534":"瑞士信贷持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4566":"资本集团"},"source_url":"https://www.fool.com/investing/2021/12/24/2-top-tech-stocks-to-buy-during-a-recession/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2193781141","content_text":"We're days away from the end of 2021, and the S&P 500 has put on a master class in outperforming expectations. Even with its pullback in recent days, the broad market index has gained nearly 30% this year, more than double its long-term historical average.\nYet that just means we're another day closer to the inevitable market correction. Just as night follows day, a stock market crash is inevitable because market declines are a natural part of the normal business and investment cycle. No one can forecast exactly when it will strike, but smart investors realize it's best to prepare for the eventuality.\nFor as long as people have been investing, stretching even as far back to the Dutch tulip mania in the 1600s, busts have followed booms. And what a boom we've enjoyed! Since the bottom of the Great Recession, the S&P 500 has quadrupled in value.\n2020's pandemic-driven 34% drop in the stock indexes within the span of just a few weeks was the worst on record. But savvy investors don't have to worry. These events are not a problem when you're invested in the right companies. Being prepared for the worst and hoping for the best means when the next stock market crash or correction occurs, you'll want to have your money invested in stocks that will help lead the way forward. Here are two tech stocks you'll want to buy.\n1. Apple\nThe burden that inflation is imposing on consumers also poses a threat to some of the biggest, best-run businesses, like Apple (NASDAQ:AAPL), which is currently benefiting from the smartphone upgrade cycle and the rollout of 5G network infrastructure. Any attempt by the Federal Reserve to raise interest rates to contain runaway inflation could cause an economic slowdown by making money more expensive to borrow. Stock valuations would also turn lower.\nThat's not necessarily bad news for investors who might find Apple's $2.8 trillion valuation a bit rich to buy into at the moment. The stock trades at 30 times trailing earnings, or about double its typical multiple. A correction would bring Apple back into the realm of the attainable, even as its business continues jogging forward.\nSales of the iPhone 13 are outpacing those of the iPhone 12 at the same time, but Apple reportedly warned suppliers that demand is waning as the calendar year progresses. It's not necessarily for a lack of consumer desire, but rather the global supply chain constraints that have made it difficult to find the product. Apple previously cut its iPhone production target by 10 million units from its original goal of 90 million.\nAnalysts think many consumers may choose to forgo the iPhone 13 and wait for the next upgrade. Coupled with a market crash, that could put Apple stock at a very attractive entry point with pent-up demand for the next iteration of the iPhone.\n2. Amazon\nFew companies are as essential to the working of the U.S. economy as Amazon (NASDAQ:AMZN). It will account for 41.4% of all online spending in the U.S. this year, according to eMarketer estimates. At the same time, Amazon Web Services (AWS), its cloud infrastructure business, is on track to generate over $60 billion in annual revenue in 2021 based on its year-to-date performance. The company is responsible for thousands of web-based businesses and the federal government's ability to remain online, making Amazon crucial to a well-functioning economy.\nThat won't change if the stock market collapses. Its share of U.S. retail e-commerce sales will be more than 50% larger than the shares of the next nine e-commerce companies combined. Amazon's piece of the online market is nearly six times more than Walmart's second-place share at just 7.2%, and 10 times greater than third-place eBay. E-commerce data tracker Edge by Ascential expects Amazon will see $26.7 billion just in online grocery sales five from now years, or nearly double its current amount.\nAmid rising prices and supply chain woes, Amazon has become a lifeline for many, and that will continue long after any financial restructuring. The stock gained 76% during the first year of the pandemic and took a breather during the reopening of the economy. Amazon shares have been relatively flat all year long. A correction would allow investors to buy a tech stock at a more reasonable valuation even as its crucial role only gets reinforced.","news_type":1},"isVote":1,"tweetType":1,"viewCount":231,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698505482,"gmtCreate":1640432661839,"gmtModify":1640433182799,"author":{"id":"3578047933589423","authorId":"3578047933589423","name":"PengsieX","avatar":"https://static.tigerbbs.com/ebe92821eba3b91a6431d698b66bbed5","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"Don't blindly follow Warren cos he has the major shareholding whereas you are just a tiny retail investor","listText":"Don't blindly follow Warren cos he has the major shareholding whereas you are just a tiny retail investor","text":"Don't blindly follow Warren cos he has the major shareholding whereas you are just a tiny retail investor","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":10,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/698505482","repostId":"2193917872","repostType":4,"repost":{"id":"2193917872","pubTimestamp":1640398248,"share":"https://www.laohu8.com/m/news/2193917872?lang=&edition=full","pubTime":"2021-12-25 10:10","market":"us","language":"en","title":"3 Best Buffett Stocks to Buy for the Long Haul","url":"https://stock-news.laohu8.com/highlight/detail?id=2193917872","media":"Motley Fool","summary":"Each of these three big pharma stocks are featured in Berkshire Hathaway's massive portfolio.","content":"<p>Since Warren Buffett took full control of <b>Berkshire Hathaway</b> in 1965, it became a diversified holding company with investments in publicly traded companies totaling nearly $345 billion at the time of writing.</p>\n<p>The Oracle of Omaha's reputation of buying the highest quality businesses means that many individual investors could also benefit from adding these stocks to their portfolios. Here are three healthcare stocks that Buffett owns, which you may also want to consider buying and holding for the long run.</p>\n<h2>1. Johnson &amp; Johnson</h2>\n<p>The first pharma stock within Berkshire's portfolio to contemplate purchasing is <b>Johnson &amp; Johnson</b> (NYSE:JNJ). While the stock is one of Buffett's smallest holdings, valued at just under $55 million, this doesn't take away from its 59 consecutive years of dividend increases that make the stock a Dividend King.</p>\n<p>J&amp;J will be spinning off its slower-growing and less profitable consumer health segment in the next 18 to 24 months, which should allow the company to focus on its faster-growing, more profitable pharmaceutical segment.</p>\n<p>J&amp;J has a strong existing drug portfolio, which should be able to make up for the upcoming 2025 to 2026 patent expirations for its top-selling drug known, Stelara. Year to date, the immunology drug made up just 9.9% of J&amp;J's $69 billion in net sales.</p>\n<p>These drugs include the immunology blockbuster Tremfya, which received its first of three U.S. Food and Drug Administration (FDA) approvals to date in July 2017. Another drug that was recently approved by the FDA was the oncology blockbuster called Darzalex, which received its first of nine FDA approvals to date in November 2015. These two drugs have grown their year-to-date revenue at high-40% clips year over year and should remain under patent most of this decade.</p>\n<p>J&amp;J's enviable existing drug portfolio and its nearly four dozen indications in late-stage clinical trials explain why analysts anticipate that the stock will deliver 8% annual non-GAAP (adjusted) earnings per share (EPS) growth over the next five years.</p>\n<p>Income investors can scoop up J&amp;J's 2.5% dividend yield at a forward P/E ratio of just 16.2 times, which makes the steady healthcare stock a great buy for the long term.</p>\n<h2>2. Bristol Myers Squibb</h2>\n<p>Another Buffett stock that could be a great fit in your portfolio is <b>Bristol Myers Squibb</b> (NYSE:BMY). Berkshire's Bristol Myers Squibb stake totals nearly $1.4 billion, making it one of the largest healthcare holdings in Berkshire's portfolio.</p>\n<p>Bristol Myers Squibb's oncology blockbusters Revlimid and Opdivo and the anticoagulant blockbuster co-owned with <b>Pfizer</b> (NYSE:PFE) named Eliquis each face patent expirations later this decade. While looming patent expirations on three drugs that account for approximately two-thirds of your company's total revenue sounds frightening, this is nothing new; it's just the nature of Bristol Myers Squibb's industry.</p>\n<p>What matters most is that a company is proactive in developing and acquiring its next generation of blockbuster drugs to absorb key patent expirations. With more than 50 compounds in over 40 different disease areas currently in development at Bristol Myers Squibb, this is exactly what the company has been doing for years now.</p>\n<p>As a result, analysts are projecting that Bristol Myers Squibb will be able to generate 6% annual earnings growth through the next five years.</p>\n<p>Yield-hungry investors can buy Bristol Myers Squibb's market-crushing 3.5% yield at a ridiculously cheap forward P/E ratio of 7.9, which is what makes the stock a buy for those looking to hedge against inflation.</p>\n<h2>3. AbbVie</h2>\n<p>Finally, a Buffett stock that'd also be a good fit for income investors is <b>AbbVie</b> (NYSE:ABBV). Berkshire currently holds about $1.9 billion worth of AbbVie stock.</p>\n<p>It's well known at this point that the biopharmaceutical's top-selling drug in the world, Humira, will be facing intense biosimilar competition in the U.S. beginning in 2023. Even though the immunology drug's U.S. sales made up 31% of AbbVie's $41.24 billion total year-to-date sales, the company's pipeline should be able to stabilize and grow its net revenue beyond 2023.</p>\n<p>AbbVie has 54 compounds in various stages of clinical trials, which is why analysts are forecasting that the stock will grow its adjusted EPS 4.5% annually in the next five years.</p>\n<p>AbbVie's massive 4.4% dividend yield can be picked up at a forward P/E ratio of only 9.3.&nbsp;This is an attractive valuation for a stock with the ability to fight off inflation with healthy dividend hikes.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Best Buffett Stocks to Buy for the Long Haul</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Best Buffett Stocks to Buy for the Long Haul\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-25 10:10 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/24/3-best-buffett-stocks-to-buy-for-the-long-haul/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Since Warren Buffett took full control of Berkshire Hathaway in 1965, it became a diversified holding company with investments in publicly traded companies totaling nearly $345 billion at the time of ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/24/3-best-buffett-stocks-to-buy-for-the-long-haul/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ABBV":"艾伯维公司","BMY":"施贵宝","JNJ":"强生"},"source_url":"https://www.fool.com/investing/2021/12/24/3-best-buffett-stocks-to-buy-for-the-long-haul/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2193917872","content_text":"Since Warren Buffett took full control of Berkshire Hathaway in 1965, it became a diversified holding company with investments in publicly traded companies totaling nearly $345 billion at the time of writing.\nThe Oracle of Omaha's reputation of buying the highest quality businesses means that many individual investors could also benefit from adding these stocks to their portfolios. Here are three healthcare stocks that Buffett owns, which you may also want to consider buying and holding for the long run.\n1. Johnson & Johnson\nThe first pharma stock within Berkshire's portfolio to contemplate purchasing is Johnson & Johnson (NYSE:JNJ). While the stock is one of Buffett's smallest holdings, valued at just under $55 million, this doesn't take away from its 59 consecutive years of dividend increases that make the stock a Dividend King.\nJ&J will be spinning off its slower-growing and less profitable consumer health segment in the next 18 to 24 months, which should allow the company to focus on its faster-growing, more profitable pharmaceutical segment.\nJ&J has a strong existing drug portfolio, which should be able to make up for the upcoming 2025 to 2026 patent expirations for its top-selling drug known, Stelara. Year to date, the immunology drug made up just 9.9% of J&J's $69 billion in net sales.\nThese drugs include the immunology blockbuster Tremfya, which received its first of three U.S. Food and Drug Administration (FDA) approvals to date in July 2017. Another drug that was recently approved by the FDA was the oncology blockbuster called Darzalex, which received its first of nine FDA approvals to date in November 2015. These two drugs have grown their year-to-date revenue at high-40% clips year over year and should remain under patent most of this decade.\nJ&J's enviable existing drug portfolio and its nearly four dozen indications in late-stage clinical trials explain why analysts anticipate that the stock will deliver 8% annual non-GAAP (adjusted) earnings per share (EPS) growth over the next five years.\nIncome investors can scoop up J&J's 2.5% dividend yield at a forward P/E ratio of just 16.2 times, which makes the steady healthcare stock a great buy for the long term.\n2. Bristol Myers Squibb\nAnother Buffett stock that could be a great fit in your portfolio is Bristol Myers Squibb (NYSE:BMY). Berkshire's Bristol Myers Squibb stake totals nearly $1.4 billion, making it one of the largest healthcare holdings in Berkshire's portfolio.\nBristol Myers Squibb's oncology blockbusters Revlimid and Opdivo and the anticoagulant blockbuster co-owned with Pfizer (NYSE:PFE) named Eliquis each face patent expirations later this decade. While looming patent expirations on three drugs that account for approximately two-thirds of your company's total revenue sounds frightening, this is nothing new; it's just the nature of Bristol Myers Squibb's industry.\nWhat matters most is that a company is proactive in developing and acquiring its next generation of blockbuster drugs to absorb key patent expirations. With more than 50 compounds in over 40 different disease areas currently in development at Bristol Myers Squibb, this is exactly what the company has been doing for years now.\nAs a result, analysts are projecting that Bristol Myers Squibb will be able to generate 6% annual earnings growth through the next five years.\nYield-hungry investors can buy Bristol Myers Squibb's market-crushing 3.5% yield at a ridiculously cheap forward P/E ratio of 7.9, which is what makes the stock a buy for those looking to hedge against inflation.\n3. AbbVie\nFinally, a Buffett stock that'd also be a good fit for income investors is AbbVie (NYSE:ABBV). Berkshire currently holds about $1.9 billion worth of AbbVie stock.\nIt's well known at this point that the biopharmaceutical's top-selling drug in the world, Humira, will be facing intense biosimilar competition in the U.S. beginning in 2023. Even though the immunology drug's U.S. sales made up 31% of AbbVie's $41.24 billion total year-to-date sales, the company's pipeline should be able to stabilize and grow its net revenue beyond 2023.\nAbbVie has 54 compounds in various stages of clinical trials, which is why analysts are forecasting that the stock will grow its adjusted EPS 4.5% annually in the next five years.\nAbbVie's massive 4.4% dividend yield can be picked up at a forward P/E ratio of only 9.3. This is an attractive valuation for a stock with the ability to fight off inflation with healthy dividend hikes.","news_type":1},"isVote":1,"tweetType":1,"viewCount":297,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698823270,"gmtCreate":1640344147374,"gmtModify":1640344147742,"author":{"id":"3578047933589423","authorId":"3578047933589423","name":"PengsieX","avatar":"https://static.tigerbbs.com/ebe92821eba3b91a6431d698b66bbed5","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"What about retail investors","listText":"What about retail investors","text":"What about retail investors","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698823270","repostId":"1117254761","repostType":4,"repost":{"id":"1117254761","pubTimestamp":1640328069,"share":"https://www.laohu8.com/m/news/1117254761?lang=&edition=full","pubTime":"2021-12-24 14:41","market":"us","language":"en","title":"Didi’s Early Investors Get Window to Exit After IPO Disaster","url":"https://stock-news.laohu8.com/highlight/detail?id=1117254761","media":"Bloomberg","summary":"The end of a lock-up period after a new listing is often a triumphant time when pre-IPO investors ca","content":"<p>The end of a lock-up period after a new listing is often a triumphant time when pre-IPO investors can cash out and book profits. ForDidi Global Inc., whose shares have lost more than half of their value since going public, it’s a different story.</p>\n<p>It’s lost $40 billion in market value since the June&nbsp;IPO-- a stunning blow for what was expected to be one of the largest and most successful deals in 2021.</p>\n<p>Certain company directors and executives that hold shares as well as firms that invested in Didi ahead of the listing have been spectators to the stock’s collapse, restricted from selling for a customary 180-day period after its public sale. Come Monday when that lock-up ends, they have a decision to make: sell now -- potentially for a loss -- or wait months for more clarity on Didi’s plans to list in Hong Kong.</p>\n<p>“Once Didi lists in Hong Kong, the dark cloud of uncertainty will largely dissipate, which would be positive for the shares,” Jason Hsu, founder and chief investment officer of&nbsp;Rayliant Global Advisors&nbsp;said.</p>\n<p>Didi shares closed down 0.5% in New York on Thursday to a record low of $5.60.</p>\n<p>Uber Technologies Inc., which owned 11.9% of the company right after the IPO in June, isn’t planning to sell immediately upon the expiration of the lock-up, according to a company spokesperson. Chances are other early investors also stay on the sidelines, according to analysts.</p>\n<p>“Optically, it would be quite a bad look if insiders started reducing holdings materially with the plan for a delisting in the US and offering in HK in the new year so I wouldn’t expect too many to be selling just yet,” according to Matthew Kanterman, an analyst at Bloomberg Intelligence. “Insiders selling a significant number of shares given all of these uncertainties and risks would be a very bad message to the market.”</p>\n<p>The lockup applies to company directors, executive officers and holders that own at least 90% of total share capital. SoftBank Group Corp. and&nbsp;Tencent Holdings Ltd.were listed as holders as of June, while Didi’s directors and executives collectively held about a 10% stake in the company, according to the&nbsp;IPO prospectus.</p>\n<p>Didi, SoftBank and Tencent didn’t immediately respond to requests for comment.</p>\n<p>Didi’s migration to Hong Kong may provide investors with an alternative, albeit a protracted one. Bloomberg News reported earlier this month the company had begun setting the groundwork to withdraw from U.S. and was aiming to file the paperwork to start trading in Hong Kong around March. Based on the typical process there, it could target a summer listing.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Didi’s Early Investors Get Window to Exit After IPO Disaster</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDidi’s Early Investors Get Window to Exit After IPO Disaster\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-24 14:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-12-23/didi-s-early-investors-get-window-to-exit-after-disastrous-ipo><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The end of a lock-up period after a new listing is often a triumphant time when pre-IPO investors can cash out and book profits. ForDidi Global Inc., whose shares have lost more than half of their ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-12-23/didi-s-early-investors-get-window-to-exit-after-disastrous-ipo\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DIDI":"滴滴(已退市)"},"source_url":"https://www.bloomberg.com/news/articles/2021-12-23/didi-s-early-investors-get-window-to-exit-after-disastrous-ipo","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1117254761","content_text":"The end of a lock-up period after a new listing is often a triumphant time when pre-IPO investors can cash out and book profits. ForDidi Global Inc., whose shares have lost more than half of their value since going public, it’s a different story.\nIt’s lost $40 billion in market value since the June IPO-- a stunning blow for what was expected to be one of the largest and most successful deals in 2021.\nCertain company directors and executives that hold shares as well as firms that invested in Didi ahead of the listing have been spectators to the stock’s collapse, restricted from selling for a customary 180-day period after its public sale. Come Monday when that lock-up ends, they have a decision to make: sell now -- potentially for a loss -- or wait months for more clarity on Didi’s plans to list in Hong Kong.\n“Once Didi lists in Hong Kong, the dark cloud of uncertainty will largely dissipate, which would be positive for the shares,” Jason Hsu, founder and chief investment officer of Rayliant Global Advisors said.\nDidi shares closed down 0.5% in New York on Thursday to a record low of $5.60.\nUber Technologies Inc., which owned 11.9% of the company right after the IPO in June, isn’t planning to sell immediately upon the expiration of the lock-up, according to a company spokesperson. Chances are other early investors also stay on the sidelines, according to analysts.\n“Optically, it would be quite a bad look if insiders started reducing holdings materially with the plan for a delisting in the US and offering in HK in the new year so I wouldn’t expect too many to be selling just yet,” according to Matthew Kanterman, an analyst at Bloomberg Intelligence. “Insiders selling a significant number of shares given all of these uncertainties and risks would be a very bad message to the market.”\nThe lockup applies to company directors, executive officers and holders that own at least 90% of total share capital. SoftBank Group Corp. and Tencent Holdings Ltd.were listed as holders as of June, while Didi’s directors and executives collectively held about a 10% stake in the company, according to the IPO prospectus.\nDidi, SoftBank and Tencent didn’t immediately respond to requests for comment.\nDidi’s migration to Hong Kong may provide investors with an alternative, albeit a protracted one. Bloomberg News reported earlier this month the company had begun setting the groundwork to withdraw from U.S. and was aiming to file the paperwork to start trading in Hong Kong around March. Based on the typical process there, it could target a summer listing.","news_type":1},"isVote":1,"tweetType":1,"viewCount":129,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698823097,"gmtCreate":1640344023224,"gmtModify":1640344080198,"author":{"id":"3578047933589423","authorId":"3578047933589423","name":"PengsieX","avatar":"https://static.tigerbbs.com/ebe92821eba3b91a6431d698b66bbed5","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"There can only be one...&nbsp;","listText":"There can only be one...&nbsp;","text":"There can only be one...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698823097","repostId":"1175608113","repostType":4,"repost":{"id":"1175608113","pubTimestamp":1640342686,"share":"https://www.laohu8.com/m/news/1175608113?lang=&edition=full","pubTime":"2021-12-24 18:44","market":"us","language":"en","title":"Is Amazon Stock A Buy Right Now As Epic Battle With Walmart Escalates","url":"https://stock-news.laohu8.com/highlight/detail?id=1175608113","media":"Investors","summary":"Amazon(AMZN) plans to build its first large-format retail stores, making a new foray into physical o","content":"<p><b>Amazon</b>(AMZN) plans to build its first large-format retail stores, making a new foray into physical outlets and stepping up its battle against&nbsp;<b>Walmart</b>(WMT). Is Amazon stock a buy?</p>\n<p>Amazon's 30,000-square-foot stores, which will&nbsp;debut in California and Ohio, are less than one-third the size of Walmart's conventional outlets. They're about one-sixth the size of Walmart Supercenter stores.</p>\n<p>Walmart, the behemoth of brick-and-mortar discount stores, is dueling Amazon, the giant of online shopping, in a battle over the future of retail, e-commerce and grocery shopping.</p>\n<p>Much work remains for either company to win theAmazon vs. Walmart battle. Walmart needs to expand online operations while also managing 11,500 stores across 28 countries, of which 4,743 are in the U.S. It's in the process of redesigning 1,000 stores by the end of 2021. Its goal is to create a more streamlined and faster shopping experience for customers.</p>\n<p>At the same time, Amazon must continue its aggressive rollout of warehouse distribution centers and figure out its strategy for building physical stores.</p>\n<p>Amazon Is Making Critical Investments</p>\n<p>\"The key question from here is when/if does the current investment cycle drive evidence of share gains and margin leverage,\" RBC Capital Markets analyst Brad Erickson said in a note. \"Only time will tell, but in our view AMZN stock is making critical investments as consumers increasingly demand faster shipping which should at least maintain share gains while, importantly, growing gross profit dollars.\"</p>\n<p>Amazon reported&nbsp;third-quarter results&nbsp;on Oct. 28. Adjusted earnings fell 51% from the year-ago period to $6.12 a share. Analysts expected $8.92 a share. Revenue climbed 15% to $110.8 billion, below expectations of $111.6 billion.</p>\n<p>For its fourth quarter, Amazon forecast revenue in the range of $130 billion to $140 billion. That missed analyst estimates for $142 billion. Amazon forecast earnings before interest and taxes, called EBIT, of $1.5 billion, versus estimates of $8.1 billion.</p>\n<p>The company's cloud-computing unit, Amazon Web Services, reported revenue growth of 39% to $11.6 billion. That topped estimates for 35% cloud-computing growth.</p>\n<p>Cowen analyst John Blackledge recently raised his price target on Amazon stock to 4,500, from 4,300. He listed Amazon as one of the \"best ideas\" for 2022, in the mega-cap category.</p>\n<p><b>Amazon Introduces Numerous New Gadgets</b></p>\n<p>On Sept. 28, Amazon introduced aplethora of consumer electronics gadgets, including smart displays and a home robot, at a fall product launch event.</p>\n<p>The Seattle-based e-commerce giant unveiled several devices that leverage its Alexa voice assistant technology. They include theEcho Show 15smart display, which is designed to keep families organized, connected and entertained.</p>\n<p>Another Alexa-enabled device is Amazon's first robot, which is named&nbsp;Astro. The robot will act as a security guard, companion and mobile smart display. It brings together new advancements in artificial intelligence, computer vision, sensor technology, and voice and edge computing, the company said.</p>\n<p>Earlier this month, Amazon moved deeper into the television market with an&nbsp;all-new lineup of devices&nbsp;and its first Amazon-branded 4K smart TVs. The Amazon TV products go on sale in October. Amazon also introduced a 4K version of its Fire TV stick.</p>\n<p><b>Plenty Of Growth Opportunities</b></p>\n<p>Amazon entered 2021 with plenty of big growth opportunities. This included plans to expand its virtual health care program across the U.S. It is also expanding its prescription drug business.</p>\n<p>On March 17, Amazon announced that its telehealth pilot program, called Amazon Care, would expand to all of its U.S. employees and their families as well as other firms this summer. The program first launched at its Seattle headquarters 18 months ago.</p>\n<p>If Amazon can deliver more efficient health care services, the potential is enormous for fueling its growth engine — and by extension Amazon stock. Health care now comprises nearly a fifth of the U.S. economy.</p>\n<p>Amazon said the program enables workers to connect with medical professionals via chat or video conference, and connect patients with medical professionals. In addition, Amazon Care can dispatch a medical professional to a patient's home for additional care.</p>\n<p>Analysts at Jefferies give Amazon a buy rating and price target or 4,000.</p>\n<p>\"We believe low expectations following two consecutive guide-downs better positions AMZN for upside in the core retail business,\" according to a Jefferies report.</p>\n<p>\"We also see attractive growth at AWS and advertising, AMZN's two highest margin businesses, serving to more than offset near-term cost headwinds from labor shortages and supply chain disruption,\" it said.</p>\n<p><b>Tapping The Market For Prescription Drugs</b></p>\n<p>In addition, Amazon is tapping into the $350 billion market for prescription drugs. The company fired a big shot across the bow of drugstores and prescription drug wholesalers late last year when it&nbsp;launched Amazon Pharmacy. The new unit will offer Amazon Prime members discounts of up to 80% on generic drugs and 40% on brand medications.</p>\n<p>On May 26, Amazon announced it is acquiring&nbsp;iconic film studio Metro-Goldwyn-Mayer&nbsp;for $8.45 billion, looking broadly expand its position in streaming video and increase the value of its Prime rewards program. The acquisition is Amazon's largest since buying Whole Foods for $13.7 billion in 2017.</p>\n<p>To get Amazon Prime, users pay an annual or monthly fee for the service and receive multiple perks. This includes free access to Amazon Video and Amazon Music. Amazon has invested billions of dollars in its film and TV operations as well as live sports.</p>\n<p>Another growth vehicle for Amazon in 2021 is advertising.&nbsp;When looking for a product, about half of U.S. adults start their search with Amazon. More searches draw more advertisers.&nbsp;And as Covid-19 has caused more consumers to shop online that will keep Amazon's ad growth humming.</p>","source":"lsy1610449120050","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Amazon Stock A Buy Right Now As Epic Battle With Walmart Escalates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Amazon Stock A Buy Right Now As Epic Battle With Walmart Escalates\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-24 18:44 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.investors.com/news/technology/amazon-stock-buy-now/?src=A00220><strong>Investors</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Amazon(AMZN) plans to build its first large-format retail stores, making a new foray into physical outlets and stepping up its battle against Walmart(WMT). Is Amazon stock a buy?\nAmazon's 30,000-...</p>\n\n<a href=\"https://www.investors.com/news/technology/amazon-stock-buy-now/?src=A00220\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"WMT":"沃尔玛","AMZN":"亚马逊"},"source_url":"https://www.investors.com/news/technology/amazon-stock-buy-now/?src=A00220","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1175608113","content_text":"Amazon(AMZN) plans to build its first large-format retail stores, making a new foray into physical outlets and stepping up its battle against Walmart(WMT). Is Amazon stock a buy?\nAmazon's 30,000-square-foot stores, which will debut in California and Ohio, are less than one-third the size of Walmart's conventional outlets. They're about one-sixth the size of Walmart Supercenter stores.\nWalmart, the behemoth of brick-and-mortar discount stores, is dueling Amazon, the giant of online shopping, in a battle over the future of retail, e-commerce and grocery shopping.\nMuch work remains for either company to win theAmazon vs. Walmart battle. Walmart needs to expand online operations while also managing 11,500 stores across 28 countries, of which 4,743 are in the U.S. It's in the process of redesigning 1,000 stores by the end of 2021. Its goal is to create a more streamlined and faster shopping experience for customers.\nAt the same time, Amazon must continue its aggressive rollout of warehouse distribution centers and figure out its strategy for building physical stores.\nAmazon Is Making Critical Investments\n\"The key question from here is when/if does the current investment cycle drive evidence of share gains and margin leverage,\" RBC Capital Markets analyst Brad Erickson said in a note. \"Only time will tell, but in our view AMZN stock is making critical investments as consumers increasingly demand faster shipping which should at least maintain share gains while, importantly, growing gross profit dollars.\"\nAmazon reported third-quarter results on Oct. 28. Adjusted earnings fell 51% from the year-ago period to $6.12 a share. Analysts expected $8.92 a share. Revenue climbed 15% to $110.8 billion, below expectations of $111.6 billion.\nFor its fourth quarter, Amazon forecast revenue in the range of $130 billion to $140 billion. That missed analyst estimates for $142 billion. Amazon forecast earnings before interest and taxes, called EBIT, of $1.5 billion, versus estimates of $8.1 billion.\nThe company's cloud-computing unit, Amazon Web Services, reported revenue growth of 39% to $11.6 billion. That topped estimates for 35% cloud-computing growth.\nCowen analyst John Blackledge recently raised his price target on Amazon stock to 4,500, from 4,300. He listed Amazon as one of the \"best ideas\" for 2022, in the mega-cap category.\nAmazon Introduces Numerous New Gadgets\nOn Sept. 28, Amazon introduced aplethora of consumer electronics gadgets, including smart displays and a home robot, at a fall product launch event.\nThe Seattle-based e-commerce giant unveiled several devices that leverage its Alexa voice assistant technology. They include theEcho Show 15smart display, which is designed to keep families organized, connected and entertained.\nAnother Alexa-enabled device is Amazon's first robot, which is named Astro. The robot will act as a security guard, companion and mobile smart display. It brings together new advancements in artificial intelligence, computer vision, sensor technology, and voice and edge computing, the company said.\nEarlier this month, Amazon moved deeper into the television market with an all-new lineup of devices and its first Amazon-branded 4K smart TVs. The Amazon TV products go on sale in October. Amazon also introduced a 4K version of its Fire TV stick.\nPlenty Of Growth Opportunities\nAmazon entered 2021 with plenty of big growth opportunities. This included plans to expand its virtual health care program across the U.S. It is also expanding its prescription drug business.\nOn March 17, Amazon announced that its telehealth pilot program, called Amazon Care, would expand to all of its U.S. employees and their families as well as other firms this summer. The program first launched at its Seattle headquarters 18 months ago.\nIf Amazon can deliver more efficient health care services, the potential is enormous for fueling its growth engine — and by extension Amazon stock. Health care now comprises nearly a fifth of the U.S. economy.\nAmazon said the program enables workers to connect with medical professionals via chat or video conference, and connect patients with medical professionals. In addition, Amazon Care can dispatch a medical professional to a patient's home for additional care.\nAnalysts at Jefferies give Amazon a buy rating and price target or 4,000.\n\"We believe low expectations following two consecutive guide-downs better positions AMZN for upside in the core retail business,\" according to a Jefferies report.\n\"We also see attractive growth at AWS and advertising, AMZN's two highest margin businesses, serving to more than offset near-term cost headwinds from labor shortages and supply chain disruption,\" it said.\nTapping The Market For Prescription Drugs\nIn addition, Amazon is tapping into the $350 billion market for prescription drugs. The company fired a big shot across the bow of drugstores and prescription drug wholesalers late last year when it launched Amazon Pharmacy. The new unit will offer Amazon Prime members discounts of up to 80% on generic drugs and 40% on brand medications.\nOn May 26, Amazon announced it is acquiring iconic film studio Metro-Goldwyn-Mayer for $8.45 billion, looking broadly expand its position in streaming video and increase the value of its Prime rewards program. The acquisition is Amazon's largest since buying Whole Foods for $13.7 billion in 2017.\nTo get Amazon Prime, users pay an annual or monthly fee for the service and receive multiple perks. This includes free access to Amazon Video and Amazon Music. Amazon has invested billions of dollars in its film and TV operations as well as live sports.\nAnother growth vehicle for Amazon in 2021 is advertising. When looking for a product, about half of U.S. adults start their search with Amazon. More searches draw more advertisers. And as Covid-19 has caused more consumers to shop online that will keep Amazon's ad growth humming.","news_type":1},"isVote":1,"tweetType":1,"viewCount":87,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691245877,"gmtCreate":1640216018508,"gmtModify":1640216018874,"author":{"id":"3578047933589423","authorId":"3578047933589423","name":"PengsieX","avatar":"https://static.tigerbbs.com/ebe92821eba3b91a6431d698b66bbed5","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"Convenience could be a dangerous thing&nbsp;","listText":"Convenience could be a dangerous thing&nbsp;","text":"Convenience could be a dangerous thing","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/691245877","repostId":"1131862374","repostType":4,"repost":{"id":"1131862374","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1640213195,"share":"https://www.laohu8.com/m/news/1131862374?lang=&edition=full","pubTime":"2021-12-23 06:46","market":"us","language":"en","title":"U.S. authorizes Pfizer oral COVID-19 treatment, first for at-home use","url":"https://stock-news.laohu8.com/highlight/detail?id=1131862374","media":"Reuters","summary":"Dec 22 (Reuters) - The United States on Wednesday authorized Pfizer Inc's antiviral COVID-19 pill fo","content":"<p>Dec 22 (Reuters) - The United States on Wednesday authorized Pfizer Inc's&nbsp;antiviral COVID-19 pill for at-risk people aged 12 and above, making it the first oral treatment and which can be taken at home, providing a potentially important tool in the fight against the fast-spreading&nbsp;Omicron variant.</p>\n<p>Pfizer's antiviral regimen, Paxlovid, was nearly 90% effective in preventing hospitalizations and deaths in patients at high risk of severe illness, according to data from the company's clinical trial. Recent lab data suggests the drug retains its effectiveness against Omicron, Pfizer said.</p>\n<p>Pfizer raised its 2022 production projections to 120 million courses of treatment from 80 million and said it was ready to start immediate delivery in the United States. The treatment's two-drug regimen includes a new medicine and a second older antiviral called ritonavir.</p>\n<p>\"Paxlovid's approval is a major milestone that marks another step towards making COVID-19 a much more manageable infection,\" said Amesh Adalja, a senior scholar at the Johns Hopkins Institute for Health Security.</p>\n<p>\"There are two key issues, however, that remain: It will be scarce in the coming weeks and its optimal use requires prompt diagnosis, which can be difficult with the continual testing problems that plague us,\" Adalja added.</p>\n<p>Pfizer has said it has 180,000 treatment courses ready to ship this year. The U.S. government's contract for 10 million courses of the drug is priced at $530 per course.</p>\n<p>The Food and Drug Administration's decision to issue emergency authorization for the treatment comes as the U.S. combats a surge in COVID-19 cases driven by the Omicron variant, with President Joe Biden announcing&nbsp;plans for more federal&nbsp;vaccination and testing sites.</p>\n<p>The pills can fill a treatment gap opened by the Omicron variant, said William Schaffner, a leading infectious disease expert from the Vanderbilt University School of Medicine. The most widely used monoclonal antibody treatments for COVID-19 have proven to be less effective at fighting the variant and there is limited supply of the one remaining treatment that works, he said.</p>\n<p>Monoclonal antibodies are typically given intravenously in hospitals, are not widely available and are more than twice the cost of the Pfizer pill.</p>\n<p>The Omicron variant, first identified in southern Africa and Hong Kong in November, has spread across the world and now constitutes over 70% of new coronavirus cases in the United States, according to data from the U.S. Centers for Disease Control and Prevention. Prior infection and vaccines have been shown in studies to only partly prevent infection from the variant, though a booster shot does increase protection.</p>\n<p>The FDA said it authorized Paxlovid for emergency use for the treatment of mild-to-moderate disease in adults and children 12 years and older, who are at high risk for progression to severe COVID-19.</p>\n<p>The drug is available by prescription only and should be initiated as soon as possible after diagnosis of COVID-19 and within five days of symptom onset, the FDA&nbsp;said. The pills are meant to be taken every 12 hours for five days beginning shortly after the onset of symptoms.</p>\n<p>While the clinical trials did not include patients under the age of 18, Pfizer said, the authorized adult dosing regimen is expected to result in comparable blood concentration levels of the drug in pediatric patients 12 and older weighing at least 40 kg (88.2 lbs).</p>\n<p>The second drug, ritonavir, is known to have interactions with some other prescription medicines. Pfizer has said that should be manageable and suggested most patients would be able to lower the dose of their other medications while being treated for COVID-19.</p>\n<p>Pfizer said it plans to file a new drug application with the FDA in 2022 for potential full regulatory approval. The European Union's drug regulator last week said that EU countries can use Paxlovid early after diagnosis of an infector, although the its full review of the drug has not been completed.</p>\n<p>Pfizer has agreed to allow generic manufacturers to supply versions of the treatment to 95 low- and middle-income countries through a licensing agreement with international public health group Medicines Patent Pool (MPP). The generic versions are expected later next year.</p>\n<p>A rival pill from Merck &amp; Co&nbsp;is under review by the FDA. The drug, molnupiravir, developed with Ridgeback Biotherapeutics, cut hospitalization and death risk by 30% in a trial.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.S. authorizes Pfizer oral COVID-19 treatment, first for at-home use</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.S. authorizes Pfizer oral COVID-19 treatment, first for at-home use\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-12-23 06:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Dec 22 (Reuters) - The United States on Wednesday authorized Pfizer Inc's&nbsp;antiviral COVID-19 pill for at-risk people aged 12 and above, making it the first oral treatment and which can be taken at home, providing a potentially important tool in the fight against the fast-spreading&nbsp;Omicron variant.</p>\n<p>Pfizer's antiviral regimen, Paxlovid, was nearly 90% effective in preventing hospitalizations and deaths in patients at high risk of severe illness, according to data from the company's clinical trial. Recent lab data suggests the drug retains its effectiveness against Omicron, Pfizer said.</p>\n<p>Pfizer raised its 2022 production projections to 120 million courses of treatment from 80 million and said it was ready to start immediate delivery in the United States. The treatment's two-drug regimen includes a new medicine and a second older antiviral called ritonavir.</p>\n<p>\"Paxlovid's approval is a major milestone that marks another step towards making COVID-19 a much more manageable infection,\" said Amesh Adalja, a senior scholar at the Johns Hopkins Institute for Health Security.</p>\n<p>\"There are two key issues, however, that remain: It will be scarce in the coming weeks and its optimal use requires prompt diagnosis, which can be difficult with the continual testing problems that plague us,\" Adalja added.</p>\n<p>Pfizer has said it has 180,000 treatment courses ready to ship this year. The U.S. government's contract for 10 million courses of the drug is priced at $530 per course.</p>\n<p>The Food and Drug Administration's decision to issue emergency authorization for the treatment comes as the U.S. combats a surge in COVID-19 cases driven by the Omicron variant, with President Joe Biden announcing&nbsp;plans for more federal&nbsp;vaccination and testing sites.</p>\n<p>The pills can fill a treatment gap opened by the Omicron variant, said William Schaffner, a leading infectious disease expert from the Vanderbilt University School of Medicine. The most widely used monoclonal antibody treatments for COVID-19 have proven to be less effective at fighting the variant and there is limited supply of the one remaining treatment that works, he said.</p>\n<p>Monoclonal antibodies are typically given intravenously in hospitals, are not widely available and are more than twice the cost of the Pfizer pill.</p>\n<p>The Omicron variant, first identified in southern Africa and Hong Kong in November, has spread across the world and now constitutes over 70% of new coronavirus cases in the United States, according to data from the U.S. Centers for Disease Control and Prevention. Prior infection and vaccines have been shown in studies to only partly prevent infection from the variant, though a booster shot does increase protection.</p>\n<p>The FDA said it authorized Paxlovid for emergency use for the treatment of mild-to-moderate disease in adults and children 12 years and older, who are at high risk for progression to severe COVID-19.</p>\n<p>The drug is available by prescription only and should be initiated as soon as possible after diagnosis of COVID-19 and within five days of symptom onset, the FDA&nbsp;said. The pills are meant to be taken every 12 hours for five days beginning shortly after the onset of symptoms.</p>\n<p>While the clinical trials did not include patients under the age of 18, Pfizer said, the authorized adult dosing regimen is expected to result in comparable blood concentration levels of the drug in pediatric patients 12 and older weighing at least 40 kg (88.2 lbs).</p>\n<p>The second drug, ritonavir, is known to have interactions with some other prescription medicines. Pfizer has said that should be manageable and suggested most patients would be able to lower the dose of their other medications while being treated for COVID-19.</p>\n<p>Pfizer said it plans to file a new drug application with the FDA in 2022 for potential full regulatory approval. The European Union's drug regulator last week said that EU countries can use Paxlovid early after diagnosis of an infector, although the its full review of the drug has not been completed.</p>\n<p>Pfizer has agreed to allow generic manufacturers to supply versions of the treatment to 95 low- and middle-income countries through a licensing agreement with international public health group Medicines Patent Pool (MPP). The generic versions are expected later next year.</p>\n<p>A rival pill from Merck &amp; Co&nbsp;is under review by the FDA. The drug, molnupiravir, developed with Ridgeback Biotherapeutics, cut hospitalization and death risk by 30% in a trial.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1131862374","content_text":"Dec 22 (Reuters) - The United States on Wednesday authorized Pfizer Inc's antiviral COVID-19 pill for at-risk people aged 12 and above, making it the first oral treatment and which can be taken at home, providing a potentially important tool in the fight against the fast-spreading Omicron variant.\nPfizer's antiviral regimen, Paxlovid, was nearly 90% effective in preventing hospitalizations and deaths in patients at high risk of severe illness, according to data from the company's clinical trial. Recent lab data suggests the drug retains its effectiveness against Omicron, Pfizer said.\nPfizer raised its 2022 production projections to 120 million courses of treatment from 80 million and said it was ready to start immediate delivery in the United States. The treatment's two-drug regimen includes a new medicine and a second older antiviral called ritonavir.\n\"Paxlovid's approval is a major milestone that marks another step towards making COVID-19 a much more manageable infection,\" said Amesh Adalja, a senior scholar at the Johns Hopkins Institute for Health Security.\n\"There are two key issues, however, that remain: It will be scarce in the coming weeks and its optimal use requires prompt diagnosis, which can be difficult with the continual testing problems that plague us,\" Adalja added.\nPfizer has said it has 180,000 treatment courses ready to ship this year. The U.S. government's contract for 10 million courses of the drug is priced at $530 per course.\nThe Food and Drug Administration's decision to issue emergency authorization for the treatment comes as the U.S. combats a surge in COVID-19 cases driven by the Omicron variant, with President Joe Biden announcing plans for more federal vaccination and testing sites.\nThe pills can fill a treatment gap opened by the Omicron variant, said William Schaffner, a leading infectious disease expert from the Vanderbilt University School of Medicine. The most widely used monoclonal antibody treatments for COVID-19 have proven to be less effective at fighting the variant and there is limited supply of the one remaining treatment that works, he said.\nMonoclonal antibodies are typically given intravenously in hospitals, are not widely available and are more than twice the cost of the Pfizer pill.\nThe Omicron variant, first identified in southern Africa and Hong Kong in November, has spread across the world and now constitutes over 70% of new coronavirus cases in the United States, according to data from the U.S. Centers for Disease Control and Prevention. Prior infection and vaccines have been shown in studies to only partly prevent infection from the variant, though a booster shot does increase protection.\nThe FDA said it authorized Paxlovid for emergency use for the treatment of mild-to-moderate disease in adults and children 12 years and older, who are at high risk for progression to severe COVID-19.\nThe drug is available by prescription only and should be initiated as soon as possible after diagnosis of COVID-19 and within five days of symptom onset, the FDA said. The pills are meant to be taken every 12 hours for five days beginning shortly after the onset of symptoms.\nWhile the clinical trials did not include patients under the age of 18, Pfizer said, the authorized adult dosing regimen is expected to result in comparable blood concentration levels of the drug in pediatric patients 12 and older weighing at least 40 kg (88.2 lbs).\nThe second drug, ritonavir, is known to have interactions with some other prescription medicines. Pfizer has said that should be manageable and suggested most patients would be able to lower the dose of their other medications while being treated for COVID-19.\nPfizer said it plans to file a new drug application with the FDA in 2022 for potential full regulatory approval. The European Union's drug regulator last week said that EU countries can use Paxlovid early after diagnosis of an infector, although the its full review of the drug has not been completed.\nPfizer has agreed to allow generic manufacturers to supply versions of the treatment to 95 low- and middle-income countries through a licensing agreement with international public health group Medicines Patent Pool (MPP). The generic versions are expected later next year.\nA rival pill from Merck & Co is under review by the FDA. The drug, molnupiravir, developed with Ridgeback Biotherapeutics, cut hospitalization and death risk by 30% in a trial.","news_type":1},"isVote":1,"tweetType":1,"viewCount":234,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691245108,"gmtCreate":1640215999963,"gmtModify":1640216000339,"author":{"id":"3578047933589423","authorId":"3578047933589423","name":"PengsieX","avatar":"https://static.tigerbbs.com/ebe92821eba3b91a6431d698b66bbed5","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"Hope no overdose incidents","listText":"Hope no overdose incidents","text":"Hope no overdose incidents","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691245108","repostId":"1131862374","repostType":4,"repost":{"id":"1131862374","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1640213195,"share":"https://www.laohu8.com/m/news/1131862374?lang=&edition=full","pubTime":"2021-12-23 06:46","market":"us","language":"en","title":"U.S. authorizes Pfizer oral COVID-19 treatment, first for at-home use","url":"https://stock-news.laohu8.com/highlight/detail?id=1131862374","media":"Reuters","summary":"Dec 22 (Reuters) - The United States on Wednesday authorized Pfizer Inc's antiviral COVID-19 pill fo","content":"<p>Dec 22 (Reuters) - The United States on Wednesday authorized Pfizer Inc's&nbsp;antiviral COVID-19 pill for at-risk people aged 12 and above, making it the first oral treatment and which can be taken at home, providing a potentially important tool in the fight against the fast-spreading&nbsp;Omicron variant.</p>\n<p>Pfizer's antiviral regimen, Paxlovid, was nearly 90% effective in preventing hospitalizations and deaths in patients at high risk of severe illness, according to data from the company's clinical trial. Recent lab data suggests the drug retains its effectiveness against Omicron, Pfizer said.</p>\n<p>Pfizer raised its 2022 production projections to 120 million courses of treatment from 80 million and said it was ready to start immediate delivery in the United States. The treatment's two-drug regimen includes a new medicine and a second older antiviral called ritonavir.</p>\n<p>\"Paxlovid's approval is a major milestone that marks another step towards making COVID-19 a much more manageable infection,\" said Amesh Adalja, a senior scholar at the Johns Hopkins Institute for Health Security.</p>\n<p>\"There are two key issues, however, that remain: It will be scarce in the coming weeks and its optimal use requires prompt diagnosis, which can be difficult with the continual testing problems that plague us,\" Adalja added.</p>\n<p>Pfizer has said it has 180,000 treatment courses ready to ship this year. The U.S. government's contract for 10 million courses of the drug is priced at $530 per course.</p>\n<p>The Food and Drug Administration's decision to issue emergency authorization for the treatment comes as the U.S. combats a surge in COVID-19 cases driven by the Omicron variant, with President Joe Biden announcing&nbsp;plans for more federal&nbsp;vaccination and testing sites.</p>\n<p>The pills can fill a treatment gap opened by the Omicron variant, said William Schaffner, a leading infectious disease expert from the Vanderbilt University School of Medicine. The most widely used monoclonal antibody treatments for COVID-19 have proven to be less effective at fighting the variant and there is limited supply of the one remaining treatment that works, he said.</p>\n<p>Monoclonal antibodies are typically given intravenously in hospitals, are not widely available and are more than twice the cost of the Pfizer pill.</p>\n<p>The Omicron variant, first identified in southern Africa and Hong Kong in November, has spread across the world and now constitutes over 70% of new coronavirus cases in the United States, according to data from the U.S. Centers for Disease Control and Prevention. Prior infection and vaccines have been shown in studies to only partly prevent infection from the variant, though a booster shot does increase protection.</p>\n<p>The FDA said it authorized Paxlovid for emergency use for the treatment of mild-to-moderate disease in adults and children 12 years and older, who are at high risk for progression to severe COVID-19.</p>\n<p>The drug is available by prescription only and should be initiated as soon as possible after diagnosis of COVID-19 and within five days of symptom onset, the FDA&nbsp;said. The pills are meant to be taken every 12 hours for five days beginning shortly after the onset of symptoms.</p>\n<p>While the clinical trials did not include patients under the age of 18, Pfizer said, the authorized adult dosing regimen is expected to result in comparable blood concentration levels of the drug in pediatric patients 12 and older weighing at least 40 kg (88.2 lbs).</p>\n<p>The second drug, ritonavir, is known to have interactions with some other prescription medicines. Pfizer has said that should be manageable and suggested most patients would be able to lower the dose of their other medications while being treated for COVID-19.</p>\n<p>Pfizer said it plans to file a new drug application with the FDA in 2022 for potential full regulatory approval. The European Union's drug regulator last week said that EU countries can use Paxlovid early after diagnosis of an infector, although the its full review of the drug has not been completed.</p>\n<p>Pfizer has agreed to allow generic manufacturers to supply versions of the treatment to 95 low- and middle-income countries through a licensing agreement with international public health group Medicines Patent Pool (MPP). The generic versions are expected later next year.</p>\n<p>A rival pill from Merck &amp; Co&nbsp;is under review by the FDA. The drug, molnupiravir, developed with Ridgeback Biotherapeutics, cut hospitalization and death risk by 30% in a trial.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.S. authorizes Pfizer oral COVID-19 treatment, first for at-home use</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.S. authorizes Pfizer oral COVID-19 treatment, first for at-home use\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-12-23 06:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Dec 22 (Reuters) - The United States on Wednesday authorized Pfizer Inc's&nbsp;antiviral COVID-19 pill for at-risk people aged 12 and above, making it the first oral treatment and which can be taken at home, providing a potentially important tool in the fight against the fast-spreading&nbsp;Omicron variant.</p>\n<p>Pfizer's antiviral regimen, Paxlovid, was nearly 90% effective in preventing hospitalizations and deaths in patients at high risk of severe illness, according to data from the company's clinical trial. Recent lab data suggests the drug retains its effectiveness against Omicron, Pfizer said.</p>\n<p>Pfizer raised its 2022 production projections to 120 million courses of treatment from 80 million and said it was ready to start immediate delivery in the United States. The treatment's two-drug regimen includes a new medicine and a second older antiviral called ritonavir.</p>\n<p>\"Paxlovid's approval is a major milestone that marks another step towards making COVID-19 a much more manageable infection,\" said Amesh Adalja, a senior scholar at the Johns Hopkins Institute for Health Security.</p>\n<p>\"There are two key issues, however, that remain: It will be scarce in the coming weeks and its optimal use requires prompt diagnosis, which can be difficult with the continual testing problems that plague us,\" Adalja added.</p>\n<p>Pfizer has said it has 180,000 treatment courses ready to ship this year. The U.S. government's contract for 10 million courses of the drug is priced at $530 per course.</p>\n<p>The Food and Drug Administration's decision to issue emergency authorization for the treatment comes as the U.S. combats a surge in COVID-19 cases driven by the Omicron variant, with President Joe Biden announcing&nbsp;plans for more federal&nbsp;vaccination and testing sites.</p>\n<p>The pills can fill a treatment gap opened by the Omicron variant, said William Schaffner, a leading infectious disease expert from the Vanderbilt University School of Medicine. The most widely used monoclonal antibody treatments for COVID-19 have proven to be less effective at fighting the variant and there is limited supply of the one remaining treatment that works, he said.</p>\n<p>Monoclonal antibodies are typically given intravenously in hospitals, are not widely available and are more than twice the cost of the Pfizer pill.</p>\n<p>The Omicron variant, first identified in southern Africa and Hong Kong in November, has spread across the world and now constitutes over 70% of new coronavirus cases in the United States, according to data from the U.S. Centers for Disease Control and Prevention. Prior infection and vaccines have been shown in studies to only partly prevent infection from the variant, though a booster shot does increase protection.</p>\n<p>The FDA said it authorized Paxlovid for emergency use for the treatment of mild-to-moderate disease in adults and children 12 years and older, who are at high risk for progression to severe COVID-19.</p>\n<p>The drug is available by prescription only and should be initiated as soon as possible after diagnosis of COVID-19 and within five days of symptom onset, the FDA&nbsp;said. The pills are meant to be taken every 12 hours for five days beginning shortly after the onset of symptoms.</p>\n<p>While the clinical trials did not include patients under the age of 18, Pfizer said, the authorized adult dosing regimen is expected to result in comparable blood concentration levels of the drug in pediatric patients 12 and older weighing at least 40 kg (88.2 lbs).</p>\n<p>The second drug, ritonavir, is known to have interactions with some other prescription medicines. Pfizer has said that should be manageable and suggested most patients would be able to lower the dose of their other medications while being treated for COVID-19.</p>\n<p>Pfizer said it plans to file a new drug application with the FDA in 2022 for potential full regulatory approval. The European Union's drug regulator last week said that EU countries can use Paxlovid early after diagnosis of an infector, although the its full review of the drug has not been completed.</p>\n<p>Pfizer has agreed to allow generic manufacturers to supply versions of the treatment to 95 low- and middle-income countries through a licensing agreement with international public health group Medicines Patent Pool (MPP). The generic versions are expected later next year.</p>\n<p>A rival pill from Merck &amp; Co&nbsp;is under review by the FDA. The drug, molnupiravir, developed with Ridgeback Biotherapeutics, cut hospitalization and death risk by 30% in a trial.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1131862374","content_text":"Dec 22 (Reuters) - The United States on Wednesday authorized Pfizer Inc's antiviral COVID-19 pill for at-risk people aged 12 and above, making it the first oral treatment and which can be taken at home, providing a potentially important tool in the fight against the fast-spreading Omicron variant.\nPfizer's antiviral regimen, Paxlovid, was nearly 90% effective in preventing hospitalizations and deaths in patients at high risk of severe illness, according to data from the company's clinical trial. Recent lab data suggests the drug retains its effectiveness against Omicron, Pfizer said.\nPfizer raised its 2022 production projections to 120 million courses of treatment from 80 million and said it was ready to start immediate delivery in the United States. The treatment's two-drug regimen includes a new medicine and a second older antiviral called ritonavir.\n\"Paxlovid's approval is a major milestone that marks another step towards making COVID-19 a much more manageable infection,\" said Amesh Adalja, a senior scholar at the Johns Hopkins Institute for Health Security.\n\"There are two key issues, however, that remain: It will be scarce in the coming weeks and its optimal use requires prompt diagnosis, which can be difficult with the continual testing problems that plague us,\" Adalja added.\nPfizer has said it has 180,000 treatment courses ready to ship this year. The U.S. government's contract for 10 million courses of the drug is priced at $530 per course.\nThe Food and Drug Administration's decision to issue emergency authorization for the treatment comes as the U.S. combats a surge in COVID-19 cases driven by the Omicron variant, with President Joe Biden announcing plans for more federal vaccination and testing sites.\nThe pills can fill a treatment gap opened by the Omicron variant, said William Schaffner, a leading infectious disease expert from the Vanderbilt University School of Medicine. The most widely used monoclonal antibody treatments for COVID-19 have proven to be less effective at fighting the variant and there is limited supply of the one remaining treatment that works, he said.\nMonoclonal antibodies are typically given intravenously in hospitals, are not widely available and are more than twice the cost of the Pfizer pill.\nThe Omicron variant, first identified in southern Africa and Hong Kong in November, has spread across the world and now constitutes over 70% of new coronavirus cases in the United States, according to data from the U.S. Centers for Disease Control and Prevention. Prior infection and vaccines have been shown in studies to only partly prevent infection from the variant, though a booster shot does increase protection.\nThe FDA said it authorized Paxlovid for emergency use for the treatment of mild-to-moderate disease in adults and children 12 years and older, who are at high risk for progression to severe COVID-19.\nThe drug is available by prescription only and should be initiated as soon as possible after diagnosis of COVID-19 and within five days of symptom onset, the FDA said. The pills are meant to be taken every 12 hours for five days beginning shortly after the onset of symptoms.\nWhile the clinical trials did not include patients under the age of 18, Pfizer said, the authorized adult dosing regimen is expected to result in comparable blood concentration levels of the drug in pediatric patients 12 and older weighing at least 40 kg (88.2 lbs).\nThe second drug, ritonavir, is known to have interactions with some other prescription medicines. Pfizer has said that should be manageable and suggested most patients would be able to lower the dose of their other medications while being treated for COVID-19.\nPfizer said it plans to file a new drug application with the FDA in 2022 for potential full regulatory approval. The European Union's drug regulator last week said that EU countries can use Paxlovid early after diagnosis of an infector, although the its full review of the drug has not been completed.\nPfizer has agreed to allow generic manufacturers to supply versions of the treatment to 95 low- and middle-income countries through a licensing agreement with international public health group Medicines Patent Pool (MPP). The generic versions are expected later next year.\nA rival pill from Merck & Co is under review by the FDA. The drug, molnupiravir, developed with Ridgeback Biotherapeutics, cut hospitalization and death risk by 30% in a trial.","news_type":1},"isVote":1,"tweetType":1,"viewCount":180,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691925495,"gmtCreate":1640129191844,"gmtModify":1640129192233,"author":{"id":"3578047933589423","authorId":"3578047933589423","name":"PengsieX","avatar":"https://static.tigerbbs.com/ebe92821eba3b91a6431d698b66bbed5","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"Jabs, pills... What's next","listText":"Jabs, pills... What's next","text":"Jabs, pills... What's next","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691925495","repostId":"1113826245","repostType":4,"repost":{"id":"1113826245","pubTimestamp":1640127256,"share":"https://www.laohu8.com/m/news/1113826245?lang=&edition=full","pubTime":"2021-12-22 06:54","market":"us","language":"en","title":"FDA Expected to Authorize Pfizer and Merck Covid Pills This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=1113826245","media":"Bloomberg","summary":"Two drugs would be first at-home treatments for Covid-19\nU.S. has ordered 13 million courses of medi","content":"<ul>\n <li>Two drugs would be first at-home treatments for Covid-19</li>\n <li>U.S. has ordered 13 million courses of medicines so far</li>\n</ul>\n<p>The U.S. Food and Drug Administration is poised to authorize a pair of pills from&nbsp;Pfizer Inc.&nbsp;and&nbsp;Merck &amp; Co.&nbsp;to treat Covid-19 as soon as this week, according to people familiar with the matter -- a milestone in the fight against the pandemic that will soon expand therapies for the ill.</p>\n<p>An announcement may come as early as Wednesday, according to three of the people. They asked not to be identified ahead of the authorization and cautioned that the plan could change.</p>\n<p>Pfizer’s pill, Paxlovid, and Merck’s molnupiravir are intended for higher-risk people who test positive for the coronavirus. The treatments, in which patients take a series of pills at home over several days, could ease the burden on stretched hospitals with infections poised to soar through the winter in the U.S.</p>\n<p>The FDA declined to comment.</p>\n<p>“It’s the biggest thing to happen in the pandemic after vaccines,” said Eric Topol, director of the Scripps Research Translational Institute. The timing of the announcement, so late in the year, is unusual for the FDA and reflects the urgency behind the medicines, he added.</p>\n<p>The FDA authorizations may come with limitations on who should get which drugs., one of the people familiar with the matter said. A Food and Drug Administration advisory committee narrowly recommended the Merck pill last month, with some members of the panel citing safety concerns including for pregnant women.</p>\n<p>Pfizer closed at $58.95 a share in New York, down about 3.4%, while Merck closed at $75.54, down about 1.1%.</p>\n<p>White House Press Secretary Jen Psaki said she wouldn’t get ahead of any FDA decision.</p>\n<p>“But certainly, having antivirals available is another component that will help us fight the virus, address the pandemic, help people return to a version of normal and we will be prepared like Boy Scouts and Girl Scouts to ensure we are making these antivirals available to the public,” she said Tuesday.</p>\n<p>President Joe Biden, speaking at the White House on Tuesday about the omicron variant, said the current spike in cases is not like previous surges because of the availability of medical supplies and vaccines. He warned of increasing breakthrough cases in vaccinated people but assured Americans that almost of all of them would be mild or entirely asymptomatic.</p>\n<p>“No, this is not March of 2020,” he said.</p>\n<p>The U.S. government has ordered 10 million courses of the Pfizer pill and about 3 million courses of Merck’s, which isn’t as effective, clinical studies indicate, and may carry risks. However, the pills are likely to not be immediately available in widespread supply.</p>\n<p>In a clinical trial, Pfizer’s pill showed an 89% reduction in hospitalization for patients who received the medicine within three days of developing symptoms, compared to patients who got a placebo. None of the patients treated with the drug died.</p>\n<p>Authorization for Pfizer’s pill would represent a vote of confidence in the medicine from regulators, as FDA advisers have not been asked to consider the drug’s clinical evidence.</p>\n<p>Merck developed molnupiravir with partner&nbsp;Ridgeback Biotherapeutics LP.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FDA Expected to Authorize Pfizer and Merck Covid Pills This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFDA Expected to Authorize Pfizer and Merck Covid Pills This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-22 06:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-12-21/fda-expected-to-authorize-pfizer-merck-covid-pills-this-week><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Two drugs would be first at-home treatments for Covid-19\nU.S. has ordered 13 million courses of medicines so far\n\nThe U.S. Food and Drug Administration is poised to authorize a pair of pills from ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-12-21/fda-expected-to-authorize-pfizer-merck-covid-pills-this-week\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE","MRK":"默沙东","PFE":"辉瑞"},"source_url":"https://www.bloomberg.com/news/articles/2021-12-21/fda-expected-to-authorize-pfizer-merck-covid-pills-this-week","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1113826245","content_text":"Two drugs would be first at-home treatments for Covid-19\nU.S. has ordered 13 million courses of medicines so far\n\nThe U.S. Food and Drug Administration is poised to authorize a pair of pills from Pfizer Inc. and Merck & Co. to treat Covid-19 as soon as this week, according to people familiar with the matter -- a milestone in the fight against the pandemic that will soon expand therapies for the ill.\nAn announcement may come as early as Wednesday, according to three of the people. They asked not to be identified ahead of the authorization and cautioned that the plan could change.\nPfizer’s pill, Paxlovid, and Merck’s molnupiravir are intended for higher-risk people who test positive for the coronavirus. The treatments, in which patients take a series of pills at home over several days, could ease the burden on stretched hospitals with infections poised to soar through the winter in the U.S.\nThe FDA declined to comment.\n“It’s the biggest thing to happen in the pandemic after vaccines,” said Eric Topol, director of the Scripps Research Translational Institute. The timing of the announcement, so late in the year, is unusual for the FDA and reflects the urgency behind the medicines, he added.\nThe FDA authorizations may come with limitations on who should get which drugs., one of the people familiar with the matter said. A Food and Drug Administration advisory committee narrowly recommended the Merck pill last month, with some members of the panel citing safety concerns including for pregnant women.\nPfizer closed at $58.95 a share in New York, down about 3.4%, while Merck closed at $75.54, down about 1.1%.\nWhite House Press Secretary Jen Psaki said she wouldn’t get ahead of any FDA decision.\n“But certainly, having antivirals available is another component that will help us fight the virus, address the pandemic, help people return to a version of normal and we will be prepared like Boy Scouts and Girl Scouts to ensure we are making these antivirals available to the public,” she said Tuesday.\nPresident Joe Biden, speaking at the White House on Tuesday about the omicron variant, said the current spike in cases is not like previous surges because of the availability of medical supplies and vaccines. He warned of increasing breakthrough cases in vaccinated people but assured Americans that almost of all of them would be mild or entirely asymptomatic.\n“No, this is not March of 2020,” he said.\nThe U.S. government has ordered 10 million courses of the Pfizer pill and about 3 million courses of Merck’s, which isn’t as effective, clinical studies indicate, and may carry risks. However, the pills are likely to not be immediately available in widespread supply.\nIn a clinical trial, Pfizer’s pill showed an 89% reduction in hospitalization for patients who received the medicine within three days of developing symptoms, compared to patients who got a placebo. None of the patients treated with the drug died.\nAuthorization for Pfizer’s pill would represent a vote of confidence in the medicine from regulators, as FDA advisers have not been asked to consider the drug’s clinical evidence.\nMerck developed molnupiravir with partner Ridgeback Biotherapeutics LP.","news_type":1},"isVote":1,"tweetType":1,"viewCount":135,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":693266394,"gmtCreate":1640042200416,"gmtModify":1640042208616,"author":{"id":"3578047933589423","authorId":"3578047933589423","name":"PengsieX","avatar":"https://static.tigerbbs.com/ebe92821eba3b91a6431d698b66bbed5","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"Time for acquisitions again","listText":"Time for acquisitions again","text":"Time for acquisitions again","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/693266394","repostId":"2192804351","repostType":4,"repost":{"id":"2192804351","pubTimestamp":1640013682,"share":"https://www.laohu8.com/m/news/2192804351?lang=&edition=full","pubTime":"2021-12-20 23:21","market":"us","language":"en","title":"Oracle to buy Cerner for $28 bln in healthcare sector push","url":"https://stock-news.laohu8.com/highlight/detail?id=2192804351","media":"Reuters","summary":"Dec 20 (Reuters) - Enterprise software maker Oracle Corp said on Monday it would buy electronic medi","content":"<p>Dec 20 (Reuters) - Enterprise software maker Oracle Corp said on Monday it would buy electronic medical records company Cerner Corp for $28.3 billion, in a bid to strengthen its presence in the healthcare sector.</p>\n<p>Cerner shareholders will receive $95 in cash for each share they hold, representing a premium of 5.8% to the company's closing price on Friday.</p>\n<p>The deal, which will be Oracle's biggest ever after its acquisition of PeopleSoft in 2004, will help the software maker bolster the services its provides to healthcare clients, including insurers.</p>\n<p>Cerner, the biggest seller of software used for electronic recording of healthcare data in the United States after Epic Systems Corp, will give Oracle access to data it can use to train and improve its artificial intelligence-based cloud services.</p>\n<p>Since the pandemic began, demand for cloud-based solutions in the healthcare sector has picked up pace, including telehealth services as well as automation of health records.</p>\n<p>The deal is expected to close in 2022, the company said. (Reporting by Chavi Mehta and Tiyashi Datta in Bengaluru; Editing by Krishna Chandra Eluri)</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Oracle to buy Cerner for $28 bln in healthcare sector push</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOracle to buy Cerner for $28 bln in healthcare sector push\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-20 23:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/1-oracle-buy-cerner-28-144822643.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Dec 20 (Reuters) - Enterprise software maker Oracle Corp said on Monday it would buy electronic medical records company Cerner Corp for $28.3 billion, in a bid to strengthen its presence in the ...</p>\n\n<a href=\"https://finance.yahoo.com/news/1-oracle-buy-cerner-28-144822643.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ORCL":"甲骨文","BK4167":"医疗保健技术","CERN":"美国塞纳"},"source_url":"https://finance.yahoo.com/news/1-oracle-buy-cerner-28-144822643.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2192804351","content_text":"Dec 20 (Reuters) - Enterprise software maker Oracle Corp said on Monday it would buy electronic medical records company Cerner Corp for $28.3 billion, in a bid to strengthen its presence in the healthcare sector.\nCerner shareholders will receive $95 in cash for each share they hold, representing a premium of 5.8% to the company's closing price on Friday.\nThe deal, which will be Oracle's biggest ever after its acquisition of PeopleSoft in 2004, will help the software maker bolster the services its provides to healthcare clients, including insurers.\nCerner, the biggest seller of software used for electronic recording of healthcare data in the United States after Epic Systems Corp, will give Oracle access to data it can use to train and improve its artificial intelligence-based cloud services.\nSince the pandemic began, demand for cloud-based solutions in the healthcare sector has picked up pace, including telehealth services as well as automation of health records.\nThe deal is expected to close in 2022, the company said. (Reporting by Chavi Mehta and Tiyashi Datta in Bengaluru; Editing by Krishna Chandra Eluri)","news_type":1},"isVote":1,"tweetType":1,"viewCount":84,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":698505482,"gmtCreate":1640432661839,"gmtModify":1640433182799,"author":{"id":"3578047933589423","authorId":"3578047933589423","name":"PengsieX","avatar":"https://static.tigerbbs.com/ebe92821eba3b91a6431d698b66bbed5","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"Don't blindly follow Warren cos he has the major shareholding whereas you are just a tiny retail investor","listText":"Don't blindly follow Warren cos he has the major shareholding whereas you are just a tiny retail investor","text":"Don't blindly follow Warren cos he has the major shareholding whereas you are just a tiny retail investor","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":10,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/698505482","repostId":"2193917872","repostType":4,"repost":{"id":"2193917872","pubTimestamp":1640398248,"share":"https://www.laohu8.com/m/news/2193917872?lang=&edition=full","pubTime":"2021-12-25 10:10","market":"us","language":"en","title":"3 Best Buffett Stocks to Buy for the Long Haul","url":"https://stock-news.laohu8.com/highlight/detail?id=2193917872","media":"Motley Fool","summary":"Each of these three big pharma stocks are featured in Berkshire Hathaway's massive portfolio.","content":"<p>Since Warren Buffett took full control of <b>Berkshire Hathaway</b> in 1965, it became a diversified holding company with investments in publicly traded companies totaling nearly $345 billion at the time of writing.</p>\n<p>The Oracle of Omaha's reputation of buying the highest quality businesses means that many individual investors could also benefit from adding these stocks to their portfolios. Here are three healthcare stocks that Buffett owns, which you may also want to consider buying and holding for the long run.</p>\n<h2>1. Johnson &amp; Johnson</h2>\n<p>The first pharma stock within Berkshire's portfolio to contemplate purchasing is <b>Johnson &amp; Johnson</b> (NYSE:JNJ). While the stock is one of Buffett's smallest holdings, valued at just under $55 million, this doesn't take away from its 59 consecutive years of dividend increases that make the stock a Dividend King.</p>\n<p>J&amp;J will be spinning off its slower-growing and less profitable consumer health segment in the next 18 to 24 months, which should allow the company to focus on its faster-growing, more profitable pharmaceutical segment.</p>\n<p>J&amp;J has a strong existing drug portfolio, which should be able to make up for the upcoming 2025 to 2026 patent expirations for its top-selling drug known, Stelara. Year to date, the immunology drug made up just 9.9% of J&amp;J's $69 billion in net sales.</p>\n<p>These drugs include the immunology blockbuster Tremfya, which received its first of three U.S. Food and Drug Administration (FDA) approvals to date in July 2017. Another drug that was recently approved by the FDA was the oncology blockbuster called Darzalex, which received its first of nine FDA approvals to date in November 2015. These two drugs have grown their year-to-date revenue at high-40% clips year over year and should remain under patent most of this decade.</p>\n<p>J&amp;J's enviable existing drug portfolio and its nearly four dozen indications in late-stage clinical trials explain why analysts anticipate that the stock will deliver 8% annual non-GAAP (adjusted) earnings per share (EPS) growth over the next five years.</p>\n<p>Income investors can scoop up J&amp;J's 2.5% dividend yield at a forward P/E ratio of just 16.2 times, which makes the steady healthcare stock a great buy for the long term.</p>\n<h2>2. Bristol Myers Squibb</h2>\n<p>Another Buffett stock that could be a great fit in your portfolio is <b>Bristol Myers Squibb</b> (NYSE:BMY). Berkshire's Bristol Myers Squibb stake totals nearly $1.4 billion, making it one of the largest healthcare holdings in Berkshire's portfolio.</p>\n<p>Bristol Myers Squibb's oncology blockbusters Revlimid and Opdivo and the anticoagulant blockbuster co-owned with <b>Pfizer</b> (NYSE:PFE) named Eliquis each face patent expirations later this decade. While looming patent expirations on three drugs that account for approximately two-thirds of your company's total revenue sounds frightening, this is nothing new; it's just the nature of Bristol Myers Squibb's industry.</p>\n<p>What matters most is that a company is proactive in developing and acquiring its next generation of blockbuster drugs to absorb key patent expirations. With more than 50 compounds in over 40 different disease areas currently in development at Bristol Myers Squibb, this is exactly what the company has been doing for years now.</p>\n<p>As a result, analysts are projecting that Bristol Myers Squibb will be able to generate 6% annual earnings growth through the next five years.</p>\n<p>Yield-hungry investors can buy Bristol Myers Squibb's market-crushing 3.5% yield at a ridiculously cheap forward P/E ratio of 7.9, which is what makes the stock a buy for those looking to hedge against inflation.</p>\n<h2>3. AbbVie</h2>\n<p>Finally, a Buffett stock that'd also be a good fit for income investors is <b>AbbVie</b> (NYSE:ABBV). Berkshire currently holds about $1.9 billion worth of AbbVie stock.</p>\n<p>It's well known at this point that the biopharmaceutical's top-selling drug in the world, Humira, will be facing intense biosimilar competition in the U.S. beginning in 2023. Even though the immunology drug's U.S. sales made up 31% of AbbVie's $41.24 billion total year-to-date sales, the company's pipeline should be able to stabilize and grow its net revenue beyond 2023.</p>\n<p>AbbVie has 54 compounds in various stages of clinical trials, which is why analysts are forecasting that the stock will grow its adjusted EPS 4.5% annually in the next five years.</p>\n<p>AbbVie's massive 4.4% dividend yield can be picked up at a forward P/E ratio of only 9.3.&nbsp;This is an attractive valuation for a stock with the ability to fight off inflation with healthy dividend hikes.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Best Buffett Stocks to Buy for the Long Haul</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Best Buffett Stocks to Buy for the Long Haul\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-25 10:10 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/24/3-best-buffett-stocks-to-buy-for-the-long-haul/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Since Warren Buffett took full control of Berkshire Hathaway in 1965, it became a diversified holding company with investments in publicly traded companies totaling nearly $345 billion at the time of ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/24/3-best-buffett-stocks-to-buy-for-the-long-haul/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ABBV":"艾伯维公司","BMY":"施贵宝","JNJ":"强生"},"source_url":"https://www.fool.com/investing/2021/12/24/3-best-buffett-stocks-to-buy-for-the-long-haul/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2193917872","content_text":"Since Warren Buffett took full control of Berkshire Hathaway in 1965, it became a diversified holding company with investments in publicly traded companies totaling nearly $345 billion at the time of writing.\nThe Oracle of Omaha's reputation of buying the highest quality businesses means that many individual investors could also benefit from adding these stocks to their portfolios. Here are three healthcare stocks that Buffett owns, which you may also want to consider buying and holding for the long run.\n1. Johnson & Johnson\nThe first pharma stock within Berkshire's portfolio to contemplate purchasing is Johnson & Johnson (NYSE:JNJ). While the stock is one of Buffett's smallest holdings, valued at just under $55 million, this doesn't take away from its 59 consecutive years of dividend increases that make the stock a Dividend King.\nJ&J will be spinning off its slower-growing and less profitable consumer health segment in the next 18 to 24 months, which should allow the company to focus on its faster-growing, more profitable pharmaceutical segment.\nJ&J has a strong existing drug portfolio, which should be able to make up for the upcoming 2025 to 2026 patent expirations for its top-selling drug known, Stelara. Year to date, the immunology drug made up just 9.9% of J&J's $69 billion in net sales.\nThese drugs include the immunology blockbuster Tremfya, which received its first of three U.S. Food and Drug Administration (FDA) approvals to date in July 2017. Another drug that was recently approved by the FDA was the oncology blockbuster called Darzalex, which received its first of nine FDA approvals to date in November 2015. These two drugs have grown their year-to-date revenue at high-40% clips year over year and should remain under patent most of this decade.\nJ&J's enviable existing drug portfolio and its nearly four dozen indications in late-stage clinical trials explain why analysts anticipate that the stock will deliver 8% annual non-GAAP (adjusted) earnings per share (EPS) growth over the next five years.\nIncome investors can scoop up J&J's 2.5% dividend yield at a forward P/E ratio of just 16.2 times, which makes the steady healthcare stock a great buy for the long term.\n2. Bristol Myers Squibb\nAnother Buffett stock that could be a great fit in your portfolio is Bristol Myers Squibb (NYSE:BMY). Berkshire's Bristol Myers Squibb stake totals nearly $1.4 billion, making it one of the largest healthcare holdings in Berkshire's portfolio.\nBristol Myers Squibb's oncology blockbusters Revlimid and Opdivo and the anticoagulant blockbuster co-owned with Pfizer (NYSE:PFE) named Eliquis each face patent expirations later this decade. While looming patent expirations on three drugs that account for approximately two-thirds of your company's total revenue sounds frightening, this is nothing new; it's just the nature of Bristol Myers Squibb's industry.\nWhat matters most is that a company is proactive in developing and acquiring its next generation of blockbuster drugs to absorb key patent expirations. With more than 50 compounds in over 40 different disease areas currently in development at Bristol Myers Squibb, this is exactly what the company has been doing for years now.\nAs a result, analysts are projecting that Bristol Myers Squibb will be able to generate 6% annual earnings growth through the next five years.\nYield-hungry investors can buy Bristol Myers Squibb's market-crushing 3.5% yield at a ridiculously cheap forward P/E ratio of 7.9, which is what makes the stock a buy for those looking to hedge against inflation.\n3. AbbVie\nFinally, a Buffett stock that'd also be a good fit for income investors is AbbVie (NYSE:ABBV). Berkshire currently holds about $1.9 billion worth of AbbVie stock.\nIt's well known at this point that the biopharmaceutical's top-selling drug in the world, Humira, will be facing intense biosimilar competition in the U.S. beginning in 2023. Even though the immunology drug's U.S. sales made up 31% of AbbVie's $41.24 billion total year-to-date sales, the company's pipeline should be able to stabilize and grow its net revenue beyond 2023.\nAbbVie has 54 compounds in various stages of clinical trials, which is why analysts are forecasting that the stock will grow its adjusted EPS 4.5% annually in the next five years.\nAbbVie's massive 4.4% dividend yield can be picked up at a forward P/E ratio of only 9.3. This is an attractive valuation for a stock with the ability to fight off inflation with healthy dividend hikes.","news_type":1},"isVote":1,"tweetType":1,"viewCount":297,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":630960226,"gmtCreate":1642667643831,"gmtModify":1642667644226,"author":{"id":"3578047933589423","authorId":"3578047933589423","name":"PengsieX","avatar":"https://static.tigerbbs.com/ebe92821eba3b91a6431d698b66bbed5","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"Spending too much on new shows without the intention to continue when the ratings or response wasn't as good as expected","listText":"Spending too much on new shows without the intention to continue when the ratings or response wasn't as good as expected","text":"Spending too much on new shows without the intention to continue when the ratings or response wasn't as good as expected","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/630960226","repostId":"1105696017","repostType":4,"repost":{"id":"1105696017","pubTimestamp":1642666637,"share":"https://www.laohu8.com/m/news/1105696017?lang=&edition=full","pubTime":"2022-01-20 16:17","market":"us","language":"en","title":"Netflix Is Still on a Tear. Why the Stock Is Limping Into Earnings.","url":"https://stock-news.laohu8.com/highlight/detail?id=1105696017","media":"Barrons","summary":"Netflix shares head into Thursday’s fourth-quarter earnings report under a cloud. The streaming-vide","content":"<html><head></head><body><p>Netflix shares head into Thursday’s fourth-quarter earnings report under a cloud. The streaming-video service’s shares are off nearly 20% since it posted third-quarter results in October—and 6% below where they were at the end of 2020.</p><p>Investors have been treating Netflix (ticker: NFLX) as an out-of-favor stay-at-home play, a segment in which stocks like Zoom Video Communications (ZM), Peloton Interactive (PTON), and Chegg (CHGG) have cratered as some parts of the economy reopen—even while the pandemic drags on.</p><p>That’s a little surprising. Unlike Zoom, Peloton, and Chegg, Netflix is showing no signs of slowing. Third-quarter earnings included better-than-expected user growth — the company added 4.4 million net new subscribers, above its own forecast of 3.5 million. Netflix had third-quarter revenue of $7.48 billion, in line with estimates, and profits of $3.18 a share, well ahead of the Street consensus at $2.56 a share.</p><p>For the December quarter, the company is projecting 8.5 million net new subscriber additions, with revenue of $7.7 billion, up 16%. Street consensus calls for 8.3 million net adds, $7.7 billion in revenue, and profits of 83 cents a share. For the March quarter, Street estimates call for revenue of 8.2 million, profits of $3.47 a share, and 5.7 million net subscriber additions.</p><p>Just last week, Netflix ratcheted up subscription prices in the U.S. and Canada. In the U.S., a standard subscription, which includes HD-quality video and the ability to stream on two devices at the same time, is now $15.49 a month, up from $13.99. Basic service is now $9.99 a month, up from $8.99. Premium service, which allows up to four simultaneous streams, jumps to $19.99 a month, from $17.99.</p><p>In a research note Wednesday, Wells Fargo analyst Steven Cahall repeated his Overweight rating and $800 target on Netflix shares. He writes that an analysis of download data from the research firm Apptopia suggests the company’s new-subscriber guidance is conservative. He raised his forecast for the December-quarter net adds to 10 million from a previous 9.5 million, which already was way ahead of both guidance and consensus.</p><p>Cahall notes that the December quarter was a “monster” from a content perspective, including popular movies like <i>Don’t Look Up</i>and <i>Red Notice</i>, and ongoing interest in <i>Squid Game</i>.</p><p>Piper Sandler analyst Thomas Champion likewise repeats his Overweight rating and $705 target on the stock heading into the earnings report. Champion writes that while subscriber data could be “erratic” in the near term, he sees long-term growth above 25 million subscribers a year “for the foreseeable future.” He notes that free cash flow should be “handily positive” in 2022, and contends that “valuation looks compelling relative to the last 5 years.”</p><p>Likewise, BofA Securities analyst Nat Schindler keeps his Buy rating and $750 target on Netflix shares. “With a massive content slate lineup in 2022 and continued growth in Asia, we see opportunity for subscriber upside and potential for new subscriber models as key positive stock drivers in 2022,” Schindler wrote in a research note this week.</p><p>MoffettNathanson analyst Michael Nathanson is more cautious. In a recent research note, he predicted that fourth-quarter financial data will show that two of the newer entrants into the streaming market—Paramount+ from ViacomCBS (VIAC) and Peacock from Comcast (CMCSA)—will post the most net subscriber adds in the U.S. “In fact, looking out into 2022, we think the narrative of improving content slates at virtually every [subscription video-on-demand] platform will underscore the increasingly competitive nature and current low return profile of this business,” he writes.</p><p>For Netflix, Nathanson adds, the story from here is about growth in Asia, and eventually lower-priced mobile-first markets. “2022 should prove that no one single company has a monopoly on great content,” he writes.</p><p>He recently repeated his Neutral rating on Netflix shares while trimming his price target on the stock to $460 from $465. He thinks investors “will focus on Netflix’s relatively high valuation and the longer-term implications of hitting a subscriber ceiling in their most valuable regions of the world.”</p></body></html>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Netflix Is Still on a Tear. Why the Stock Is Limping Into Earnings.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNetflix Is Still on a Tear. Why the Stock Is Limping Into Earnings.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-20 16:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/netflix-stock-price-earnings-subscribers-51642625439?mod=hp_LEADSUPP_2><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Netflix shares head into Thursday’s fourth-quarter earnings report under a cloud. The streaming-video service’s shares are off nearly 20% since it posted third-quarter results in October—and 6% below ...</p>\n\n<a href=\"https://www.barrons.com/articles/netflix-stock-price-earnings-subscribers-51642625439?mod=hp_LEADSUPP_2\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NFLX":"奈飞"},"source_url":"https://www.barrons.com/articles/netflix-stock-price-earnings-subscribers-51642625439?mod=hp_LEADSUPP_2","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1105696017","content_text":"Netflix shares head into Thursday’s fourth-quarter earnings report under a cloud. The streaming-video service’s shares are off nearly 20% since it posted third-quarter results in October—and 6% below where they were at the end of 2020.Investors have been treating Netflix (ticker: NFLX) as an out-of-favor stay-at-home play, a segment in which stocks like Zoom Video Communications (ZM), Peloton Interactive (PTON), and Chegg (CHGG) have cratered as some parts of the economy reopen—even while the pandemic drags on.That’s a little surprising. Unlike Zoom, Peloton, and Chegg, Netflix is showing no signs of slowing. Third-quarter earnings included better-than-expected user growth — the company added 4.4 million net new subscribers, above its own forecast of 3.5 million. Netflix had third-quarter revenue of $7.48 billion, in line with estimates, and profits of $3.18 a share, well ahead of the Street consensus at $2.56 a share.For the December quarter, the company is projecting 8.5 million net new subscriber additions, with revenue of $7.7 billion, up 16%. Street consensus calls for 8.3 million net adds, $7.7 billion in revenue, and profits of 83 cents a share. For the March quarter, Street estimates call for revenue of 8.2 million, profits of $3.47 a share, and 5.7 million net subscriber additions.Just last week, Netflix ratcheted up subscription prices in the U.S. and Canada. In the U.S., a standard subscription, which includes HD-quality video and the ability to stream on two devices at the same time, is now $15.49 a month, up from $13.99. Basic service is now $9.99 a month, up from $8.99. Premium service, which allows up to four simultaneous streams, jumps to $19.99 a month, from $17.99.In a research note Wednesday, Wells Fargo analyst Steven Cahall repeated his Overweight rating and $800 target on Netflix shares. He writes that an analysis of download data from the research firm Apptopia suggests the company’s new-subscriber guidance is conservative. He raised his forecast for the December-quarter net adds to 10 million from a previous 9.5 million, which already was way ahead of both guidance and consensus.Cahall notes that the December quarter was a “monster” from a content perspective, including popular movies like Don’t Look Upand Red Notice, and ongoing interest in Squid Game.Piper Sandler analyst Thomas Champion likewise repeats his Overweight rating and $705 target on the stock heading into the earnings report. Champion writes that while subscriber data could be “erratic” in the near term, he sees long-term growth above 25 million subscribers a year “for the foreseeable future.” He notes that free cash flow should be “handily positive” in 2022, and contends that “valuation looks compelling relative to the last 5 years.”Likewise, BofA Securities analyst Nat Schindler keeps his Buy rating and $750 target on Netflix shares. “With a massive content slate lineup in 2022 and continued growth in Asia, we see opportunity for subscriber upside and potential for new subscriber models as key positive stock drivers in 2022,” Schindler wrote in a research note this week.MoffettNathanson analyst Michael Nathanson is more cautious. In a recent research note, he predicted that fourth-quarter financial data will show that two of the newer entrants into the streaming market—Paramount+ from ViacomCBS (VIAC) and Peacock from Comcast (CMCSA)—will post the most net subscriber adds in the U.S. “In fact, looking out into 2022, we think the narrative of improving content slates at virtually every [subscription video-on-demand] platform will underscore the increasingly competitive nature and current low return profile of this business,” he writes.For Netflix, Nathanson adds, the story from here is about growth in Asia, and eventually lower-priced mobile-first markets. “2022 should prove that no one single company has a monopoly on great content,” he writes.He recently repeated his Neutral rating on Netflix shares while trimming his price target on the stock to $460 from $465. He thinks investors “will focus on Netflix’s relatively high valuation and the longer-term implications of hitting a subscriber ceiling in their most valuable regions of the world.”","news_type":1},"isVote":1,"tweetType":1,"viewCount":784,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"9000000000000591","authorId":"9000000000000591","name":"EvelynHoover","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0},"content":"我很同意你的看法。有时候我不太明白经理们在想什么","text":"我很同意你的看法。有时候我不太明白经理们在想什么","html":"我很同意你的看法。有时候我不太明白经理们在想什么"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":607858765,"gmtCreate":1639527428870,"gmtModify":1639527429147,"author":{"id":"3578047933589423","authorId":"3578047933589423","name":"PengsieX","avatar":"https://static.tigerbbs.com/ebe92821eba3b91a6431d698b66bbed5","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"Don't fear!&nbsp;","listText":"Don't fear!&nbsp;","text":"Don't fear!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/607858765","repostId":"2191784951","repostType":4,"repost":{"id":"2191784951","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1639522244,"share":"https://www.laohu8.com/m/news/2191784951?lang=&edition=full","pubTime":"2021-12-15 06:50","market":"us","language":"en","title":"Wall Street ends down, investors eye inflation and Omicron","url":"https://stock-news.laohu8.com/highlight/detail?id=2191784951","media":"Reuters","summary":"* Fed policy decision awaited on Wednesday\n* November PPI logs highest rise since 2010\n* Tech leads ","content":"<p>* Fed policy decision awaited on Wednesday</p>\n<p>* November PPI logs highest rise since 2010</p>\n<p>* Tech leads declines, financials rally</p>\n<p>* Indexes: Dow -0.30%, S&amp;P 500 -0.75%, Nasdaq -1.14%</p>\n<p>Dec 14 (Reuters) - Wall Street ended lower on Tuesday after data showed producer prices increased more than expected in November, solidifying expectations the Federal Reserve this week will announce a faster wind-down of asset purchases.</p>\n<p>The fast-spreading Omicron coronavirus variant also dampened investor sentiment after the S&amp;P 500 index hit an all-time closing high late last week.</p>\n<p>Declines were led by megacap tech-related stocks, with <a href=\"https://laohu8.com/S/CRM\">Salesforce</a>.com, Microsoft Corp, <a href=\"https://laohu8.com/S/ADBE\">Adobe</a> and Alphabet Inc pulling down the S&amp;P 500 and Nasdaq.</p>\n<p>Apple Inc ended down 0.8%, but off its session lows, after the iPhone maker said it would require customers and employees to wear masks at its U.S. retail stores as COVID-19 cases surge.</p>\n<p>The Dow Jones Industrial Average fell 0.3% to end at 35,544.18 points, while the S&amp;P 500 lost 0.75% to 4,634.09.</p>\n<p>The Nasdaq Composite dropped 1.14% to 15,237.64.</p>\n<p>Data from the Labor Department showed the producer price index (PPI) for final demand in the 12 months through November shot up 9.6%, clocking its largest gain since November 2010. That followed an 8.8% increase in October.</p>\n<p>About two-thirds of Nasdaq stocks traded below their 200-day moving average, according to Refinitiv data, suggesting many stocks within the index are struggling, even as the overall index remains only about 6% below its November record high close.</p>\n<p>\"COVID plus inflation is the Grinch that stole Christmas,\" said Jake Dollarhide, chief executive officer at Longbow Asset Management. \"I don’t underestimate the fact that there are some big Nasdaq names giving up some of their big gains. When the leaders sell off, it's not a good sign.\"</p>\n<p>Ten of the 11 major S&amp;P 500 sector indexes fell, with tech putting on the worst performance, down 1.6%. Financials gained 0.6% as investors bet on a hawkish tone from the Fed at the end of its two-day meeting on Wednesday.</p>\n<p>Berkshire Hathaway and Bank of America both gained more than 1% and helped keep the S&amp;P 500 from falling further.</p>\n<p>Many investors expect the U.S. central bank to signal a faster wind-down of asset purchases, and thus, a quicker start to interest rate hikes in order to contain the rapid rise in prices.</p>\n<p>\"I would say this meeting is when we start to get some clarity on how they're (the Fed) going to address this idea of inflation that has remained elevated and most likely will remain an issue going into next year,\" said David Keller, chief market strategist at StockCharts.com.</p>\n<p>A Reuters poll of economists sees the central bank hiking interest rates from near zero to 0.25%-0.50% in the third quarter of next year, followed by another in the fourth quarter.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/a6ea56cda700f032a3421aa26db08524\" tg-width=\"596\" tg-height=\"500\" width=\"100%\" height=\"auto\"><span>Inflation</span></p>\n<p>Beyond Meat Inc rallied 9.3% after Piper Sandler upgraded the plant-based meat maker's stock to \"neutral\" from \"underweight.\"</p>\n<p>Pfizer gained 0.6% after saying its antiviral COVID-19 pill showed near 90% efficacy in preventing hospitalizations and deaths in high-risk patients, and that lab data suggests the drug retains its effectiveness against the Omicron variant.</p>\n<p>Declining issues outnumbered advancing ones on the NYSE by a 2.70-to-1 ratio; on Nasdaq, a 2.59-to-1 ratio favored decliners.</p>\n<p>The S&amp;P 500 posted 15 new 52-week highs and 2 new lows; the Nasdaq Composite recorded 18 new highs and 408 new lows.</p>\n<p>Volume on U.S. exchanges was 10.8 billion shares, compared with the 11.5 billion average over the last 20 trading days.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wall Street ends down, investors eye inflation and Omicron</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWall Street ends down, investors eye inflation and Omicron\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-12-15 06:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>* Fed policy decision awaited on Wednesday</p>\n<p>* November PPI logs highest rise since 2010</p>\n<p>* Tech leads declines, financials rally</p>\n<p>* Indexes: Dow -0.30%, S&amp;P 500 -0.75%, Nasdaq -1.14%</p>\n<p>Dec 14 (Reuters) - Wall Street ended lower on Tuesday after data showed producer prices increased more than expected in November, solidifying expectations the Federal Reserve this week will announce a faster wind-down of asset purchases.</p>\n<p>The fast-spreading Omicron coronavirus variant also dampened investor sentiment after the S&amp;P 500 index hit an all-time closing high late last week.</p>\n<p>Declines were led by megacap tech-related stocks, with <a href=\"https://laohu8.com/S/CRM\">Salesforce</a>.com, Microsoft Corp, <a href=\"https://laohu8.com/S/ADBE\">Adobe</a> and Alphabet Inc pulling down the S&amp;P 500 and Nasdaq.</p>\n<p>Apple Inc ended down 0.8%, but off its session lows, after the iPhone maker said it would require customers and employees to wear masks at its U.S. retail stores as COVID-19 cases surge.</p>\n<p>The Dow Jones Industrial Average fell 0.3% to end at 35,544.18 points, while the S&amp;P 500 lost 0.75% to 4,634.09.</p>\n<p>The Nasdaq Composite dropped 1.14% to 15,237.64.</p>\n<p>Data from the Labor Department showed the producer price index (PPI) for final demand in the 12 months through November shot up 9.6%, clocking its largest gain since November 2010. That followed an 8.8% increase in October.</p>\n<p>About two-thirds of Nasdaq stocks traded below their 200-day moving average, according to Refinitiv data, suggesting many stocks within the index are struggling, even as the overall index remains only about 6% below its November record high close.</p>\n<p>\"COVID plus inflation is the Grinch that stole Christmas,\" said Jake Dollarhide, chief executive officer at Longbow Asset Management. \"I don’t underestimate the fact that there are some big Nasdaq names giving up some of their big gains. When the leaders sell off, it's not a good sign.\"</p>\n<p>Ten of the 11 major S&amp;P 500 sector indexes fell, with tech putting on the worst performance, down 1.6%. Financials gained 0.6% as investors bet on a hawkish tone from the Fed at the end of its two-day meeting on Wednesday.</p>\n<p>Berkshire Hathaway and Bank of America both gained more than 1% and helped keep the S&amp;P 500 from falling further.</p>\n<p>Many investors expect the U.S. central bank to signal a faster wind-down of asset purchases, and thus, a quicker start to interest rate hikes in order to contain the rapid rise in prices.</p>\n<p>\"I would say this meeting is when we start to get some clarity on how they're (the Fed) going to address this idea of inflation that has remained elevated and most likely will remain an issue going into next year,\" said David Keller, chief market strategist at StockCharts.com.</p>\n<p>A Reuters poll of economists sees the central bank hiking interest rates from near zero to 0.25%-0.50% in the third quarter of next year, followed by another in the fourth quarter.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/a6ea56cda700f032a3421aa26db08524\" tg-width=\"596\" tg-height=\"500\" width=\"100%\" height=\"auto\"><span>Inflation</span></p>\n<p>Beyond Meat Inc rallied 9.3% after Piper Sandler upgraded the plant-based meat maker's stock to \"neutral\" from \"underweight.\"</p>\n<p>Pfizer gained 0.6% after saying its antiviral COVID-19 pill showed near 90% efficacy in preventing hospitalizations and deaths in high-risk patients, and that lab data suggests the drug retains its effectiveness against the Omicron variant.</p>\n<p>Declining issues outnumbered advancing ones on the NYSE by a 2.70-to-1 ratio; on Nasdaq, a 2.59-to-1 ratio favored decliners.</p>\n<p>The S&amp;P 500 posted 15 new 52-week highs and 2 new lows; the Nasdaq Composite recorded 18 new highs and 408 new lows.</p>\n<p>Volume on U.S. exchanges was 10.8 billion shares, compared with the 11.5 billion average over the last 20 trading days.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4559":"巴菲特持仓","SPY":"标普500ETF","BK4550":"红杉资本持仓",".DJI":"道琼斯",".IXIC":"NASDAQ Composite",".SPX":"S&P 500 Index","SSO":"两倍做多标普500ETF","BK4079":"房地产服务","BK4504":"桥水持仓","SDS":"两倍做空标普500ETF","SH":"标普500反向ETF","COMP":"Compass, Inc.","AAPL":"苹果","BK4534":"瑞士信贷持仓","IVV":"标普500指数ETF","SPXU":"三倍做空标普500ETF","BK4539":"次新股","OEF":"标普100指数ETF-iShares","OEX":"标普100","UPRO":"三倍做多标普500ETF"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2191784951","content_text":"* Fed policy decision awaited on Wednesday\n* November PPI logs highest rise since 2010\n* Tech leads declines, financials rally\n* Indexes: Dow -0.30%, S&P 500 -0.75%, Nasdaq -1.14%\nDec 14 (Reuters) - Wall Street ended lower on Tuesday after data showed producer prices increased more than expected in November, solidifying expectations the Federal Reserve this week will announce a faster wind-down of asset purchases.\nThe fast-spreading Omicron coronavirus variant also dampened investor sentiment after the S&P 500 index hit an all-time closing high late last week.\nDeclines were led by megacap tech-related stocks, with Salesforce.com, Microsoft Corp, Adobe and Alphabet Inc pulling down the S&P 500 and Nasdaq.\nApple Inc ended down 0.8%, but off its session lows, after the iPhone maker said it would require customers and employees to wear masks at its U.S. retail stores as COVID-19 cases surge.\nThe Dow Jones Industrial Average fell 0.3% to end at 35,544.18 points, while the S&P 500 lost 0.75% to 4,634.09.\nThe Nasdaq Composite dropped 1.14% to 15,237.64.\nData from the Labor Department showed the producer price index (PPI) for final demand in the 12 months through November shot up 9.6%, clocking its largest gain since November 2010. That followed an 8.8% increase in October.\nAbout two-thirds of Nasdaq stocks traded below their 200-day moving average, according to Refinitiv data, suggesting many stocks within the index are struggling, even as the overall index remains only about 6% below its November record high close.\n\"COVID plus inflation is the Grinch that stole Christmas,\" said Jake Dollarhide, chief executive officer at Longbow Asset Management. \"I don’t underestimate the fact that there are some big Nasdaq names giving up some of their big gains. When the leaders sell off, it's not a good sign.\"\nTen of the 11 major S&P 500 sector indexes fell, with tech putting on the worst performance, down 1.6%. Financials gained 0.6% as investors bet on a hawkish tone from the Fed at the end of its two-day meeting on Wednesday.\nBerkshire Hathaway and Bank of America both gained more than 1% and helped keep the S&P 500 from falling further.\nMany investors expect the U.S. central bank to signal a faster wind-down of asset purchases, and thus, a quicker start to interest rate hikes in order to contain the rapid rise in prices.\n\"I would say this meeting is when we start to get some clarity on how they're (the Fed) going to address this idea of inflation that has remained elevated and most likely will remain an issue going into next year,\" said David Keller, chief market strategist at StockCharts.com.\nA Reuters poll of economists sees the central bank hiking interest rates from near zero to 0.25%-0.50% in the third quarter of next year, followed by another in the fourth quarter.\nInflation\nBeyond Meat Inc rallied 9.3% after Piper Sandler upgraded the plant-based meat maker's stock to \"neutral\" from \"underweight.\"\nPfizer gained 0.6% after saying its antiviral COVID-19 pill showed near 90% efficacy in preventing hospitalizations and deaths in high-risk patients, and that lab data suggests the drug retains its effectiveness against the Omicron variant.\nDeclining issues outnumbered advancing ones on the NYSE by a 2.70-to-1 ratio; on Nasdaq, a 2.59-to-1 ratio favored decliners.\nThe S&P 500 posted 15 new 52-week highs and 2 new lows; the Nasdaq Composite recorded 18 new highs and 408 new lows.\nVolume on U.S. exchanges was 10.8 billion shares, compared with the 11.5 billion average over the last 20 trading days.","news_type":1},"isVote":1,"tweetType":1,"viewCount":4,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":607091148,"gmtCreate":1639453037283,"gmtModify":1639454888755,"author":{"id":"3578047933589423","authorId":"3578047933589423","name":"PengsieX","avatar":"https://static.tigerbbs.com/ebe92821eba3b91a6431d698b66bbed5","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"Driving me mad","listText":"Driving me mad","text":"Driving me mad","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/607091148","repostId":"1174096078","repostType":4,"repost":{"id":"1174096078","pubTimestamp":1639450379,"share":"https://www.laohu8.com/m/news/1174096078?lang=&edition=full","pubTime":"2021-12-14 10:52","market":"us","language":"en","title":"These 5 stocks are driving the market","url":"https://stock-news.laohu8.com/highlight/detail?id=1174096078","media":"CNN Business","summary":"London (CNN Business) - Despiteanxiety about inflationand theOmicron variant, the stock market is on","content":"<p><b>London (CNN Business)</b>&nbsp;-&nbsp;Despiteanxiety about inflationand theOmicron variant, the stock market is on track for another banner year. That's in large part thanks to stellar gains from just a handful of stocks.</p>\n<p>What's happening: According to new research from Goldman Sachs, just five companies —Microsoft,Apple,Nvidia,Tesla&nbsp;and Google parent&nbsp;Alphabet&nbsp;— have contributed 51% of S&amp;P 500 returns since April. Going back to the beginning of the year, they account for more than a third of the index's rise.</p>\n<p>We've&nbsp;spilled plenty of ink&nbsp;talking about the clout of FAANG stocks —&nbsp;Facebook, Apple,Amazon,Netflix&nbsp;and Google. But is it time to retire FAANG and ring in the era of ... MANTA?</p>\n<p><img src=\"https://static.tigerbbs.com/54f62ca486902385551327c22d6e6c76\" tg-width=\"1200\" tg-height=\"736\" width=\"100%\" height=\"auto\"></p>\n<p>After shooting up 76% in 2020, Amazon's stock is up just 6% this year, compared to a nearly 26% rise in the S&amp;P 500. Supply chain problems and pay hikes to recruit and retain workers have eaten into Amazon's profits despite the ongoing boom in online shopping.</p>\n<p>Netflix's stock has also lost steam, rising 13% this year after skyrocketing 67% in 2020. The company has scored big with shows like \"Squid Game,\" but investors are worried about whether the company can&nbsp;keep rapidly recruiting subscribers&nbsp;as competition among streaming services grows.</p>\n<p>Facebook, now called Meta, has done slightly better, jumping 21% year-to-date. But that leaves it on track for its worst year since 2018, as investors weigh regulatory threats and the social network's pivot to virtual reality.</p>\n<p>Shares in Apple and Google have popped 35% and 69%, respectively. That's good enough to join the MANTA club.</p>\n<p>Tesla also makes the cut. After rising an eye-popping 743% in 2020, shares of Elon Musk's electric carmaker have kept pushing higher. They're up 44% since the beginning of 2021 as Wall Street tries to position itself for the green energy transition.</p>\n<p>Chipmaker Nvidia, for its part, has shaken off global supply issues and matched 122% gains last year with a 131% increase in 2021. Microsoft's surging cloud business has driven a 54% stock jump this year, also beating its performance in 2020.</p>\n<p>Step back: There have been moments over the past 12 months when investors have tried to reduce their exposure to high-growth companies, which don't look as attractive in a world where interest rates could begin to rise. But on the whole, tech and Tesla have remained the&nbsp;undisputed market champions&nbsp;— even if the basket of winners looks slightly different.</p>\n<p>A question that often arises when looking at the small number of companies that power the S&amp;P 500 is whether the concentration makes the market vulnerable to a larger pullback. If something happens to Nvidia, for example, will everyone get hurt — whether they own stock in the company or not?</p>\n<p>Goldman Sachs thinks that as it stands, the risk is low. The investment bank said investors have already priced in the beginning of interest rate hikes by the Federal Reserve and notes that borrowing costs will remain extremely low. Corporate earnings also \"continue to surpass expectations.\"</p>\n<p>\"While 'unknown unknowns' cause the largest drawdowns and by their nature are impossible to assess in advance, the macro environment does not suggest drawdown risk is elevated in the coming months,\" its strategists said.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>These 5 stocks are driving the market</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThese 5 stocks are driving the market\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-14 10:52 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://edition.cnn.com/2021/12/13/investing/premarket-stocks-trading/index.html><strong>CNN Business</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>London (CNN Business) - Despiteanxiety about inflationand theOmicron variant, the stock market is on track for another banner year. That's in large part thanks to stellar gains from just a handful of ...</p>\n\n<a href=\"https://edition.cnn.com/2021/12/13/investing/premarket-stocks-trading/index.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVDA":"英伟达","AMZN":"亚马逊","AAPL":"苹果","NFLX":"奈飞","TSLA":"特斯拉","GOOGL":"谷歌A","MSFT":"微软"},"source_url":"https://edition.cnn.com/2021/12/13/investing/premarket-stocks-trading/index.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1174096078","content_text":"London (CNN Business) - Despiteanxiety about inflationand theOmicron variant, the stock market is on track for another banner year. That's in large part thanks to stellar gains from just a handful of stocks.\nWhat's happening: According to new research from Goldman Sachs, just five companies —Microsoft,Apple,Nvidia,Tesla and Google parent Alphabet — have contributed 51% of S&P 500 returns since April. Going back to the beginning of the year, they account for more than a third of the index's rise.\nWe've spilled plenty of ink talking about the clout of FAANG stocks — Facebook, Apple,Amazon,Netflix and Google. But is it time to retire FAANG and ring in the era of ... MANTA?\n\nAfter shooting up 76% in 2020, Amazon's stock is up just 6% this year, compared to a nearly 26% rise in the S&P 500. Supply chain problems and pay hikes to recruit and retain workers have eaten into Amazon's profits despite the ongoing boom in online shopping.\nNetflix's stock has also lost steam, rising 13% this year after skyrocketing 67% in 2020. The company has scored big with shows like \"Squid Game,\" but investors are worried about whether the company can keep rapidly recruiting subscribers as competition among streaming services grows.\nFacebook, now called Meta, has done slightly better, jumping 21% year-to-date. But that leaves it on track for its worst year since 2018, as investors weigh regulatory threats and the social network's pivot to virtual reality.\nShares in Apple and Google have popped 35% and 69%, respectively. That's good enough to join the MANTA club.\nTesla also makes the cut. After rising an eye-popping 743% in 2020, shares of Elon Musk's electric carmaker have kept pushing higher. They're up 44% since the beginning of 2021 as Wall Street tries to position itself for the green energy transition.\nChipmaker Nvidia, for its part, has shaken off global supply issues and matched 122% gains last year with a 131% increase in 2021. Microsoft's surging cloud business has driven a 54% stock jump this year, also beating its performance in 2020.\nStep back: There have been moments over the past 12 months when investors have tried to reduce their exposure to high-growth companies, which don't look as attractive in a world where interest rates could begin to rise. But on the whole, tech and Tesla have remained the undisputed market champions — even if the basket of winners looks slightly different.\nA question that often arises when looking at the small number of companies that power the S&P 500 is whether the concentration makes the market vulnerable to a larger pullback. If something happens to Nvidia, for example, will everyone get hurt — whether they own stock in the company or not?\nGoldman Sachs thinks that as it stands, the risk is low. The investment bank said investors have already priced in the beginning of interest rate hikes by the Federal Reserve and notes that borrowing costs will remain extremely low. Corporate earnings also \"continue to surpass expectations.\"\n\"While 'unknown unknowns' cause the largest drawdowns and by their nature are impossible to assess in advance, the macro environment does not suggest drawdown risk is elevated in the coming months,\" its strategists said.","news_type":1},"isVote":1,"tweetType":1,"viewCount":98,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":604308773,"gmtCreate":1639325520814,"gmtModify":1639325521142,"author":{"id":"3578047933589423","authorId":"3578047933589423","name":"PengsieX","avatar":"https://static.tigerbbs.com/ebe92821eba3b91a6431d698b66bbed5","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"This week no IPO to buy then","listText":"This week no IPO to buy then","text":"This week no IPO to buy then","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/604308773","repostId":"1103250344","repostType":4,"repost":{"id":"1103250344","pubTimestamp":1639280672,"share":"https://www.laohu8.com/m/news/1103250344?lang=&edition=full","pubTime":"2021-12-12 11:44","market":"us","language":"en","title":"US IPO Week Ahead: IoT solutions, wine, and satellites in a 3 IPO week","url":"https://stock-news.laohu8.com/highlight/detail?id=1103250344","media":"renaissancecap...","summary":"The IPO market is expected to stay relatively quiet in the week ahead with three IPOs scheduled to r","content":"<p>The IPO market is expected to stay relatively quiet in the week ahead with three IPOs scheduled to raise $789 million.</p>\n<p>IoT solutions developer<b>Samsara</b>(IOT) plans to raise $753 million at an $11.6 billion market cap. This \"internet-of-things\" company provides a cloud-based platform that connects the assets of businesses with physical operations, enhancing operational efficiency and asset and employee productivity. Fast growing but highly unprofitable, Samsara saw double-digit growth for customers with $100k+ ARR in the 9mo FY22.</p>\n<p>Wine brand<b>Fresh Vine Wine</b>(VINE) plans to raise $21 million at a $116 million market cap. This celebrity-founded company produces low carb, low calorie premium wines. Growing but highly unprofitable, Fresh Vine sells its wines through wholesale, retail, and DTC channels, and is able to conduct wholesale distribution in all 50 states and Puerto Rico.</p>\n<p>Micro-cap satellite developer<b>Sidus Space</b>(SIDU) plans to raise $15 million at an $81 million market cap. This company provides commercial satellite services such as design, manufacture, launch, and data collection. &nbsp;Sidus Space has generated space-related manufacturing revenues to date, but is highly unprofitable with negative gross margin in the 9mo21.</p>\n<p><img src=\"https://static.tigerbbs.com/ead80e54642569e2b7b368c8d50dc265\" tg-width=\"1409\" tg-height=\"457\" referrerpolicy=\"no-referrer\"></p>","source":"lsy1619493174116","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US IPO Week Ahead: IoT solutions, wine, and satellites in a 3 IPO week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS IPO Week Ahead: IoT solutions, wine, and satellites in a 3 IPO week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-12 11:44 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.renaissancecapital.com/IPO-Center/News/89474/US-IPO-Week-Ahead-IoT-solutions-wine-and-satellites-in-a-3-IPO-week><strong>renaissancecap...</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The IPO market is expected to stay relatively quiet in the week ahead with three IPOs scheduled to raise $789 million.\nIoT solutions developerSamsara(IOT) plans to raise $753 million at an $11.6 ...</p>\n\n<a href=\"https://www.renaissancecapital.com/IPO-Center/News/89474/US-IPO-Week-Ahead-IoT-solutions-wine-and-satellites-in-a-3-IPO-week\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯","IOT":"Samsara, Inc.","SIDU":"Sidus Space Inc.",".IXIC":"NASDAQ Composite","VINE":"Fresh Vine Wine, Inc",".SPX":"S&P 500 Index"},"source_url":"https://www.renaissancecapital.com/IPO-Center/News/89474/US-IPO-Week-Ahead-IoT-solutions-wine-and-satellites-in-a-3-IPO-week","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1103250344","content_text":"The IPO market is expected to stay relatively quiet in the week ahead with three IPOs scheduled to raise $789 million.\nIoT solutions developerSamsara(IOT) plans to raise $753 million at an $11.6 billion market cap. This \"internet-of-things\" company provides a cloud-based platform that connects the assets of businesses with physical operations, enhancing operational efficiency and asset and employee productivity. Fast growing but highly unprofitable, Samsara saw double-digit growth for customers with $100k+ ARR in the 9mo FY22.\nWine brandFresh Vine Wine(VINE) plans to raise $21 million at a $116 million market cap. This celebrity-founded company produces low carb, low calorie premium wines. Growing but highly unprofitable, Fresh Vine sells its wines through wholesale, retail, and DTC channels, and is able to conduct wholesale distribution in all 50 states and Puerto Rico.\nMicro-cap satellite developerSidus Space(SIDU) plans to raise $15 million at an $81 million market cap. This company provides commercial satellite services such as design, manufacture, launch, and data collection.  Sidus Space has generated space-related manufacturing revenues to date, but is highly unprofitable with negative gross margin in the 9mo21.","news_type":1},"isVote":1,"tweetType":1,"viewCount":135,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":690439639,"gmtCreate":1639699906137,"gmtModify":1639699906509,"author":{"id":"3578047933589423","authorId":"3578047933589423","name":"PengsieX","avatar":"https://static.tigerbbs.com/ebe92821eba3b91a6431d698b66bbed5","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"The surge is amazing&nbsp;","listText":"The surge is amazing&nbsp;","text":"The surge is amazing","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/690439639","repostId":"1148045391","repostType":4,"repost":{"id":"1148045391","pubTimestamp":1639698518,"share":"https://www.laohu8.com/m/news/1148045391?lang=&edition=full","pubTime":"2021-12-17 07:48","market":"us","language":"en","title":"Is Ford Stock the New Tesla?","url":"https://stock-news.laohu8.com/highlight/detail?id=1148045391","media":"Barrons","summary":"Shares of Ford Motor,surprisingly, have become somewhat controversial on Wall Street headed into 202","content":"<p>Shares of&nbsp;Ford Motor,surprisingly, have become somewhat controversial on Wall Street headed into 2022. Some analysts are taking their chips off the table, while others are doubling down.</p>\n<p>On Thursday, Barclays analyst Brian Johnson increased his price target for&nbsp;Ford&nbsp;stock (ticker: F) to $23 from $18 and kept his Buy rating. Johnson believes Ford shares will keep working in 2022 amid low dealer inventories and high vehicle pricing.</p>\n<p>Ford stock has had a great 2021 so far. Shares have soared about 131% year to date.</p>\n<p>It’s the second price target bump for Ford stock in the past couple of days. On Wednesday, Wells Fargo analyst Colin Langan increased his price target to $25 from $19 a share.</p>\n<p>Not everyone is increasingly bullish on the auto maker, though. On Monday, Daiwa analyst Jairam Nathan downgraded the stock to Sell from Hold. Although he did take his price target to $19 from $16 a share.</p>\n<p>After all the recent analyst adjustments, Ford price targets now range from $12 to $25 a share. The $13 spread is about 65% of the current share price. The average bull-bear spread for stocks in the Dow is about 48%.</p>\n<p>Three months ago, target prices for Ford stock ranged from about $11 to $18 a share; the $7 spread was about 50% of the current stock price. This all illustrates that Ford stock is getting a little more controversial on Wall Street.</p>\n<p>Even though Wall Street can’t seem to agree on Ford,Tesla&nbsp;(TSLA) remains the king of car-stock controversy. The bull-bear spread for Tesla stock coming from large brokerage firms is about $1,330, or almost 140% of the current stock price.</p>\n<p>One interpretation of increasing disagreement over Ford stock’s value is that some analysts aren’t sure Ford’s 2021 gains are justified. Ford stock has benefited from improving auto demand and higher vehicle pricing. That part of Ford’s gains likely doesn’t vex analysts. But Ford shares have also gained because of improving electric vehicle sales. The company has sold about 25,000 all-electric Mustang Mach E vehicles so far this year. Ford EV momentum might be harder for analysts to reward.</p>\n<p>In 2022, Ford is launching an all-electric F-150. How sales of that vehicle ramp will go a long way in determining how Ford stock performs this coming year. Rising EV sales will be a key factor for Ford investors in 2022—just like rising EV sales are a key factor for Tesla investors every year.</p>\n<p>About 54% of analysts covering Ford stock rate share Buy. The average Buy-rating ratio for stocks in the S&amp;P is about 55%. About 48% of analysts covering Tesla stock rate shares Buy.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Ford Stock the New Tesla?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Ford Stock the New Tesla?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-17 07:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/ford-stock-tesla-evs-51639664981><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Ford Motor,surprisingly, have become somewhat controversial on Wall Street headed into 2022. Some analysts are taking their chips off the table, while others are doubling down.\nOn Thursday, ...</p>\n\n<a href=\"https://www.barrons.com/articles/ford-stock-tesla-evs-51639664981\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"F":"福特汽车"},"source_url":"https://www.barrons.com/articles/ford-stock-tesla-evs-51639664981","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1148045391","content_text":"Shares of Ford Motor,surprisingly, have become somewhat controversial on Wall Street headed into 2022. Some analysts are taking their chips off the table, while others are doubling down.\nOn Thursday, Barclays analyst Brian Johnson increased his price target for Ford stock (ticker: F) to $23 from $18 and kept his Buy rating. Johnson believes Ford shares will keep working in 2022 amid low dealer inventories and high vehicle pricing.\nFord stock has had a great 2021 so far. Shares have soared about 131% year to date.\nIt’s the second price target bump for Ford stock in the past couple of days. On Wednesday, Wells Fargo analyst Colin Langan increased his price target to $25 from $19 a share.\nNot everyone is increasingly bullish on the auto maker, though. On Monday, Daiwa analyst Jairam Nathan downgraded the stock to Sell from Hold. Although he did take his price target to $19 from $16 a share.\nAfter all the recent analyst adjustments, Ford price targets now range from $12 to $25 a share. The $13 spread is about 65% of the current share price. The average bull-bear spread for stocks in the Dow is about 48%.\nThree months ago, target prices for Ford stock ranged from about $11 to $18 a share; the $7 spread was about 50% of the current stock price. This all illustrates that Ford stock is getting a little more controversial on Wall Street.\nEven though Wall Street can’t seem to agree on Ford,Tesla (TSLA) remains the king of car-stock controversy. The bull-bear spread for Tesla stock coming from large brokerage firms is about $1,330, or almost 140% of the current stock price.\nOne interpretation of increasing disagreement over Ford stock’s value is that some analysts aren’t sure Ford’s 2021 gains are justified. Ford stock has benefited from improving auto demand and higher vehicle pricing. That part of Ford’s gains likely doesn’t vex analysts. But Ford shares have also gained because of improving electric vehicle sales. The company has sold about 25,000 all-electric Mustang Mach E vehicles so far this year. Ford EV momentum might be harder for analysts to reward.\nIn 2022, Ford is launching an all-electric F-150. How sales of that vehicle ramp will go a long way in determining how Ford stock performs this coming year. Rising EV sales will be a key factor for Ford investors in 2022—just like rising EV sales are a key factor for Tesla investors every year.\nAbout 54% of analysts covering Ford stock rate share Buy. The average Buy-rating ratio for stocks in the S&P is about 55%. About 48% of analysts covering Tesla stock rate shares Buy.","news_type":1},"isVote":1,"tweetType":1,"viewCount":107,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698456473,"gmtCreate":1640506984623,"gmtModify":1640506984989,"author":{"id":"3578047933589423","authorId":"3578047933589423","name":"PengsieX","avatar":"https://static.tigerbbs.com/ebe92821eba3b91a6431d698b66bbed5","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"200 or 3000 dollar stock... If there's a recession one way or another you'll be affected too. Don't spend money on stock","listText":"200 or 3000 dollar stock... If there's a recession one way or another you'll be affected too. Don't spend money on stock","text":"200 or 3000 dollar stock... If there's a recession one way or another you'll be affected too. Don't spend money on stock","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/698456473","repostId":"2193781141","repostType":4,"repost":{"id":"2193781141","pubTimestamp":1640485676,"share":"https://www.laohu8.com/m/news/2193781141?lang=&edition=full","pubTime":"2021-12-26 10:27","market":"us","language":"en","title":"2 Top Tech Stocks to Buy During a Recession","url":"https://stock-news.laohu8.com/highlight/detail?id=2193781141","media":"Motley Fool","summary":"Market crashes are inevitable, but they're the perfect time to buy great businesses at a discount.","content":"<p>We're days away from the end of 2021, and the <b>S&amp;P 500</b> has put on a master class in outperforming expectations. Even with its pullback in recent days, the broad market index has gained nearly 30% this year, more than double its long-term historical average.</p>\n<p>Yet that just means we're another day closer to the inevitable market correction. Just as night follows day, a stock market crash is inevitable because market declines are a natural part of the normal business and investment cycle. No <a href=\"https://laohu8.com/S/AONE.U\">one</a> can forecast exactly when it will strike, but smart investors realize it's best to prepare for the eventuality.</p>\n<p>For as long as people have been investing, stretching even as far back to the Dutch tulip mania in the 1600s, busts have followed booms. And what a boom we've enjoyed! Since the bottom of the Great Recession, the S&amp;P 500 has quadrupled in value.</p>\n<p>2020's pandemic-driven 34% drop in the stock indexes within the span of just a few weeks was the worst on record. But savvy investors don't have to worry. These events are not a problem when you're invested in the right companies. Being prepared for the worst and hoping for the best means when the next stock market crash or correction occurs, you'll want to have your money invested in stocks that will help lead the way forward. Here are two tech stocks you'll want to buy.</p>\n<h2>1. Apple</h2>\n<p>The burden that inflation is imposing on consumers also poses a threat to some of the biggest, best-run businesses, like <b>Apple</b> (NASDAQ:AAPL), which is currently benefiting from the smartphone upgrade cycle and the rollout of 5G network infrastructure. Any attempt by the Federal Reserve to raise interest rates to contain runaway inflation could cause an economic slowdown by making money more expensive to borrow. Stock valuations would also turn lower.</p>\n<p>That's not necessarily bad news for investors who might find Apple's $2.8 trillion valuation a bit rich to buy into at the moment. The stock trades at 30 times trailing earnings, or about double its typical multiple. A correction would bring Apple back into the realm of the attainable, even as its business continues jogging forward.</p>\n<p>Sales of the iPhone 13 are outpacing those of the iPhone 12 at the same time, but Apple reportedly warned suppliers that demand is waning as the calendar year progresses. It's not necessarily for a lack of consumer desire, but rather the global supply chain constraints that have made it difficult to find the product. Apple previously cut its iPhone production target by 10 million units from its original goal of 90 million.</p>\n<p>Analysts think many consumers may choose to forgo the iPhone 13 and wait for the next upgrade. Coupled with a market crash, that could put Apple stock at a very attractive entry point with pent-up demand for the next iteration of the iPhone.</p>\n<h2>2. Amazon</h2>\n<p>Few companies are as essential to the working of the U.S. economy as <b>Amazon</b>&nbsp;(NASDAQ:AMZN). It will account for 41.4% of all online spending in the U.S. this year, according to eMarketer estimates. At the same time, Amazon Web Services (AWS), its cloud infrastructure business, is on track to generate over $60 billion in annual revenue in 2021 based on its year-to-date performance. The company is responsible for thousands of web-based businesses and the federal government's ability to remain online, making Amazon crucial to a well-functioning economy.</p>\n<p>That won't change if the stock market collapses. Its share of U.S. retail e-commerce sales will be more than 50% larger than the shares of the next nine e-commerce companies combined. Amazon's piece of the online market is nearly six times more than <b>Walmart</b>'s second-place share at just 7.2%, and 10 times greater than third-place <b><a href=\"https://laohu8.com/S/EBAY\">eBay</a></b>. E-commerce data tracker Edge by Ascential expects Amazon will see $26.7 billion just in online grocery sales five from now years, or nearly double its current amount.</p>\n<p>Amid rising prices and supply chain woes, Amazon has become a lifeline for many, and that will continue long after any financial restructuring. The stock gained 76% during the first year of the pandemic and took a breather during the reopening of the economy. Amazon shares have been relatively flat all year long. A correction would allow investors to buy a tech stock at a more reasonable valuation even as its crucial role only gets reinforced.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Top Tech Stocks to Buy During a Recession</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Top Tech Stocks to Buy During a Recession\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-26 10:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/24/2-top-tech-stocks-to-buy-during-a-recession/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>We're days away from the end of 2021, and the S&P 500 has put on a master class in outperforming expectations. Even with its pullback in recent days, the broad market index has gained nearly 30% ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/24/2-top-tech-stocks-to-buy-during-a-recession/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4524":"宅经济概念","BK4535":"淡马锡持仓","BK4538":"云计算","BK4527":"明星科技股","BK4559":"巴菲特持仓","BK4501":"段永平概念","AAPL":"苹果","BK4550":"红杉资本持仓","BK4503":"景林资产持仓","BK4122":"互联网与直销零售","BK4551":"寇图资本持仓","BK4561":"索罗斯持仓","BK4505":"高瓴资本持仓","BK4548":"巴美列捷福持仓","BK4170":"电脑硬件、储存设备及电脑周边","AMZN":"亚马逊","BK4554":"元宇宙及AR概念","BK4532":"文艺复兴科技持仓","BK4515":"5G概念","BK4553":"喜马拉雅资本持仓","BK4507":"流媒体概念","BK4534":"瑞士信贷持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4566":"资本集团"},"source_url":"https://www.fool.com/investing/2021/12/24/2-top-tech-stocks-to-buy-during-a-recession/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2193781141","content_text":"We're days away from the end of 2021, and the S&P 500 has put on a master class in outperforming expectations. Even with its pullback in recent days, the broad market index has gained nearly 30% this year, more than double its long-term historical average.\nYet that just means we're another day closer to the inevitable market correction. Just as night follows day, a stock market crash is inevitable because market declines are a natural part of the normal business and investment cycle. No one can forecast exactly when it will strike, but smart investors realize it's best to prepare for the eventuality.\nFor as long as people have been investing, stretching even as far back to the Dutch tulip mania in the 1600s, busts have followed booms. And what a boom we've enjoyed! Since the bottom of the Great Recession, the S&P 500 has quadrupled in value.\n2020's pandemic-driven 34% drop in the stock indexes within the span of just a few weeks was the worst on record. But savvy investors don't have to worry. These events are not a problem when you're invested in the right companies. Being prepared for the worst and hoping for the best means when the next stock market crash or correction occurs, you'll want to have your money invested in stocks that will help lead the way forward. Here are two tech stocks you'll want to buy.\n1. Apple\nThe burden that inflation is imposing on consumers also poses a threat to some of the biggest, best-run businesses, like Apple (NASDAQ:AAPL), which is currently benefiting from the smartphone upgrade cycle and the rollout of 5G network infrastructure. Any attempt by the Federal Reserve to raise interest rates to contain runaway inflation could cause an economic slowdown by making money more expensive to borrow. Stock valuations would also turn lower.\nThat's not necessarily bad news for investors who might find Apple's $2.8 trillion valuation a bit rich to buy into at the moment. The stock trades at 30 times trailing earnings, or about double its typical multiple. A correction would bring Apple back into the realm of the attainable, even as its business continues jogging forward.\nSales of the iPhone 13 are outpacing those of the iPhone 12 at the same time, but Apple reportedly warned suppliers that demand is waning as the calendar year progresses. It's not necessarily for a lack of consumer desire, but rather the global supply chain constraints that have made it difficult to find the product. Apple previously cut its iPhone production target by 10 million units from its original goal of 90 million.\nAnalysts think many consumers may choose to forgo the iPhone 13 and wait for the next upgrade. Coupled with a market crash, that could put Apple stock at a very attractive entry point with pent-up demand for the next iteration of the iPhone.\n2. Amazon\nFew companies are as essential to the working of the U.S. economy as Amazon (NASDAQ:AMZN). It will account for 41.4% of all online spending in the U.S. this year, according to eMarketer estimates. At the same time, Amazon Web Services (AWS), its cloud infrastructure business, is on track to generate over $60 billion in annual revenue in 2021 based on its year-to-date performance. The company is responsible for thousands of web-based businesses and the federal government's ability to remain online, making Amazon crucial to a well-functioning economy.\nThat won't change if the stock market collapses. Its share of U.S. retail e-commerce sales will be more than 50% larger than the shares of the next nine e-commerce companies combined. Amazon's piece of the online market is nearly six times more than Walmart's second-place share at just 7.2%, and 10 times greater than third-place eBay. E-commerce data tracker Edge by Ascential expects Amazon will see $26.7 billion just in online grocery sales five from now years, or nearly double its current amount.\nAmid rising prices and supply chain woes, Amazon has become a lifeline for many, and that will continue long after any financial restructuring. The stock gained 76% during the first year of the pandemic and took a breather during the reopening of the economy. Amazon shares have been relatively flat all year long. A correction would allow investors to buy a tech stock at a more reasonable valuation even as its crucial role only gets reinforced.","news_type":1},"isVote":1,"tweetType":1,"viewCount":231,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":607772422,"gmtCreate":1639610572751,"gmtModify":1639610573107,"author":{"id":"3578047933589423","authorId":"3578047933589423","name":"PengsieX","avatar":"https://static.tigerbbs.com/ebe92821eba3b91a6431d698b66bbed5","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"U turn let's go!&nbsp;","listText":"U turn let's go!&nbsp;","text":"U turn let's go!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/607772422","repostId":"2191994940","repostType":4,"repost":{"id":"2191994940","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1639608624,"share":"https://www.laohu8.com/m/news/2191994940?lang=&edition=full","pubTime":"2021-12-16 06:50","market":"us","language":"en","title":"Wall St ends higher; Fed to end bond purchases in March","url":"https://stock-news.laohu8.com/highlight/detail?id=2191994940","media":"Reuters","summary":"Fed says it will end bond purchases in March\nTech and healthcare the strongest sectors\nIndexes: Dow ","content":"<ul>\n <li>Fed says it will end bond purchases in March</li>\n <li>Tech and healthcare the strongest sectors</li>\n <li>Indexes: Dow +1.08%, S&amp;P 500 +1.63%, Nasdaq +2.15%</li>\n</ul>\n<p>Dec 15 (Reuters) - Wall Street ended sharply higher on Wednesday after the Federal Reserve said it would end its pandemic-era bond purchases in March as it exits from policies enacted at the start of the health crisis.</p>\n<p>Following its two-day policy meeting, the Fed signaled its inflation target has been met, and its announcement on ending the bond purchases paved the way for three quarter-percentage-point interest rate increases by the end of 2022.</p>\n<p>All three main U.S. stock indexes reversed earlier losses and climbed into positive territory. Wall Street extended those gains as Fed Chair Jerome Powell during his news conference struck an&nbsp;upbeat tone&nbsp;about the U.S. economic recovery and expressed willingness to raise interest rates as necessary to control inflation.</p>\n<p>\"What the markets are saying is, because the Fed is increasing their taper, maybe they feel inflation is under control,\" said Tom Martin, senior portfolio manager at Globalt Investments in Atlanta. \"They did what was expected. It’s going to add to the credibility for the Fed and that will be - on balance - neutral to positive for the markets.\"</p>\n<p>The S&amp;P 500's sharp rise on Wednesday erased almost all of its losses from earlier this week and left it just short of its record-high close on Friday.</p>\n<p>For the session, the Dow Jones Industrial Average&nbsp;rose 1.08% to end at 35,927.43 points, while the S&amp;P 500&nbsp;gained 1.63% to 4,709.85.</p>\n<p>The Nasdaq Composite&nbsp;climbed 2.15% to 15,565.58.</p>\n<p>Volume on U.S. exchanges was 12.2 billion shares, strong compared with the 11.6 billion average over the last 20 trading days.</p>\n<p>Inflation and higher interest rates have become a major concern on Wall Street in recent months. Data on Tuesday showed producer prices increased more than expected in the 12 months through November, clocking their largest gain since 2010. Last week's consumer prices data showed the biggest gain in almost four decades.</p>\n<p>\"You had hedge funds positioned for the worst, in the terms of the worst for equities, coming in to the Fed statement,\" said Michael James, managing director of equity trading at Wedbush Securities in Los Angeles. \"Today, I think, is a function of sell the expectation and buy the news.\"</p>\n<p>Among the 11 S&amp;P 500 sector indexes, technology&nbsp;jumped 2.7% and healthcare&nbsp;rallied 2.1%.</p>\n<p>Apple Inc&nbsp;climbed 2.85% and Nvidia Corp&nbsp;rallied 7.49%, with both lifting the S&amp;P 500 more than any other stocks.</p>\n<p>The Philadelphia Semiconductor index&nbsp;jumped 3.7%.</p>\n<p>Albemarle Corp&nbsp;ended 1.67% lower after Goldman Sachs downgraded the lithium producer to \"sell\" from \"neutral.\"</p>\n<p>Advancing issues outnumbered declining ones on the NYSE by a 1.85-to-1 ratio; on Nasdaq, a 1.70-to-1 ratio favored advancers.</p>\n<p>The S&amp;P 500 posted 40 new 52-week highs and 10 new lows; the Nasdaq Composite recorded 38 new highs and 545 new lows.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wall St ends higher; Fed to end bond purchases in March</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWall St ends higher; Fed to end bond purchases in March\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-12-16 06:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<ul>\n <li>Fed says it will end bond purchases in March</li>\n <li>Tech and healthcare the strongest sectors</li>\n <li>Indexes: Dow +1.08%, S&amp;P 500 +1.63%, Nasdaq +2.15%</li>\n</ul>\n<p>Dec 15 (Reuters) - Wall Street ended sharply higher on Wednesday after the Federal Reserve said it would end its pandemic-era bond purchases in March as it exits from policies enacted at the start of the health crisis.</p>\n<p>Following its two-day policy meeting, the Fed signaled its inflation target has been met, and its announcement on ending the bond purchases paved the way for three quarter-percentage-point interest rate increases by the end of 2022.</p>\n<p>All three main U.S. stock indexes reversed earlier losses and climbed into positive territory. Wall Street extended those gains as Fed Chair Jerome Powell during his news conference struck an&nbsp;upbeat tone&nbsp;about the U.S. economic recovery and expressed willingness to raise interest rates as necessary to control inflation.</p>\n<p>\"What the markets are saying is, because the Fed is increasing their taper, maybe they feel inflation is under control,\" said Tom Martin, senior portfolio manager at Globalt Investments in Atlanta. \"They did what was expected. It’s going to add to the credibility for the Fed and that will be - on balance - neutral to positive for the markets.\"</p>\n<p>The S&amp;P 500's sharp rise on Wednesday erased almost all of its losses from earlier this week and left it just short of its record-high close on Friday.</p>\n<p>For the session, the Dow Jones Industrial Average&nbsp;rose 1.08% to end at 35,927.43 points, while the S&amp;P 500&nbsp;gained 1.63% to 4,709.85.</p>\n<p>The Nasdaq Composite&nbsp;climbed 2.15% to 15,565.58.</p>\n<p>Volume on U.S. exchanges was 12.2 billion shares, strong compared with the 11.6 billion average over the last 20 trading days.</p>\n<p>Inflation and higher interest rates have become a major concern on Wall Street in recent months. Data on Tuesday showed producer prices increased more than expected in the 12 months through November, clocking their largest gain since 2010. Last week's consumer prices data showed the biggest gain in almost four decades.</p>\n<p>\"You had hedge funds positioned for the worst, in the terms of the worst for equities, coming in to the Fed statement,\" said Michael James, managing director of equity trading at Wedbush Securities in Los Angeles. \"Today, I think, is a function of sell the expectation and buy the news.\"</p>\n<p>Among the 11 S&amp;P 500 sector indexes, technology&nbsp;jumped 2.7% and healthcare&nbsp;rallied 2.1%.</p>\n<p>Apple Inc&nbsp;climbed 2.85% and Nvidia Corp&nbsp;rallied 7.49%, with both lifting the S&amp;P 500 more than any other stocks.</p>\n<p>The Philadelphia Semiconductor index&nbsp;jumped 3.7%.</p>\n<p>Albemarle Corp&nbsp;ended 1.67% lower after Goldman Sachs downgraded the lithium producer to \"sell\" from \"neutral.\"</p>\n<p>Advancing issues outnumbered declining ones on the NYSE by a 1.85-to-1 ratio; on Nasdaq, a 1.70-to-1 ratio favored advancers.</p>\n<p>The S&amp;P 500 posted 40 new 52-week highs and 10 new lows; the Nasdaq Composite recorded 38 new highs and 545 new lows.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".SPX":"S&P 500 Index","ALB":"美国雅保","AAPL":"苹果",".DJI":"道琼斯","NVDA":"英伟达",".IXIC":"NASDAQ Composite"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2191994940","content_text":"Fed says it will end bond purchases in March\nTech and healthcare the strongest sectors\nIndexes: Dow +1.08%, S&P 500 +1.63%, Nasdaq +2.15%\n\nDec 15 (Reuters) - Wall Street ended sharply higher on Wednesday after the Federal Reserve said it would end its pandemic-era bond purchases in March as it exits from policies enacted at the start of the health crisis.\nFollowing its two-day policy meeting, the Fed signaled its inflation target has been met, and its announcement on ending the bond purchases paved the way for three quarter-percentage-point interest rate increases by the end of 2022.\nAll three main U.S. stock indexes reversed earlier losses and climbed into positive territory. Wall Street extended those gains as Fed Chair Jerome Powell during his news conference struck an upbeat tone about the U.S. economic recovery and expressed willingness to raise interest rates as necessary to control inflation.\n\"What the markets are saying is, because the Fed is increasing their taper, maybe they feel inflation is under control,\" said Tom Martin, senior portfolio manager at Globalt Investments in Atlanta. \"They did what was expected. It’s going to add to the credibility for the Fed and that will be - on balance - neutral to positive for the markets.\"\nThe S&P 500's sharp rise on Wednesday erased almost all of its losses from earlier this week and left it just short of its record-high close on Friday.\nFor the session, the Dow Jones Industrial Average rose 1.08% to end at 35,927.43 points, while the S&P 500 gained 1.63% to 4,709.85.\nThe Nasdaq Composite climbed 2.15% to 15,565.58.\nVolume on U.S. exchanges was 12.2 billion shares, strong compared with the 11.6 billion average over the last 20 trading days.\nInflation and higher interest rates have become a major concern on Wall Street in recent months. Data on Tuesday showed producer prices increased more than expected in the 12 months through November, clocking their largest gain since 2010. Last week's consumer prices data showed the biggest gain in almost four decades.\n\"You had hedge funds positioned for the worst, in the terms of the worst for equities, coming in to the Fed statement,\" said Michael James, managing director of equity trading at Wedbush Securities in Los Angeles. \"Today, I think, is a function of sell the expectation and buy the news.\"\nAmong the 11 S&P 500 sector indexes, technology jumped 2.7% and healthcare rallied 2.1%.\nApple Inc climbed 2.85% and Nvidia Corp rallied 7.49%, with both lifting the S&P 500 more than any other stocks.\nThe Philadelphia Semiconductor index jumped 3.7%.\nAlbemarle Corp ended 1.67% lower after Goldman Sachs downgraded the lithium producer to \"sell\" from \"neutral.\"\nAdvancing issues outnumbered declining ones on the NYSE by a 1.85-to-1 ratio; on Nasdaq, a 1.70-to-1 ratio favored advancers.\nThe S&P 500 posted 40 new 52-week highs and 10 new lows; the Nasdaq Composite recorded 38 new highs and 545 new lows.","news_type":1},"isVote":1,"tweetType":1,"viewCount":15,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":870555331,"gmtCreate":1636637815739,"gmtModify":1636637942654,"author":{"id":"3578047933589423","authorId":"3578047933589423","name":"PengsieX","avatar":"https://static.tigerbbs.com/ebe92821eba3b91a6431d698b66bbed5","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"And lose customers instead lol","listText":"And lose customers instead lol","text":"And lose customers instead lol","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/870555331","repostId":"1171908836","repostType":4,"repost":{"id":"1171908836","pubTimestamp":1636637696,"share":"https://www.laohu8.com/m/news/1171908836?lang=&edition=full","pubTime":"2021-11-11 21:34","market":"us","language":"en","title":"Uber Bumps Up Base Fares In London To Bring Back Drivers","url":"https://stock-news.laohu8.com/highlight/detail?id=1171908836","media":"Benzinga","summary":"Uber Technologies bumped up base fares in London by 10% to attract more drivers, Bloomberg reports.\n","content":"<ul>\n <li><b>Uber Technologies</b>&nbsp;bumped up base fares in London by 10% to attract more drivers,&nbsp;Bloomberg reports.</li>\n <li>Customers traveling from Heathrow, Gatwick, Luton, and Stansted airports will face an additional 15% hike in fares at peak times.</li>\n <li>Uber requires 20,000 more drivers to return to normal service levels.</li>\n <li>Some drivers switched from Uber to rapidly growing delivery businesses or rivals as the pandemic restricted the travel demand.</li>\n <li>Uber had to offer drivers more benefits after the U.K. Supreme Court ruled the firm should recognize a group of them as “workers.”</li>\n <li>Customers rebuked the ride-hailing provider on social media against longer waiting times and higher fares during peak hours as more workers opted to avoid public transit during the pandemic.</li>\n <li><b>Price Action:</b>&nbsp;UBER shares traded higher by 0.78% at $43.72 in the premarket session on the last check Thursday.</li>\n</ul>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Uber Bumps Up Base Fares In London To Bring Back Drivers</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUber Bumps Up Base Fares In London To Bring Back Drivers\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-11 21:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/21/11/24036197/uber-bumps-up-base-fares-in-london-to-bring-back-drivers><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Uber Technologies bumped up base fares in London by 10% to attract more drivers, Bloomberg reports.\nCustomers traveling from Heathrow, Gatwick, Luton, and Stansted airports will face an additional 15%...</p>\n\n<a href=\"https://www.benzinga.com/news/21/11/24036197/uber-bumps-up-base-fares-in-london-to-bring-back-drivers\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"UBER":"优步"},"source_url":"https://www.benzinga.com/news/21/11/24036197/uber-bumps-up-base-fares-in-london-to-bring-back-drivers","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1171908836","content_text":"Uber Technologies bumped up base fares in London by 10% to attract more drivers, Bloomberg reports.\nCustomers traveling from Heathrow, Gatwick, Luton, and Stansted airports will face an additional 15% hike in fares at peak times.\nUber requires 20,000 more drivers to return to normal service levels.\nSome drivers switched from Uber to rapidly growing delivery businesses or rivals as the pandemic restricted the travel demand.\nUber had to offer drivers more benefits after the U.K. Supreme Court ruled the firm should recognize a group of them as “workers.”\nCustomers rebuked the ride-hailing provider on social media against longer waiting times and higher fares during peak hours as more workers opted to avoid public transit during the pandemic.\nPrice Action: UBER shares traded higher by 0.78% at $43.72 in the premarket session on the last check Thursday.","news_type":1},"isVote":1,"tweetType":1,"viewCount":18,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":820290124,"gmtCreate":1633393612235,"gmtModify":1633393612658,"author":{"id":"3578047933589423","authorId":"3578047933589423","name":"PengsieX","avatar":"https://static.tigerbbs.com/ebe92821eba3b91a6431d698b66bbed5","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"Very likely","listText":"Very likely","text":"Very likely","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/820290124","repostId":"2172799913","repostType":4,"isVote":1,"tweetType":1,"viewCount":40,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":889258728,"gmtCreate":1631153022964,"gmtModify":1631890884821,"author":{"id":"3578047933589423","authorId":"3578047933589423","name":"PengsieX","avatar":"https://static.tigerbbs.com/ebe92821eba3b91a6431d698b66bbed5","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"So much about funds getting transferred from HK to SG&nbsp;[笑哭]&nbsp;","listText":"So much about funds getting transferred from HK to SG&nbsp;[笑哭]&nbsp;","text":"So much about funds getting transferred from HK to SG [笑哭]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/889258728","repostId":"1168983695","repostType":4,"repost":{"id":"1168983695","pubTimestamp":1631151797,"share":"https://www.laohu8.com/m/news/1168983695?lang=&edition=full","pubTime":"2021-09-09 09:43","market":"hk","language":"en","title":"Hong Kong Growth to Match Singapore’s for First Time Since 2008","url":"https://stock-news.laohu8.com/highlight/detail?id=1168983695","media":"Bloomberg","summary":"The city has maintained low cases with “Covid Zero” policy\nRekindling China travel ties may bolster ","content":"<ul>\n <li>The city has maintained low cases with “Covid Zero” policy</li>\n <li>Rekindling China travel ties may bolster Hong Kong’s economy</li>\n</ul>\n<p>Hong Kong’s economy is expected to catch up with rival financial hub Singapore’s pace of expansion this year for the first time since 2008, as it recovers from a pandemic-induced downturn.</p>\n<p>Economists have raised their&nbsp;growth forecasts&nbsp;for Hong Kong by 0.7 percentage points to 6.7% this year, while Singapore’s&nbsp;growth outlook&nbsp;was upgraded by 20 basis points to an expansion of 6.5%, according to the median estimates in a Bloomberg survey.</p>\n<p>Hong Kong’s economic rebound continued in the second quarter of 2021, with gross domestic product increasing 7.6% from a year earlier -- indicating an upturn in&nbsp;business activity&nbsp;previously hit by pandemic-control measures before that. The improvement in economic health comes as Singapore looks to tighten virus curbs to arrest anoutbreakfueled by the Delta variant.</p>\n<p><img src=\"https://static.tigerbbs.com/4e65d871949dfdc043fe5138b1b66bd8\" tg-width=\"966\" tg-height=\"731\" width=\"100%\" height=\"auto\"></p>\n<p>“Hong Kong’s economy will continue to enjoy its cyclical rebound in 2021, especially as the handout of consumption vouchers can add to GDP growth by 0.5%,” said Gary Ng, a senior economist at Natixis in Hong Kong. “Still, the real challenge may arrive next year if borders remain closed amid the fading base effect.”</p>\n<p>Singapore is seen taking a clear lead again next year, with its growth estimated at 4.1% in 2022 compared with Hong Kong’s 3%, according to the survey. That trend will probably hold in 2023 as well.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hong Kong Growth to Match Singapore’s for First Time Since 2008</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHong Kong Growth to Match Singapore’s for First Time Since 2008\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-09 09:43 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-09-09/hong-kong-growth-set-to-match-singapore-s-first-time-since-2008><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The city has maintained low cases with “Covid Zero” policy\nRekindling China travel ties may bolster Hong Kong’s economy\n\nHong Kong’s economy is expected to catch up with rival financial hub Singapore’...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-09-09/hong-kong-growth-set-to-match-singapore-s-first-time-since-2008\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"HSI":"恒生指数","STI.SI":"富时新加坡海峡指数"},"source_url":"https://www.bloomberg.com/news/articles/2021-09-09/hong-kong-growth-set-to-match-singapore-s-first-time-since-2008","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1168983695","content_text":"The city has maintained low cases with “Covid Zero” policy\nRekindling China travel ties may bolster Hong Kong’s economy\n\nHong Kong’s economy is expected to catch up with rival financial hub Singapore’s pace of expansion this year for the first time since 2008, as it recovers from a pandemic-induced downturn.\nEconomists have raised their growth forecasts for Hong Kong by 0.7 percentage points to 6.7% this year, while Singapore’s growth outlook was upgraded by 20 basis points to an expansion of 6.5%, according to the median estimates in a Bloomberg survey.\nHong Kong’s economic rebound continued in the second quarter of 2021, with gross domestic product increasing 7.6% from a year earlier -- indicating an upturn in business activity previously hit by pandemic-control measures before that. The improvement in economic health comes as Singapore looks to tighten virus curbs to arrest anoutbreakfueled by the Delta variant.\n\n“Hong Kong’s economy will continue to enjoy its cyclical rebound in 2021, especially as the handout of consumption vouchers can add to GDP growth by 0.5%,” said Gary Ng, a senior economist at Natixis in Hong Kong. “Still, the real challenge may arrive next year if borders remain closed amid the fading base effect.”\nSingapore is seen taking a clear lead again next year, with its growth estimated at 4.1% in 2022 compared with Hong Kong’s 3%, according to the survey. That trend will probably hold in 2023 as well.","news_type":1},"isVote":1,"tweetType":1,"viewCount":117,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":604309277,"gmtCreate":1639324715014,"gmtModify":1639324715337,"author":{"id":"3578047933589423","authorId":"3578047933589423","name":"PengsieX","avatar":"https://static.tigerbbs.com/ebe92821eba3b91a6431d698b66bbed5","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"The rich get richer the poor get poorer","listText":"The rich get richer the poor get poorer","text":"The rich get richer the poor get poorer","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/604309277","repostId":"2190719916","repostType":4,"repost":{"id":"2190719916","pubTimestamp":1639280175,"share":"https://www.laohu8.com/m/news/2190719916?lang=&edition=full","pubTime":"2021-12-12 11:36","market":"us","language":"en","title":"Is Inflation Going to Cool Down Anytime Soon?","url":"https://stock-news.laohu8.com/highlight/detail?id=2190719916","media":"Motley Fool","summary":"Two Motley Fool contributors discuss the issue weighing on a lot of people's minds.","content":"<p>Investors and the general public as a whole are worried about the surging rate of inflation, and these concerns continue to drive some of the volatility we're seeing in the broader market. In this segment of<i> Backstage Pass</i>, recorded on <b>Nov. 10</b>, Fool contributors Connor Allen and Rachel Warren discuss inflation and investing in this challenging market environment.</p>\n<p><b>Connor Allen</b>: But to go back to the original question about transitory inflation, I think most people have hopped off that bus by now. I think right when this started, a lot of people were on the transitory bus. They thought a lot of the bottlenecks and the supply chain issues that were being caused we're going to get solved and basically deflation will come and replace that and prices would go back to normal. I don't think a lot of people think that anymore.</p>\n<p>Because when you think about a company that's selling a product, and they realize that the market will pay $5 for something that used to be $3 and are they ever going to bring it back to $3? I don't think so. I think that's hard to make companies do, especially when there's such a variety of costs across all industries and all companies. You don't know what costs are going to come down when.</p>\n<p>Gas is <a href=\"https://laohu8.com/S/AONE.U\">one</a> that's a major issue. I think that probably is the number one issue for a lot of increasing costs for companies because everything's delivered, whether it's delivered to a warehouse like <b>Amazon</b>, whether it's delivered to a retail store like <b>Macy's</b>, or whether it's delivered to your home. There's a lot of different things and the cost obviously of gas being I think it's around a national averaged around $3.20 I believe.</p>\n<p>That's a cost that you can't get around, and you can't really innovate around those gas prices. Obviously, electric vehicles could potentially be that fix, but those costs are going up as well. [laughs] There's some projections that I was reading about how the national average of gas prices could be around $5 a gallon by the end of the year.</p>\n<p>That could be really painful, not only on my wallet, but [laughs] not on a lot of Americans' wallets. Hopefully we can get that down. But to be honest with you, I'm expecting long-term inflation. I'm not expecting this to be a transitory thing.</p>\n<p><b>Rachel Warren:</b> I agree with you Connor and unfortunately, I don't really see this inflation just dying down overnight or going anywhere anytime soon. I think it's going to be much more of a gradual recovery and perhaps in some cases like what you were saying, we're going to see permanent pricing increases in some of these consumer good categories.</p>\n<p>I think it's something that businesses and consumers are going to have to contend with for a long time. I think people are adjusting to these changes hard as they are. I think it's also helpful to remember this isn't just a U.S. issue. This is a global problem for companies and consumers.</p>\n<p>I saw this interesting article on <i>CNBC</i> today and the Chief Financial Officer of a large Belgian Dutch grocer called <b>Ahold Delhaize</b> was talking about how the company is dealing with the supply chain bottlenecks that are also having this impact on inflation and everything else and she said, \"I think what we're definitely seeing is inflation is picking up. But what I would also say is that when you look at food at the smaller share of the wallet in some other categories.\"</p>\n<p>Another thing was, a lot of these companies are saying this is something we are going to be seeing for quite a long time. The CEO of <b>Siemens</b> <b>Energy</b> told <i>CNBC</i>, the industrial world is going to be dealing with the supply chain bottleneck issues for a long time, which is also driving these other inflation problems. I don't think it's something that's going anywhere, anytime soon.</p>\n<p>As a consumer, it's obviously not fun to see. I think it's something to be patient with and deal with as it comes. But jumping off of what Taylor was saying in terms of staying invested in the stock market, but maybe you do adjust the type of stocks that you buy during these times and sometimes especially during bumpy periods in the market, it can be a good time to look at your portfolio and see maybe it needs some rebalancing.</p>\n<p>Maybe the balance of stocks that are more prone to headwinds during these bumpy times could use some balancing with more stalwart stocks that aren't necessarily as prone to these inflationary pressures. I think even amid rising prices and high inflation, you think of companies like Amazon that reported impacted earnings due to related supply chain constraints. The market still managed to deliver record highs.</p>\n<p>Recently over the last few weeks we had that happen a couple of times. Try not to focus too much on one day in the stock market. When you look at the market performance over the long term, investors who they'd invested in the market has generated pretty great portfolio returns. I'm personally not changing the way I'm investing right now, but I may change some of the type of stocks I buy in the coming months for sure.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Inflation Going to Cool Down Anytime Soon?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Inflation Going to Cool Down Anytime Soon?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-12 11:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/11/is-inflation-going-to-cool-down-anytime-soon/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Investors and the general public as a whole are worried about the surging rate of inflation, and these concerns continue to drive some of the volatility we're seeing in the broader market. In this ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/11/is-inflation-going-to-cool-down-anytime-soon/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.fool.com/investing/2021/12/11/is-inflation-going-to-cool-down-anytime-soon/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2190719916","content_text":"Investors and the general public as a whole are worried about the surging rate of inflation, and these concerns continue to drive some of the volatility we're seeing in the broader market. In this segment of Backstage Pass, recorded on Nov. 10, Fool contributors Connor Allen and Rachel Warren discuss inflation and investing in this challenging market environment.\nConnor Allen: But to go back to the original question about transitory inflation, I think most people have hopped off that bus by now. I think right when this started, a lot of people were on the transitory bus. They thought a lot of the bottlenecks and the supply chain issues that were being caused we're going to get solved and basically deflation will come and replace that and prices would go back to normal. I don't think a lot of people think that anymore.\nBecause when you think about a company that's selling a product, and they realize that the market will pay $5 for something that used to be $3 and are they ever going to bring it back to $3? I don't think so. I think that's hard to make companies do, especially when there's such a variety of costs across all industries and all companies. You don't know what costs are going to come down when.\nGas is one that's a major issue. I think that probably is the number one issue for a lot of increasing costs for companies because everything's delivered, whether it's delivered to a warehouse like Amazon, whether it's delivered to a retail store like Macy's, or whether it's delivered to your home. There's a lot of different things and the cost obviously of gas being I think it's around a national averaged around $3.20 I believe.\nThat's a cost that you can't get around, and you can't really innovate around those gas prices. Obviously, electric vehicles could potentially be that fix, but those costs are going up as well. [laughs] There's some projections that I was reading about how the national average of gas prices could be around $5 a gallon by the end of the year.\nThat could be really painful, not only on my wallet, but [laughs] not on a lot of Americans' wallets. Hopefully we can get that down. But to be honest with you, I'm expecting long-term inflation. I'm not expecting this to be a transitory thing.\nRachel Warren: I agree with you Connor and unfortunately, I don't really see this inflation just dying down overnight or going anywhere anytime soon. I think it's going to be much more of a gradual recovery and perhaps in some cases like what you were saying, we're going to see permanent pricing increases in some of these consumer good categories.\nI think it's something that businesses and consumers are going to have to contend with for a long time. I think people are adjusting to these changes hard as they are. I think it's also helpful to remember this isn't just a U.S. issue. This is a global problem for companies and consumers.\nI saw this interesting article on CNBC today and the Chief Financial Officer of a large Belgian Dutch grocer called Ahold Delhaize was talking about how the company is dealing with the supply chain bottlenecks that are also having this impact on inflation and everything else and she said, \"I think what we're definitely seeing is inflation is picking up. But what I would also say is that when you look at food at the smaller share of the wallet in some other categories.\"\nAnother thing was, a lot of these companies are saying this is something we are going to be seeing for quite a long time. The CEO of Siemens Energy told CNBC, the industrial world is going to be dealing with the supply chain bottleneck issues for a long time, which is also driving these other inflation problems. I don't think it's something that's going anywhere, anytime soon.\nAs a consumer, it's obviously not fun to see. I think it's something to be patient with and deal with as it comes. But jumping off of what Taylor was saying in terms of staying invested in the stock market, but maybe you do adjust the type of stocks that you buy during these times and sometimes especially during bumpy periods in the market, it can be a good time to look at your portfolio and see maybe it needs some rebalancing.\nMaybe the balance of stocks that are more prone to headwinds during these bumpy times could use some balancing with more stalwart stocks that aren't necessarily as prone to these inflationary pressures. I think even amid rising prices and high inflation, you think of companies like Amazon that reported impacted earnings due to related supply chain constraints. The market still managed to deliver record highs.\nRecently over the last few weeks we had that happen a couple of times. Try not to focus too much on one day in the stock market. When you look at the market performance over the long term, investors who they'd invested in the market has generated pretty great portfolio returns. I'm personally not changing the way I'm investing right now, but I may change some of the type of stocks I buy in the coming months for sure.","news_type":1},"isVote":1,"tweetType":1,"viewCount":165,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":606184713,"gmtCreate":1638843320796,"gmtModify":1638843321050,"author":{"id":"3578047933589423","authorId":"3578047933589423","name":"PengsieX","avatar":"https://static.tigerbbs.com/ebe92821eba3b91a6431d698b66bbed5","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"Christmas is coming... Hopefully...&nbsp;","listText":"Christmas is coming... Hopefully...&nbsp;","text":"Christmas is coming... Hopefully...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/606184713","repostId":"1103198732","repostType":4,"isVote":1,"tweetType":1,"viewCount":44,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":875112264,"gmtCreate":1637624385579,"gmtModify":1637624385741,"author":{"id":"3578047933589423","authorId":"3578047933589423","name":"PengsieX","avatar":"https://static.tigerbbs.com/ebe92821eba3b91a6431d698b66bbed5","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"2nd term... Hmmm...&nbsp;","listText":"2nd term... Hmmm...&nbsp;","text":"2nd term... Hmmm...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/875112264","repostId":"2185306806","repostType":4,"repost":{"id":"2185306806","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1637620044,"share":"https://www.laohu8.com/m/news/2185306806?lang=&edition=full","pubTime":"2021-11-23 06:27","market":"us","language":"en","title":"Nasdaq and S&P 500 end down after hitting record highs","url":"https://stock-news.laohu8.com/highlight/detail?id=2185306806","media":"Reuters","summary":"* Apple hits record high, JPM sees iPhone supply improving. Nov 22  - The S&P 500 ended lower and the Nasdaq tumbled deep into negative territory on Monday after both earlier hit record highs following the announcement of a second term for Federal Reserve Chair Jerome Powell.The Dow Jones Industrial Average ended slightly higher.Climbing Treasury yields kept tech stocks broadly lower, with holdouts including Microsoft and Apple, which many investors view as relatively safe, giving up gains late ","content":"<p>* Financials rally on rate hike expectations</p>\n<p>* Higher Treasury yields pressure tech stocks</p>\n<p>* Apple hits record high, JPM sees iPhone supply improving</p>\n<p>Nov 22 (Reuters) - The S&amp;P 500 ended lower and the Nasdaq tumbled deep into negative territory on Monday after both earlier hit record highs following the announcement of a second term for Federal Reserve Chair Jerome Powell.</p>\n<p>The Dow Jones Industrial Average ended slightly higher.</p>\n<p>Climbing Treasury yields kept tech stocks broadly lower, with holdouts including Microsoft and Apple, which many investors view as relatively safe, giving up gains late in the session.</p>\n<p>Apple ended up 0.3%, its highest closing level ever, after rising over 3% earlier in the day. JPMorgan flagged possible improvements to the supply of the iPhone 13 in coming months.</p>\n<p>Microsoft ended down almost 1% after earlier rising almost 2%.</p>\n<p>\"The market is nervous. We know we have Powell, but that doesn't help with the inflation issue,\" said Dennis Dick, a trader at Bright Trading LLC. \"Under the hood, growth tech got hit all day, and then all of tech got hit at the end.\"</p>\n<p>Powell's nomination was welcomed by many investors hoping for no big changes in the Fed as it guides the economy through a recovery from the pandemic. The central bank is set to herald a return to pre-pandemic policy by end-2022.</p>\n<p>Fed Governor Lael Brainard, who was the other top candidate for the job, will be vice chair, the White House said.</p>\n<p>\"Markets like predictability. ... While Brainard may have been a fine choice, the markets would not know what to expect from her even though the general consensus was that it meant lower rates for longer,\" said Randy Frederick, managing director of trading and derivatives at Charles Schwab in Austin, Texas.</p>\n<p>The S&amp;P 500 banks index rallied 2%, tracking a surge in Treasury yields as investors priced in policy tightening by the first half of 2022. Wells Fargo &amp; Co rose over 3% and was among the strongest major Wall Street banks.</p>\n<p>Futures contracts tied to the Fed's policy rate indicated that money markets are now expecting the U.S. central bank to raise interest rates by 25 basis points by next June versus a previous estimate of July.</p>\n<p>The Dow Jones Industrial Average rose 0.05% to end at 35,619.25 points, while the S&amp;P 500 lost 0.32% to 4,682.94.</p>\n<p>The Nasdaq Composite dropped 1.26% to 15,854.76.</p>\n<p>The S&amp;P 500 value index climbed 0.6%, strongly outperforming the S&amp;P 500 growth index's 1% dip.</p>\n<p>In extended trade, <a href=\"https://laohu8.com/S/ZM\">Zoom</a> Video Communications fell 3% after the video-conferencing company posted quarterly revenue that beat expectations.</p>\n<p>Investors were awaiting a slew of economic data this week, including IHS business activity readings, personal consumption expenditure, and minutes of the Fed's latest meeting.</p>\n<p>In Monday's session, Amazon fell 2.8% and Alphabet declined 1.8%, both weighing heavily on the Nasdaq.</p>\n<p>Tesla Inc gained 1.7% after CEO Elon Musk tweeted that the Model S Plaid will \"probably\" be coming to China around March. The stock has almost recovered from a steep selloff earlier this month that started after Musk polled <a href=\"https://laohu8.com/S/TWTR\">Twitter</a> users about whether he should sell some of his shares in the electric car maker.</p>\n<p>Activision Blizzard slipped 0.3% after a media report that the video game publisher's chief executive, Bobby Kotick, would consider leaving if he could not quickly address concerns about company culture.</p>\n<p>The S&amp;P 500 has now gained about 25% in 2021, while the Nasdaq is up 23%.</p>\n<p>Declining issues outnumbered advancing ones on the NYSE by a 1.28-to-1 ratio; on Nasdaq, a 1.76-to-1 ratio favored decliners.</p>\n<p>The S&amp;P 500 posted 52 new 52-week highs and 11 new lows; the Nasdaq Composite recorded 138 new highs and 507 new lows.</p>\n<p>Volume on U.S. exchanges was 11.6 billion shares, compared with the 11.1 billion average for the full session over the last 20 trading days.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nasdaq and S&P 500 end down after hitting record highs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNasdaq and S&P 500 end down after hitting record highs\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-11-23 06:27</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>* Financials rally on rate hike expectations</p>\n<p>* Higher Treasury yields pressure tech stocks</p>\n<p>* Apple hits record high, JPM sees iPhone supply improving</p>\n<p>Nov 22 (Reuters) - The S&amp;P 500 ended lower and the Nasdaq tumbled deep into negative territory on Monday after both earlier hit record highs following the announcement of a second term for Federal Reserve Chair Jerome Powell.</p>\n<p>The Dow Jones Industrial Average ended slightly higher.</p>\n<p>Climbing Treasury yields kept tech stocks broadly lower, with holdouts including Microsoft and Apple, which many investors view as relatively safe, giving up gains late in the session.</p>\n<p>Apple ended up 0.3%, its highest closing level ever, after rising over 3% earlier in the day. JPMorgan flagged possible improvements to the supply of the iPhone 13 in coming months.</p>\n<p>Microsoft ended down almost 1% after earlier rising almost 2%.</p>\n<p>\"The market is nervous. We know we have Powell, but that doesn't help with the inflation issue,\" said Dennis Dick, a trader at Bright Trading LLC. \"Under the hood, growth tech got hit all day, and then all of tech got hit at the end.\"</p>\n<p>Powell's nomination was welcomed by many investors hoping for no big changes in the Fed as it guides the economy through a recovery from the pandemic. The central bank is set to herald a return to pre-pandemic policy by end-2022.</p>\n<p>Fed Governor Lael Brainard, who was the other top candidate for the job, will be vice chair, the White House said.</p>\n<p>\"Markets like predictability. ... While Brainard may have been a fine choice, the markets would not know what to expect from her even though the general consensus was that it meant lower rates for longer,\" said Randy Frederick, managing director of trading and derivatives at Charles Schwab in Austin, Texas.</p>\n<p>The S&amp;P 500 banks index rallied 2%, tracking a surge in Treasury yields as investors priced in policy tightening by the first half of 2022. Wells Fargo &amp; Co rose over 3% and was among the strongest major Wall Street banks.</p>\n<p>Futures contracts tied to the Fed's policy rate indicated that money markets are now expecting the U.S. central bank to raise interest rates by 25 basis points by next June versus a previous estimate of July.</p>\n<p>The Dow Jones Industrial Average rose 0.05% to end at 35,619.25 points, while the S&amp;P 500 lost 0.32% to 4,682.94.</p>\n<p>The Nasdaq Composite dropped 1.26% to 15,854.76.</p>\n<p>The S&amp;P 500 value index climbed 0.6%, strongly outperforming the S&amp;P 500 growth index's 1% dip.</p>\n<p>In extended trade, <a href=\"https://laohu8.com/S/ZM\">Zoom</a> Video Communications fell 3% after the video-conferencing company posted quarterly revenue that beat expectations.</p>\n<p>Investors were awaiting a slew of economic data this week, including IHS business activity readings, personal consumption expenditure, and minutes of the Fed's latest meeting.</p>\n<p>In Monday's session, Amazon fell 2.8% and Alphabet declined 1.8%, both weighing heavily on the Nasdaq.</p>\n<p>Tesla Inc gained 1.7% after CEO Elon Musk tweeted that the Model S Plaid will \"probably\" be coming to China around March. The stock has almost recovered from a steep selloff earlier this month that started after Musk polled <a href=\"https://laohu8.com/S/TWTR\">Twitter</a> users about whether he should sell some of his shares in the electric car maker.</p>\n<p>Activision Blizzard slipped 0.3% after a media report that the video game publisher's chief executive, Bobby Kotick, would consider leaving if he could not quickly address concerns about company culture.</p>\n<p>The S&amp;P 500 has now gained about 25% in 2021, while the Nasdaq is up 23%.</p>\n<p>Declining issues outnumbered advancing ones on the NYSE by a 1.28-to-1 ratio; on Nasdaq, a 1.76-to-1 ratio favored decliners.</p>\n<p>The S&amp;P 500 posted 52 new 52-week highs and 11 new lows; the Nasdaq Composite recorded 138 new highs and 507 new lows.</p>\n<p>Volume on U.S. exchanges was 11.6 billion shares, compared with the 11.1 billion average for the full session over the last 20 trading days.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"161125":"标普500","513500":"标普500ETF","BK4534":"瑞士信贷持仓","SPY":"标普500ETF","UPRO":"三倍做多标普500ETF","MSFT":"微软","BK4559":"巴菲特持仓","BK4550":"红杉资本持仓",".DJI":"道琼斯",".IXIC":"NASDAQ Composite","OEX":"标普100",".SPX":"S&P 500 Index","BK4504":"桥水持仓","SSO":"两倍做多标普500ETF","AAPL":"苹果","SDS":"两倍做空标普500ETF","SH":"标普500反向ETF","COMP":"Compass, Inc.","IVV":"标普500指数ETF","SPXU":"三倍做空标普500ETF","ZM":"Zoom","OEF":"标普100指数ETF-iShares"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2185306806","content_text":"* Financials rally on rate hike expectations\n* Higher Treasury yields pressure tech stocks\n* Apple hits record high, JPM sees iPhone supply improving\nNov 22 (Reuters) - The S&P 500 ended lower and the Nasdaq tumbled deep into negative territory on Monday after both earlier hit record highs following the announcement of a second term for Federal Reserve Chair Jerome Powell.\nThe Dow Jones Industrial Average ended slightly higher.\nClimbing Treasury yields kept tech stocks broadly lower, with holdouts including Microsoft and Apple, which many investors view as relatively safe, giving up gains late in the session.\nApple ended up 0.3%, its highest closing level ever, after rising over 3% earlier in the day. JPMorgan flagged possible improvements to the supply of the iPhone 13 in coming months.\nMicrosoft ended down almost 1% after earlier rising almost 2%.\n\"The market is nervous. We know we have Powell, but that doesn't help with the inflation issue,\" said Dennis Dick, a trader at Bright Trading LLC. \"Under the hood, growth tech got hit all day, and then all of tech got hit at the end.\"\nPowell's nomination was welcomed by many investors hoping for no big changes in the Fed as it guides the economy through a recovery from the pandemic. The central bank is set to herald a return to pre-pandemic policy by end-2022.\nFed Governor Lael Brainard, who was the other top candidate for the job, will be vice chair, the White House said.\n\"Markets like predictability. ... While Brainard may have been a fine choice, the markets would not know what to expect from her even though the general consensus was that it meant lower rates for longer,\" said Randy Frederick, managing director of trading and derivatives at Charles Schwab in Austin, Texas.\nThe S&P 500 banks index rallied 2%, tracking a surge in Treasury yields as investors priced in policy tightening by the first half of 2022. Wells Fargo & Co rose over 3% and was among the strongest major Wall Street banks.\nFutures contracts tied to the Fed's policy rate indicated that money markets are now expecting the U.S. central bank to raise interest rates by 25 basis points by next June versus a previous estimate of July.\nThe Dow Jones Industrial Average rose 0.05% to end at 35,619.25 points, while the S&P 500 lost 0.32% to 4,682.94.\nThe Nasdaq Composite dropped 1.26% to 15,854.76.\nThe S&P 500 value index climbed 0.6%, strongly outperforming the S&P 500 growth index's 1% dip.\nIn extended trade, Zoom Video Communications fell 3% after the video-conferencing company posted quarterly revenue that beat expectations.\nInvestors were awaiting a slew of economic data this week, including IHS business activity readings, personal consumption expenditure, and minutes of the Fed's latest meeting.\nIn Monday's session, Amazon fell 2.8% and Alphabet declined 1.8%, both weighing heavily on the Nasdaq.\nTesla Inc gained 1.7% after CEO Elon Musk tweeted that the Model S Plaid will \"probably\" be coming to China around March. The stock has almost recovered from a steep selloff earlier this month that started after Musk polled Twitter users about whether he should sell some of his shares in the electric car maker.\nActivision Blizzard slipped 0.3% after a media report that the video game publisher's chief executive, Bobby Kotick, would consider leaving if he could not quickly address concerns about company culture.\nThe S&P 500 has now gained about 25% in 2021, while the Nasdaq is up 23%.\nDeclining issues outnumbered advancing ones on the NYSE by a 1.28-to-1 ratio; on Nasdaq, a 1.76-to-1 ratio favored decliners.\nThe S&P 500 posted 52 new 52-week highs and 11 new lows; the Nasdaq Composite recorded 138 new highs and 507 new lows.\nVolume on U.S. exchanges was 11.6 billion shares, compared with the 11.1 billion average for the full session over the last 20 trading days.","news_type":1},"isVote":1,"tweetType":1,"viewCount":7,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":840283443,"gmtCreate":1635649531435,"gmtModify":1635653461323,"author":{"id":"3578047933589423","authorId":"3578047933589423","name":"PengsieX","avatar":"https://static.tigerbbs.com/ebe92821eba3b91a6431d698b66bbed5","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"Almost every stock is overvalued but you can't go wrong with Microsoft&nbsp;","listText":"Almost every stock is overvalued but you can't go wrong with Microsoft&nbsp;","text":"Almost every stock is overvalued but you can't go wrong with Microsoft","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/840283443","repostId":"2179225670","repostType":4,"repost":{"id":"2179225670","pubTimestamp":1635648689,"share":"https://www.laohu8.com/m/news/2179225670?lang=&edition=full","pubTime":"2021-10-31 10:51","market":"us","language":"en","title":"3 Reasons to Buy Microsoft, And 1 Reason to Sell","url":"https://stock-news.laohu8.com/highlight/detail?id=2179225670","media":"Motley Fool","summary":"The tech giant continues to dazzle investors.","content":"<p><b>Microsoft</b>'s (NASDAQ:MSFT) stock price hit an all-time high after the tech giant posted its first-quarter report on Tuesday, Oct. 26. Its revenue rose 22% year over year to $45.3 billion, beating analysts' estimates by $1.3 billion. Its adjusted earnings grew 25% to $2.27 per share, which cleared expectations by $0.19.</p>\n<p>For the second quarter, Microsoft expects its revenue to rise 16%-18% year over year, which also surpasses analysts' expectations for 14% growth.</p>\n<p>Microsoft's numbers were impressive, but some investors might be reluctant to buy its stock after its price has already risen nearly 50% this year. Let's review three reasons to buy Microsoft's stock -- as well as <a href=\"https://laohu8.com/S/AONE.U\">one</a> reason to sell it -- to see if it's still a compelling investment at these prices.</p>\n<p><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F649271%2Fgettyimages-656522720.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"431\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>Image source: Getty Images.</p>\n<h2>1. Microsoft Cloud's growth</h2>\n<p>Microsoft's dramatic growth over the past seven years was led by the expansion of its cloud services, which include Azure, Office 365, Dynamics, LinkedIn, and its other cloud-based software. The company reports the growth of these businesses together as the \"Microsoft Cloud.\"</p>\n<p>Microsoft Cloud's revenue rose 36% year over year to $20.7 billion during the first quarter, which matched its 36% growth rate in the fourth quarter.</p>\n<p>Azure, Microsoft Cloud's most closely watched segment, grew its revenue 48% on a constant currency basis. That represented an acceleration from Azure's 45% constant currency growth in the fourth quarter, and should allay concerns about a potential slowdown.</p>\n<p>Azure's share of the global cloud infrastructure market also rose from 19% to 21% between the third quarters of 2020 and 2021, according to Canalys. That puts it firmly in second place behind <b>Amazon</b> (NASDAQ:AMZN) Web Services (AWS), which saw its market share stay flat year over year at 32%.</p>\n<p>Microsoft likely wouldn't have achieved that growth without Satya Nadella, who took the helm as the company's third CEO in 2014 and aggressively expanded those services with his \"mobile first, cloud first\" mantra.</p>\n<h2>2. Reopening tailwinds</h2>\n<p>During the onset of the pandemic, several of Microsoft's enterprise-facing services -- including Office 365 Commercial, Dynamics 365, and LinkedIn Marketing Solutions -- suffered slowdowns as businesses closed.</p>\n<p>But those headwinds waned as more businesses reopened. Office 365 Commercial and Dynamics 365 generated accelerating growth on a constant currency basis in the first quarter, while LinkedIn Marketing continued to grow:</p>\n<table border=\"1\" width=\"600\">\n <colgroup></colgroup>\n <tbody>\n  <tr valign=\"TOP\">\n   <th width=\"236\"><p>Revenue Growth (YOY)</p></th>\n   <th width=\"152\"><p>Q4 2021</p></th>\n   <th width=\"168\"><p>Q1 2022</p></th>\n  </tr>\n  <tr valign=\"TOP\">\n   <td width=\"236\"><p><b>Office 365 Commercial</b></p></td>\n   <td width=\"152\"><p>20%</p></td>\n   <td width=\"168\"><p>21%</p></td>\n  </tr>\n  <tr valign=\"TOP\">\n   <td width=\"236\"><p><b>Dynamics 365</b></p></td>\n   <td width=\"152\"><p>42%</p></td>\n   <td width=\"168\"><p>45%</p></td>\n  </tr>\n  <tr valign=\"TOP\">\n   <td width=\"236\"><p><b>LinkedIn Marketing</b></p></td>\n   <td width=\"152\"><p>91%</p></td>\n   <td width=\"168\"><p>59%</p></td>\n  </tr>\n </tbody>\n</table>\n<p>Source: Microsoft. Constant currency basis. YOY = Year over year.</p>\n<p>That growth of these \"reopening\" segments, along with the ongoing growth of Azure and its other cloud services, is offsetting the slower growth of Microsoft's Surface and Xbox divisions, which were both affected by the chip shortage and other supply chain constraints during the first quarter.</p>\n<h2>3. Returning plenty of cash to shareholders</h2>\n<p>Microsoft transformed into a high-growth company again over the past few years, but it continues to return tens of billions of dollars to its investors.</p>\n<p>Microsoft spent over $39 billion on dividends and buybacks in fiscal 2021, which represented about 70% of its free cash flow (FCF). It spent another $10.9 billion, or 58% of its FCF, on both plans in the first quarter of 2022.</p>\n<p>Microsoft's forward dividend yield of 0.8% won't attract any serious income investors, but it reduced its share count by nearly 10% over the past seven years, while offsetting the dilution from its share-based compensation plans.</p>\n<h2>The one reason to sell Microsoft: its valuation</h2>\n<p>Microsoft is worth $2.4 trillion today, roughly eight times its market cap of about $300 billion when Satya Nadella took over as its CEO.</p>\n<p>Its stock currently trades at 13 times this year's sales and 35 times forward earnings. Those valuations are a bit frothy compared to analysts' expectations for 14% sales growth and 9% earnings growth this year.</p>\n<p>That massive market cap and high valuation could make it difficult for Microsoft to replicate its multibagger gains from the past seven years.</p>\n<h2>Is it the right time to buy Microsoft?</h2>\n<p>Microsoft's stock is richly valued, but the bears have been banging that same drum for years as its shares have skyrocketed. I believe Microsoft deserves that premium valuation since it's still a solid long-term investment that will continue to profit from the secular expansion of the cloud services market.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Reasons to Buy Microsoft, And 1 Reason to Sell</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Reasons to Buy Microsoft, And 1 Reason to Sell\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-31 10:51 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/10/30/3-reasons-to-buy-microsoft-and-1-reason-to-sell/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Microsoft's (NASDAQ:MSFT) stock price hit an all-time high after the tech giant posted its first-quarter report on Tuesday, Oct. 26. Its revenue rose 22% year over year to $45.3 billion, beating ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/10/30/3-reasons-to-buy-microsoft-and-1-reason-to-sell/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.fool.com/investing/2021/10/30/3-reasons-to-buy-microsoft-and-1-reason-to-sell/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2179225670","content_text":"Microsoft's (NASDAQ:MSFT) stock price hit an all-time high after the tech giant posted its first-quarter report on Tuesday, Oct. 26. Its revenue rose 22% year over year to $45.3 billion, beating analysts' estimates by $1.3 billion. Its adjusted earnings grew 25% to $2.27 per share, which cleared expectations by $0.19.\nFor the second quarter, Microsoft expects its revenue to rise 16%-18% year over year, which also surpasses analysts' expectations for 14% growth.\nMicrosoft's numbers were impressive, but some investors might be reluctant to buy its stock after its price has already risen nearly 50% this year. Let's review three reasons to buy Microsoft's stock -- as well as one reason to sell it -- to see if it's still a compelling investment at these prices.\n\nImage source: Getty Images.\n1. Microsoft Cloud's growth\nMicrosoft's dramatic growth over the past seven years was led by the expansion of its cloud services, which include Azure, Office 365, Dynamics, LinkedIn, and its other cloud-based software. The company reports the growth of these businesses together as the \"Microsoft Cloud.\"\nMicrosoft Cloud's revenue rose 36% year over year to $20.7 billion during the first quarter, which matched its 36% growth rate in the fourth quarter.\nAzure, Microsoft Cloud's most closely watched segment, grew its revenue 48% on a constant currency basis. That represented an acceleration from Azure's 45% constant currency growth in the fourth quarter, and should allay concerns about a potential slowdown.\nAzure's share of the global cloud infrastructure market also rose from 19% to 21% between the third quarters of 2020 and 2021, according to Canalys. That puts it firmly in second place behind Amazon (NASDAQ:AMZN) Web Services (AWS), which saw its market share stay flat year over year at 32%.\nMicrosoft likely wouldn't have achieved that growth without Satya Nadella, who took the helm as the company's third CEO in 2014 and aggressively expanded those services with his \"mobile first, cloud first\" mantra.\n2. Reopening tailwinds\nDuring the onset of the pandemic, several of Microsoft's enterprise-facing services -- including Office 365 Commercial, Dynamics 365, and LinkedIn Marketing Solutions -- suffered slowdowns as businesses closed.\nBut those headwinds waned as more businesses reopened. Office 365 Commercial and Dynamics 365 generated accelerating growth on a constant currency basis in the first quarter, while LinkedIn Marketing continued to grow:\n\n\n\n\nRevenue Growth (YOY)\nQ4 2021\nQ1 2022\n\n\nOffice 365 Commercial\n20%\n21%\n\n\nDynamics 365\n42%\n45%\n\n\nLinkedIn Marketing\n91%\n59%\n\n\n\nSource: Microsoft. Constant currency basis. YOY = Year over year.\nThat growth of these \"reopening\" segments, along with the ongoing growth of Azure and its other cloud services, is offsetting the slower growth of Microsoft's Surface and Xbox divisions, which were both affected by the chip shortage and other supply chain constraints during the first quarter.\n3. Returning plenty of cash to shareholders\nMicrosoft transformed into a high-growth company again over the past few years, but it continues to return tens of billions of dollars to its investors.\nMicrosoft spent over $39 billion on dividends and buybacks in fiscal 2021, which represented about 70% of its free cash flow (FCF). It spent another $10.9 billion, or 58% of its FCF, on both plans in the first quarter of 2022.\nMicrosoft's forward dividend yield of 0.8% won't attract any serious income investors, but it reduced its share count by nearly 10% over the past seven years, while offsetting the dilution from its share-based compensation plans.\nThe one reason to sell Microsoft: its valuation\nMicrosoft is worth $2.4 trillion today, roughly eight times its market cap of about $300 billion when Satya Nadella took over as its CEO.\nIts stock currently trades at 13 times this year's sales and 35 times forward earnings. Those valuations are a bit frothy compared to analysts' expectations for 14% sales growth and 9% earnings growth this year.\nThat massive market cap and high valuation could make it difficult for Microsoft to replicate its multibagger gains from the past seven years.\nIs it the right time to buy Microsoft?\nMicrosoft's stock is richly valued, but the bears have been banging that same drum for years as its shares have skyrocketed. I believe Microsoft deserves that premium valuation since it's still a solid long-term investment that will continue to profit from the secular expansion of the cloud services market.","news_type":1},"isVote":1,"tweetType":1,"viewCount":39,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691245877,"gmtCreate":1640216018508,"gmtModify":1640216018874,"author":{"id":"3578047933589423","authorId":"3578047933589423","name":"PengsieX","avatar":"https://static.tigerbbs.com/ebe92821eba3b91a6431d698b66bbed5","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"Convenience could be a dangerous thing&nbsp;","listText":"Convenience could be a dangerous thing&nbsp;","text":"Convenience could be a dangerous thing","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/691245877","repostId":"1131862374","repostType":4,"repost":{"id":"1131862374","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1640213195,"share":"https://www.laohu8.com/m/news/1131862374?lang=&edition=full","pubTime":"2021-12-23 06:46","market":"us","language":"en","title":"U.S. authorizes Pfizer oral COVID-19 treatment, first for at-home use","url":"https://stock-news.laohu8.com/highlight/detail?id=1131862374","media":"Reuters","summary":"Dec 22 (Reuters) - The United States on Wednesday authorized Pfizer Inc's antiviral COVID-19 pill fo","content":"<p>Dec 22 (Reuters) - The United States on Wednesday authorized Pfizer Inc's&nbsp;antiviral COVID-19 pill for at-risk people aged 12 and above, making it the first oral treatment and which can be taken at home, providing a potentially important tool in the fight against the fast-spreading&nbsp;Omicron variant.</p>\n<p>Pfizer's antiviral regimen, Paxlovid, was nearly 90% effective in preventing hospitalizations and deaths in patients at high risk of severe illness, according to data from the company's clinical trial. Recent lab data suggests the drug retains its effectiveness against Omicron, Pfizer said.</p>\n<p>Pfizer raised its 2022 production projections to 120 million courses of treatment from 80 million and said it was ready to start immediate delivery in the United States. The treatment's two-drug regimen includes a new medicine and a second older antiviral called ritonavir.</p>\n<p>\"Paxlovid's approval is a major milestone that marks another step towards making COVID-19 a much more manageable infection,\" said Amesh Adalja, a senior scholar at the Johns Hopkins Institute for Health Security.</p>\n<p>\"There are two key issues, however, that remain: It will be scarce in the coming weeks and its optimal use requires prompt diagnosis, which can be difficult with the continual testing problems that plague us,\" Adalja added.</p>\n<p>Pfizer has said it has 180,000 treatment courses ready to ship this year. The U.S. government's contract for 10 million courses of the drug is priced at $530 per course.</p>\n<p>The Food and Drug Administration's decision to issue emergency authorization for the treatment comes as the U.S. combats a surge in COVID-19 cases driven by the Omicron variant, with President Joe Biden announcing&nbsp;plans for more federal&nbsp;vaccination and testing sites.</p>\n<p>The pills can fill a treatment gap opened by the Omicron variant, said William Schaffner, a leading infectious disease expert from the Vanderbilt University School of Medicine. The most widely used monoclonal antibody treatments for COVID-19 have proven to be less effective at fighting the variant and there is limited supply of the one remaining treatment that works, he said.</p>\n<p>Monoclonal antibodies are typically given intravenously in hospitals, are not widely available and are more than twice the cost of the Pfizer pill.</p>\n<p>The Omicron variant, first identified in southern Africa and Hong Kong in November, has spread across the world and now constitutes over 70% of new coronavirus cases in the United States, according to data from the U.S. Centers for Disease Control and Prevention. Prior infection and vaccines have been shown in studies to only partly prevent infection from the variant, though a booster shot does increase protection.</p>\n<p>The FDA said it authorized Paxlovid for emergency use for the treatment of mild-to-moderate disease in adults and children 12 years and older, who are at high risk for progression to severe COVID-19.</p>\n<p>The drug is available by prescription only and should be initiated as soon as possible after diagnosis of COVID-19 and within five days of symptom onset, the FDA&nbsp;said. The pills are meant to be taken every 12 hours for five days beginning shortly after the onset of symptoms.</p>\n<p>While the clinical trials did not include patients under the age of 18, Pfizer said, the authorized adult dosing regimen is expected to result in comparable blood concentration levels of the drug in pediatric patients 12 and older weighing at least 40 kg (88.2 lbs).</p>\n<p>The second drug, ritonavir, is known to have interactions with some other prescription medicines. Pfizer has said that should be manageable and suggested most patients would be able to lower the dose of their other medications while being treated for COVID-19.</p>\n<p>Pfizer said it plans to file a new drug application with the FDA in 2022 for potential full regulatory approval. The European Union's drug regulator last week said that EU countries can use Paxlovid early after diagnosis of an infector, although the its full review of the drug has not been completed.</p>\n<p>Pfizer has agreed to allow generic manufacturers to supply versions of the treatment to 95 low- and middle-income countries through a licensing agreement with international public health group Medicines Patent Pool (MPP). The generic versions are expected later next year.</p>\n<p>A rival pill from Merck &amp; Co&nbsp;is under review by the FDA. The drug, molnupiravir, developed with Ridgeback Biotherapeutics, cut hospitalization and death risk by 30% in a trial.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.S. authorizes Pfizer oral COVID-19 treatment, first for at-home use</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.S. authorizes Pfizer oral COVID-19 treatment, first for at-home use\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-12-23 06:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Dec 22 (Reuters) - The United States on Wednesday authorized Pfizer Inc's&nbsp;antiviral COVID-19 pill for at-risk people aged 12 and above, making it the first oral treatment and which can be taken at home, providing a potentially important tool in the fight against the fast-spreading&nbsp;Omicron variant.</p>\n<p>Pfizer's antiviral regimen, Paxlovid, was nearly 90% effective in preventing hospitalizations and deaths in patients at high risk of severe illness, according to data from the company's clinical trial. Recent lab data suggests the drug retains its effectiveness against Omicron, Pfizer said.</p>\n<p>Pfizer raised its 2022 production projections to 120 million courses of treatment from 80 million and said it was ready to start immediate delivery in the United States. The treatment's two-drug regimen includes a new medicine and a second older antiviral called ritonavir.</p>\n<p>\"Paxlovid's approval is a major milestone that marks another step towards making COVID-19 a much more manageable infection,\" said Amesh Adalja, a senior scholar at the Johns Hopkins Institute for Health Security.</p>\n<p>\"There are two key issues, however, that remain: It will be scarce in the coming weeks and its optimal use requires prompt diagnosis, which can be difficult with the continual testing problems that plague us,\" Adalja added.</p>\n<p>Pfizer has said it has 180,000 treatment courses ready to ship this year. The U.S. government's contract for 10 million courses of the drug is priced at $530 per course.</p>\n<p>The Food and Drug Administration's decision to issue emergency authorization for the treatment comes as the U.S. combats a surge in COVID-19 cases driven by the Omicron variant, with President Joe Biden announcing&nbsp;plans for more federal&nbsp;vaccination and testing sites.</p>\n<p>The pills can fill a treatment gap opened by the Omicron variant, said William Schaffner, a leading infectious disease expert from the Vanderbilt University School of Medicine. The most widely used monoclonal antibody treatments for COVID-19 have proven to be less effective at fighting the variant and there is limited supply of the one remaining treatment that works, he said.</p>\n<p>Monoclonal antibodies are typically given intravenously in hospitals, are not widely available and are more than twice the cost of the Pfizer pill.</p>\n<p>The Omicron variant, first identified in southern Africa and Hong Kong in November, has spread across the world and now constitutes over 70% of new coronavirus cases in the United States, according to data from the U.S. Centers for Disease Control and Prevention. Prior infection and vaccines have been shown in studies to only partly prevent infection from the variant, though a booster shot does increase protection.</p>\n<p>The FDA said it authorized Paxlovid for emergency use for the treatment of mild-to-moderate disease in adults and children 12 years and older, who are at high risk for progression to severe COVID-19.</p>\n<p>The drug is available by prescription only and should be initiated as soon as possible after diagnosis of COVID-19 and within five days of symptom onset, the FDA&nbsp;said. The pills are meant to be taken every 12 hours for five days beginning shortly after the onset of symptoms.</p>\n<p>While the clinical trials did not include patients under the age of 18, Pfizer said, the authorized adult dosing regimen is expected to result in comparable blood concentration levels of the drug in pediatric patients 12 and older weighing at least 40 kg (88.2 lbs).</p>\n<p>The second drug, ritonavir, is known to have interactions with some other prescription medicines. Pfizer has said that should be manageable and suggested most patients would be able to lower the dose of their other medications while being treated for COVID-19.</p>\n<p>Pfizer said it plans to file a new drug application with the FDA in 2022 for potential full regulatory approval. The European Union's drug regulator last week said that EU countries can use Paxlovid early after diagnosis of an infector, although the its full review of the drug has not been completed.</p>\n<p>Pfizer has agreed to allow generic manufacturers to supply versions of the treatment to 95 low- and middle-income countries through a licensing agreement with international public health group Medicines Patent Pool (MPP). The generic versions are expected later next year.</p>\n<p>A rival pill from Merck &amp; Co&nbsp;is under review by the FDA. The drug, molnupiravir, developed with Ridgeback Biotherapeutics, cut hospitalization and death risk by 30% in a trial.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1131862374","content_text":"Dec 22 (Reuters) - The United States on Wednesday authorized Pfizer Inc's antiviral COVID-19 pill for at-risk people aged 12 and above, making it the first oral treatment and which can be taken at home, providing a potentially important tool in the fight against the fast-spreading Omicron variant.\nPfizer's antiviral regimen, Paxlovid, was nearly 90% effective in preventing hospitalizations and deaths in patients at high risk of severe illness, according to data from the company's clinical trial. Recent lab data suggests the drug retains its effectiveness against Omicron, Pfizer said.\nPfizer raised its 2022 production projections to 120 million courses of treatment from 80 million and said it was ready to start immediate delivery in the United States. The treatment's two-drug regimen includes a new medicine and a second older antiviral called ritonavir.\n\"Paxlovid's approval is a major milestone that marks another step towards making COVID-19 a much more manageable infection,\" said Amesh Adalja, a senior scholar at the Johns Hopkins Institute for Health Security.\n\"There are two key issues, however, that remain: It will be scarce in the coming weeks and its optimal use requires prompt diagnosis, which can be difficult with the continual testing problems that plague us,\" Adalja added.\nPfizer has said it has 180,000 treatment courses ready to ship this year. The U.S. government's contract for 10 million courses of the drug is priced at $530 per course.\nThe Food and Drug Administration's decision to issue emergency authorization for the treatment comes as the U.S. combats a surge in COVID-19 cases driven by the Omicron variant, with President Joe Biden announcing plans for more federal vaccination and testing sites.\nThe pills can fill a treatment gap opened by the Omicron variant, said William Schaffner, a leading infectious disease expert from the Vanderbilt University School of Medicine. The most widely used monoclonal antibody treatments for COVID-19 have proven to be less effective at fighting the variant and there is limited supply of the one remaining treatment that works, he said.\nMonoclonal antibodies are typically given intravenously in hospitals, are not widely available and are more than twice the cost of the Pfizer pill.\nThe Omicron variant, first identified in southern Africa and Hong Kong in November, has spread across the world and now constitutes over 70% of new coronavirus cases in the United States, according to data from the U.S. Centers for Disease Control and Prevention. Prior infection and vaccines have been shown in studies to only partly prevent infection from the variant, though a booster shot does increase protection.\nThe FDA said it authorized Paxlovid for emergency use for the treatment of mild-to-moderate disease in adults and children 12 years and older, who are at high risk for progression to severe COVID-19.\nThe drug is available by prescription only and should be initiated as soon as possible after diagnosis of COVID-19 and within five days of symptom onset, the FDA said. The pills are meant to be taken every 12 hours for five days beginning shortly after the onset of symptoms.\nWhile the clinical trials did not include patients under the age of 18, Pfizer said, the authorized adult dosing regimen is expected to result in comparable blood concentration levels of the drug in pediatric patients 12 and older weighing at least 40 kg (88.2 lbs).\nThe second drug, ritonavir, is known to have interactions with some other prescription medicines. Pfizer has said that should be manageable and suggested most patients would be able to lower the dose of their other medications while being treated for COVID-19.\nPfizer said it plans to file a new drug application with the FDA in 2022 for potential full regulatory approval. The European Union's drug regulator last week said that EU countries can use Paxlovid early after diagnosis of an infector, although the its full review of the drug has not been completed.\nPfizer has agreed to allow generic manufacturers to supply versions of the treatment to 95 low- and middle-income countries through a licensing agreement with international public health group Medicines Patent Pool (MPP). The generic versions are expected later next year.\nA rival pill from Merck & Co is under review by the FDA. The drug, molnupiravir, developed with Ridgeback Biotherapeutics, cut hospitalization and death risk by 30% in a trial.","news_type":1},"isVote":1,"tweetType":1,"viewCount":234,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":699503493,"gmtCreate":1639828874069,"gmtModify":1639828874403,"author":{"id":"3578047933589423","authorId":"3578047933589423","name":"PengsieX","avatar":"https://static.tigerbbs.com/ebe92821eba3b91a6431d698b66bbed5","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"Please be a merry Christmas next week!&nbsp;","listText":"Please be a merry Christmas next week!&nbsp;","text":"Please be a merry Christmas next week!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/699503493","repostId":"1116106959","repostType":4,"repost":{"id":"1116106959","pubTimestamp":1639785552,"share":"https://www.laohu8.com/m/news/1116106959?lang=&edition=full","pubTime":"2021-12-18 07:59","market":"us","language":"en","title":"Wall Street ends down after mostly negative week","url":"https://stock-news.laohu8.com/highlight/detail?id=1116106959","media":"Reuters","summary":" - Wall Street finished lower on Friday, weighed down by Big Tech as investors worried about the Omicron coronavirus variant and digested the Federal Reserve's decision to end its pandemic-era stimulus faster.All three main U.S. stock indexes ended with a decline for the week after the Fed on Wednesday signaled three quarter-percentage-point interest rate hikes by the end of 2022 to combat surging inflation.Nvidia dropped 2.1% and Alphabet lost 1.9%, both weighing on the S&P 500 and Nasdaq.The S","content":"<p>(Reuters) - Wall Street finished lower on Friday, weighed down by Big Tech as investors worried about the Omicron coronavirus variant and digested the Federal Reserve's decision to end its pandemic-era stimulus faster.</p>\n<p>All three main U.S. stock indexes ended with a decline for the week after the Fed on Wednesday signaled three quarter-percentage-point interest rate hikes by the end of 2022 to combat surging inflation.</p>\n<p>Nvidia dropped 2.1% and Alphabet lost 1.9%, both weighing on the S&amp;P 500 and Nasdaq.</p>\n<p>The S&amp;P 500 growth index lost 0.7% and the value index declined 1.4%.</p>\n<p>All of the 11 major S&amp;P 500 sector indexes fell, with financials leading the way down with a 2.3% drop. Energy lost 2.2%.</p>\n<p>Adding to uncertainty, Pfizer said on Friday the pandemic could extend through next year. European countries geared up for further travel and social restrictions and a study warned that the rapidly spreading Omicron coronavirus variant was five times more likely to reinfect people than its predecessor, Delta.</p>\n<p>Traders also pointed to year-end tax selling and the simultaneous expiration of stock options, stock index futures and index options contracts - known as triple witching - as potential causes for volatility.</p>\n<p>\"It's a big options expiration day,\" said Joe Saluzzi, co-manager of trading at Themis Trading in Chatham, New Jersey. \"And now you draw on top of that some Omicron, and you've got volatility, and I think it creates a lot of uncertainty amongst investors. Where are you going to position for the end of the year?\"</p>\n<p>Heavyweight growth stocks including Nvidia and Microsoft have outperformed the broader market in 2021, while the Philadelphia SE Semiconductor index has surged about 35%. The benchmark S&amp;P 500 index gained around 23% in the same period.</p>\n<p>In Friday's session, the Dow Jones Industrial Average fell 1.48% to end at 35,365.44 points, while the S&amp;P 500 lost 1.03% to 4,620.64.</p>\n<p>The Nasdaq Composite dropped 0.07% to 15,169.68.</p>\n<p>On a positive note, the small-cap Russell 2000 index rallied 1% after having fallen more than 10% from a record high in early November.</p>\n<p>With options expiring, volume on U.S. exchanges jumped to 16.6 billion shares, far above the 11.9 billion average over the last 20 trading days.</p>\n<p>For the week, the S&amp;P 500 fell 1.9%, the Dow lost 1.7% and the Nasdaq declined 2.9%.</p>\n<p>In Friday's session, Oracle tumbled 6.4% after the Wall Street Journal reported the enterprise software maker is in talks to buy electronic medical records company Cerner in a deal that could be valued at $30 billion. Shares of Cerner surged 12.9%.</p>\n<p>FedEx Corp rose almost 5% after the delivery firm reinstated its original fiscal 2022 forecast on Thursday, even as persistent labor woes chipped away profits.</p>\n<p>Declining issues outnumbered advancing ones on the NYSE by a 1.50-to-1 ratio; on Nasdaq, a 1.16-to-1 ratio favored advancers.</p>\n<p>The S&amp;P 500 posted 22 new 52-week highs and seven new lows; the Nasdaq Composite recorded 28 new highs and 341 new lows.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wall Street ends down after mostly negative week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWall Street ends down after mostly negative week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-18 07:59 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/us-stocks-wall-street-ends-212015460.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Reuters) - Wall Street finished lower on Friday, weighed down by Big Tech as investors worried about the Omicron coronavirus variant and digested the Federal Reserve's decision to end its pandemic-...</p>\n\n<a href=\"https://finance.yahoo.com/news/us-stocks-wall-street-ends-212015460.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯",".IXIC":"NASDAQ Composite",".SPX":"S&P 500 Index"},"source_url":"https://finance.yahoo.com/news/us-stocks-wall-street-ends-212015460.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1116106959","content_text":"(Reuters) - Wall Street finished lower on Friday, weighed down by Big Tech as investors worried about the Omicron coronavirus variant and digested the Federal Reserve's decision to end its pandemic-era stimulus faster.\nAll three main U.S. stock indexes ended with a decline for the week after the Fed on Wednesday signaled three quarter-percentage-point interest rate hikes by the end of 2022 to combat surging inflation.\nNvidia dropped 2.1% and Alphabet lost 1.9%, both weighing on the S&P 500 and Nasdaq.\nThe S&P 500 growth index lost 0.7% and the value index declined 1.4%.\nAll of the 11 major S&P 500 sector indexes fell, with financials leading the way down with a 2.3% drop. Energy lost 2.2%.\nAdding to uncertainty, Pfizer said on Friday the pandemic could extend through next year. European countries geared up for further travel and social restrictions and a study warned that the rapidly spreading Omicron coronavirus variant was five times more likely to reinfect people than its predecessor, Delta.\nTraders also pointed to year-end tax selling and the simultaneous expiration of stock options, stock index futures and index options contracts - known as triple witching - as potential causes for volatility.\n\"It's a big options expiration day,\" said Joe Saluzzi, co-manager of trading at Themis Trading in Chatham, New Jersey. \"And now you draw on top of that some Omicron, and you've got volatility, and I think it creates a lot of uncertainty amongst investors. Where are you going to position for the end of the year?\"\nHeavyweight growth stocks including Nvidia and Microsoft have outperformed the broader market in 2021, while the Philadelphia SE Semiconductor index has surged about 35%. The benchmark S&P 500 index gained around 23% in the same period.\nIn Friday's session, the Dow Jones Industrial Average fell 1.48% to end at 35,365.44 points, while the S&P 500 lost 1.03% to 4,620.64.\nThe Nasdaq Composite dropped 0.07% to 15,169.68.\nOn a positive note, the small-cap Russell 2000 index rallied 1% after having fallen more than 10% from a record high in early November.\nWith options expiring, volume on U.S. exchanges jumped to 16.6 billion shares, far above the 11.9 billion average over the last 20 trading days.\nFor the week, the S&P 500 fell 1.9%, the Dow lost 1.7% and the Nasdaq declined 2.9%.\nIn Friday's session, Oracle tumbled 6.4% after the Wall Street Journal reported the enterprise software maker is in talks to buy electronic medical records company Cerner in a deal that could be valued at $30 billion. Shares of Cerner surged 12.9%.\nFedEx Corp rose almost 5% after the delivery firm reinstated its original fiscal 2022 forecast on Thursday, even as persistent labor woes chipped away profits.\nDeclining issues outnumbered advancing ones on the NYSE by a 1.50-to-1 ratio; on Nasdaq, a 1.16-to-1 ratio favored advancers.\nThe S&P 500 posted 22 new 52-week highs and seven new lows; the Nasdaq Composite recorded 28 new highs and 341 new lows.","news_type":1},"isVote":1,"tweetType":1,"viewCount":48,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":609434046,"gmtCreate":1638316605034,"gmtModify":1638316605208,"author":{"id":"3578047933589423","authorId":"3578047933589423","name":"PengsieX","avatar":"https://static.tigerbbs.com/ebe92821eba3b91a6431d698b66bbed5","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"Moment of truth","listText":"Moment of truth","text":"Moment of truth","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/609434046","repostId":"1176118155","repostType":4,"repost":{"id":"1176118155","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638315561,"share":"https://www.laohu8.com/m/news/1176118155?lang=&edition=full","pubTime":"2021-12-01 07:39","market":"us","language":"en","title":"Grab Heads for Public Market After Investors Approve SPAC Merger","url":"https://stock-news.laohu8.com/highlight/detail?id=1176118155","media":"Tiger Newspress","summary":"Altimeter Growth Corp. shareholders approved the previously announced business combination with Grab","content":"<p> Altimeter Growth Corp. shareholders approved the previously announced business combination with Grab, Southeast Asia's leading superapp, at an extraordinary meeting of shareholders today.</p>\n<p>Class A common stock is expected to begin trading on the Nasdaq on December 2, 2021 under the ticker symbol \"GRAB.\"</p>\n<p>Shares of Altimeter Growth Corporation fell 5.8 per cent to close at US$12.72 on Tuesday (Nov 30), after the proposal passed at an extraordinary general meeting. It rebounded slightly in post-market trading.<img src=\"https://static.tigerbbs.com/3c44cc96b82fbb5b8e1da121b6951971\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\">Investors that back a&nbsp;SPAC (special purpose acquisition company) have a chance to redeem their bets at the issue price before the merger is completed. In Grab's case, 0.02 per cent of shares were redeemed, Altimeter said in a statement. Grab's redemption rate could be considered low compared to its US peers, where interest in SPAC deals have sizzled out of late.</p>\n<p>As a result of the transaction, Grab will receive a US$4.5 billion cash injection, which includes US$4 billion in private investment in public equity arrangement, from the SPAC promoted by Silicon Valley investor Brad Gerstner.</p>\n<p>But the road to public markets has been rocky. After Grab unveiled plans to merge with Altimeter Capital Management’s SPAC in a $40 billion deal, they had to postpone the closing to work on an audit of the past three years’ accounts. Meanwhile, regulatory scrutiny of SPACs and a resurgence of fears about Covid-19 infections threatened to derail the agreement.</p>\n<p>Singapore-based Grab, led by Chief Executive Officer Anthony Tan, had long been viewed as a marquee company in Southeast Asia and a promising candidate to go public. Tan and co-founder Hooi Ling Tan, backed by SoftBank Group Corp., fought off aggressive competition to become one of the largest ride-hailing and delivery companies in the region -- and the most valuable startup.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Grab Heads for Public Market After Investors Approve SPAC Merger</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGrab Heads for Public Market After Investors Approve SPAC Merger\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-01 07:39</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p> Altimeter Growth Corp. shareholders approved the previously announced business combination with Grab, Southeast Asia's leading superapp, at an extraordinary meeting of shareholders today.</p>\n<p>Class A common stock is expected to begin trading on the Nasdaq on December 2, 2021 under the ticker symbol \"GRAB.\"</p>\n<p>Shares of Altimeter Growth Corporation fell 5.8 per cent to close at US$12.72 on Tuesday (Nov 30), after the proposal passed at an extraordinary general meeting. It rebounded slightly in post-market trading.<img src=\"https://static.tigerbbs.com/3c44cc96b82fbb5b8e1da121b6951971\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\">Investors that back a&nbsp;SPAC (special purpose acquisition company) have a chance to redeem their bets at the issue price before the merger is completed. In Grab's case, 0.02 per cent of shares were redeemed, Altimeter said in a statement. Grab's redemption rate could be considered low compared to its US peers, where interest in SPAC deals have sizzled out of late.</p>\n<p>As a result of the transaction, Grab will receive a US$4.5 billion cash injection, which includes US$4 billion in private investment in public equity arrangement, from the SPAC promoted by Silicon Valley investor Brad Gerstner.</p>\n<p>But the road to public markets has been rocky. After Grab unveiled plans to merge with Altimeter Capital Management’s SPAC in a $40 billion deal, they had to postpone the closing to work on an audit of the past three years’ accounts. Meanwhile, regulatory scrutiny of SPACs and a resurgence of fears about Covid-19 infections threatened to derail the agreement.</p>\n<p>Singapore-based Grab, led by Chief Executive Officer Anthony Tan, had long been viewed as a marquee company in Southeast Asia and a promising candidate to go public. Tan and co-founder Hooi Ling Tan, backed by SoftBank Group Corp., fought off aggressive competition to become one of the largest ride-hailing and delivery companies in the region -- and the most valuable startup.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GRAB":"Grab Holdings"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1176118155","content_text":"Altimeter Growth Corp. shareholders approved the previously announced business combination with Grab, Southeast Asia's leading superapp, at an extraordinary meeting of shareholders today.\nClass A common stock is expected to begin trading on the Nasdaq on December 2, 2021 under the ticker symbol \"GRAB.\"\nShares of Altimeter Growth Corporation fell 5.8 per cent to close at US$12.72 on Tuesday (Nov 30), after the proposal passed at an extraordinary general meeting. It rebounded slightly in post-market trading.Investors that back a SPAC (special purpose acquisition company) have a chance to redeem their bets at the issue price before the merger is completed. In Grab's case, 0.02 per cent of shares were redeemed, Altimeter said in a statement. Grab's redemption rate could be considered low compared to its US peers, where interest in SPAC deals have sizzled out of late.\nAs a result of the transaction, Grab will receive a US$4.5 billion cash injection, which includes US$4 billion in private investment in public equity arrangement, from the SPAC promoted by Silicon Valley investor Brad Gerstner.\nBut the road to public markets has been rocky. After Grab unveiled plans to merge with Altimeter Capital Management’s SPAC in a $40 billion deal, they had to postpone the closing to work on an audit of the past three years’ accounts. Meanwhile, regulatory scrutiny of SPACs and a resurgence of fears about Covid-19 infections threatened to derail the agreement.\nSingapore-based Grab, led by Chief Executive Officer Anthony Tan, had long been viewed as a marquee company in Southeast Asia and a promising candidate to go public. Tan and co-founder Hooi Ling Tan, backed by SoftBank Group Corp., fought off aggressive competition to become one of the largest ride-hailing and delivery companies in the region -- and the most valuable startup.","news_type":1},"isVote":1,"tweetType":1,"viewCount":31,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":877751897,"gmtCreate":1637988888071,"gmtModify":1637990500994,"author":{"id":"3578047933589423","authorId":"3578047933589423","name":"PengsieX","avatar":"https://static.tigerbbs.com/ebe92821eba3b91a6431d698b66bbed5","crmLevel":4,"crmLevelSwitch":0},"themes":[],"htmlText":"I hope the world just treats covid as an act of God.&nbsp;It's really not in our hands anymore and no reason for pharmaceuticals to keep creating and literally testing drugs on people to only be able to stop 1 variant.&nbsp;","listText":"I hope the world just treats covid as an act of God.&nbsp;It's really not in our hands anymore and no reason for pharmaceuticals to keep creating and literally testing drugs on people to only be able to stop 1 variant.&nbsp;","text":"I hope the world just treats covid as an act of God. It's really not in our hands anymore and no reason for pharmaceuticals to keep creating and literally testing drugs on people to only be able to stop 1 variant.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/877751897","repostId":"2186344334","repostType":4,"repost":{"id":"2186344334","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1637967996,"share":"https://www.laohu8.com/m/news/2186344334?lang=&edition=full","pubTime":"2021-11-27 07:06","market":"us","language":"en","title":"Dow plunges 905 points in Black Friday selloff, books worst day in over a year as WHO declares new COVID 'variant of concern'","url":"https://stock-news.laohu8.com/highlight/detail?id=2186344334","media":"Dow Jones","summary":"Dow notches worst day for blue chips since Oct. 28, 2020, FactSet data show\nU.S. stock benchmarks su","content":"<p>Dow notches worst day for blue chips since Oct. 28, 2020, FactSet data show</p>\n<p>U.S. stock benchmarks suffered withering losses on Friday as stock and commodity markets plunged, after scientists detected a new COVID variant in South Africa that could be to blame for a recent sharp surge in cases, especially in Europe.</p>\n<p>U.S. markets were closed for Thanksgiving on Thursday and ended at 1 p.m. Eastern Time on Friday, three hours earlier than usual, and bond market trading ends at 2 p.m., an hour earlier than is typical.</p>\n<p>How are stock-index futures trading?</p>\n<p>On Wednesday, the Dow industrials fell 9.42 points to finish nearly flat at 35,804.38. The S&amp;P 500 slipped 0.2% to close at 4,701.46, just 0.1% below its Nov. 18 record close of 4,704.54, according to Dow Jones Market Data. The Nasdaq Composite Index rose 0.4% to 15,84.23.</p>\n<p>What's driving the market?</p>\n<p>It was an ugly day for stock investors during a thinly traded Black Friday session, which was susceptible to big swings on alarming news from public health officials who were assessing a new variant of the coronavirus that causes COVID-19.</p>\n<p>Late in the session, the World Health Organization's technical advisory group assigned the B. 1.1.529 variant of the virus the Greek letter omicron and declared it a \"variant of concern,\" as it did with the delta variant.</p>\n<p>Fear of a new variant overshadowed the usual focus on U.S. Black Friday shopping day, which puts the focus on retailers as consumers shop for bargains.</p>\n<p>Particularly notable about the variant is the \"large number of mutations, some of which are concerning,\" the WHO group said in a statement. The mutations could make omicron more resistant to the current batch of vaccines.</p>\n<p>The discovery of the new COVID strain was announced on Friday by South Africa's health minister Joe Phaahla. He said scientists were concerned because of its high number of mutations and the dramatic surge in infections the country had seen over the past four or five days.</p>\n<p>\"The pandemic and COVID variants remain <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the biggest risks to markets, and are likely to continue to inject volatility over the next year(s),\" wrote Keith Lerner, co-chief investment officer and chief market strategist at Truist Advisory Services, in a Friday note. \"It's hard to say at this point how lasting or impactful this latest variant will be for markets,\" the analyst wrote.</p>\n<p>The omicron strain has been detected in Botswana and in Hong Kong in travelers who had visited South Africa.</p>\n<p>\"The one bull in the China shop that could truly derail the global recovery has always been a new strain of Covid-19 that swept the world and caused the reimposition of mass social retractions,\" said Jeffrey Halley, senior market analyst, at OANDA, in a note. \"All we know so far is the B. 1.1.529 is heavily mutated but markets are taking no chances.\"</p>\n<p>\"Just when you thought Covid was being controlled in a holiday shortened week,\" said Sam Stovall, chief investment strategist at CFRA Research, in emailed comments.</p>\n<p>Trading around the Thanksgiving holiday is often associated with lower trading volumes as traders typically wait until Monday to return to work. There was no U.S. economic data on the calendar for Friday.</p>\n<p>After new cases stabilized at 200 a day, South Africa reported more than 1,200 on Wednesday and 2,465 on Thursday.</p>\n<p>The U.K. government is banning flights from South Africa along with five other African nations, effective Friday.</p>\n<p>\"Predictably, energy, travel related and financials are the leading decliners and treasuries are rallying,\" wrote Jay Hatfield, CEO and portfolio manager at Infrastructure Capital Management, in emailed comments on Friday.</p>\n<p>\"It makes sense to have a market significant correction given the high level of uncertainty,\" the money manager wrote.</p>\n<p>\"At this stage very little is known,\" Deutsche Bank strategists, led by Jim Reid, told clients in a note. \"Mutations are often less severe so we shouldn't jump to conclusions but there is clearly a lot of concern about this one. Also South Africa is one of the world leaders in sequencing so we are more likely to see this sort of news originate from there than many countries. Suffice to say at this stage no one in markets will have any idea which way this will go.\"</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Dow plunges 905 points in Black Friday selloff, books worst day in over a year as WHO declares new COVID 'variant of concern'</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDow plunges 905 points in Black Friday selloff, books worst day in over a year as WHO declares new COVID 'variant of concern'\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-11-27 07:06</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Dow notches worst day for blue chips since Oct. 28, 2020, FactSet data show</p>\n<p>U.S. stock benchmarks suffered withering losses on Friday as stock and commodity markets plunged, after scientists detected a new COVID variant in South Africa that could be to blame for a recent sharp surge in cases, especially in Europe.</p>\n<p>U.S. markets were closed for Thanksgiving on Thursday and ended at 1 p.m. Eastern Time on Friday, three hours earlier than usual, and bond market trading ends at 2 p.m., an hour earlier than is typical.</p>\n<p>How are stock-index futures trading?</p>\n<p>On Wednesday, the Dow industrials fell 9.42 points to finish nearly flat at 35,804.38. The S&amp;P 500 slipped 0.2% to close at 4,701.46, just 0.1% below its Nov. 18 record close of 4,704.54, according to Dow Jones Market Data. The Nasdaq Composite Index rose 0.4% to 15,84.23.</p>\n<p>What's driving the market?</p>\n<p>It was an ugly day for stock investors during a thinly traded Black Friday session, which was susceptible to big swings on alarming news from public health officials who were assessing a new variant of the coronavirus that causes COVID-19.</p>\n<p>Late in the session, the World Health Organization's technical advisory group assigned the B. 1.1.529 variant of the virus the Greek letter omicron and declared it a \"variant of concern,\" as it did with the delta variant.</p>\n<p>Fear of a new variant overshadowed the usual focus on U.S. Black Friday shopping day, which puts the focus on retailers as consumers shop for bargains.</p>\n<p>Particularly notable about the variant is the \"large number of mutations, some of which are concerning,\" the WHO group said in a statement. The mutations could make omicron more resistant to the current batch of vaccines.</p>\n<p>The discovery of the new COVID strain was announced on Friday by South Africa's health minister Joe Phaahla. He said scientists were concerned because of its high number of mutations and the dramatic surge in infections the country had seen over the past four or five days.</p>\n<p>\"The pandemic and COVID variants remain <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the biggest risks to markets, and are likely to continue to inject volatility over the next year(s),\" wrote Keith Lerner, co-chief investment officer and chief market strategist at Truist Advisory Services, in a Friday note. \"It's hard to say at this point how lasting or impactful this latest variant will be for markets,\" the analyst wrote.</p>\n<p>The omicron strain has been detected in Botswana and in Hong Kong in travelers who had visited South Africa.</p>\n<p>\"The one bull in the China shop that could truly derail the global recovery has always been a new strain of Covid-19 that swept the world and caused the reimposition of mass social retractions,\" said Jeffrey Halley, senior market analyst, at OANDA, in a note. \"All we know so far is the B. 1.1.529 is heavily mutated but markets are taking no chances.\"</p>\n<p>\"Just when you thought Covid was being controlled in a holiday shortened week,\" said Sam Stovall, chief investment strategist at CFRA Research, in emailed comments.</p>\n<p>Trading around the Thanksgiving holiday is often associated with lower trading volumes as traders typically wait until Monday to return to work. There was no U.S. economic data on the calendar for Friday.</p>\n<p>After new cases stabilized at 200 a day, South Africa reported more than 1,200 on Wednesday and 2,465 on Thursday.</p>\n<p>The U.K. government is banning flights from South Africa along with five other African nations, effective Friday.</p>\n<p>\"Predictably, energy, travel related and financials are the leading decliners and treasuries are rallying,\" wrote Jay Hatfield, CEO and portfolio manager at Infrastructure Capital Management, in emailed comments on Friday.</p>\n<p>\"It makes sense to have a market significant correction given the high level of uncertainty,\" the money manager wrote.</p>\n<p>\"At this stage very little is known,\" Deutsche Bank strategists, led by Jim Reid, told clients in a note. \"Mutations are often less severe so we shouldn't jump to conclusions but there is clearly a lot of concern about this one. Also South Africa is one of the world leaders in sequencing so we are more likely to see this sort of news originate from there than many countries. Suffice to say at this stage no one in markets will have any idea which way this will go.\"</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4551":"寇图资本持仓","BK4548":"巴美列捷福持仓","BK4535":"淡马锡持仓","BK4554":"元宇宙及AR概念","BK4505":"高瓴资本持仓","BK4525":"远程办公概念","BK4532":"文艺复兴科技持仓","PTON":"Peloton Interactive, Inc.","ZM":"Zoom","BK4190":"消闲用品","BK4528":"SaaS概念","BK4023":"应用软件","BK4566":"资本集团"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2186344334","content_text":"Dow notches worst day for blue chips since Oct. 28, 2020, FactSet data show\nU.S. stock benchmarks suffered withering losses on Friday as stock and commodity markets plunged, after scientists detected a new COVID variant in South Africa that could be to blame for a recent sharp surge in cases, especially in Europe.\nU.S. markets were closed for Thanksgiving on Thursday and ended at 1 p.m. Eastern Time on Friday, three hours earlier than usual, and bond market trading ends at 2 p.m., an hour earlier than is typical.\nHow are stock-index futures trading?\nOn Wednesday, the Dow industrials fell 9.42 points to finish nearly flat at 35,804.38. The S&P 500 slipped 0.2% to close at 4,701.46, just 0.1% below its Nov. 18 record close of 4,704.54, according to Dow Jones Market Data. The Nasdaq Composite Index rose 0.4% to 15,84.23.\nWhat's driving the market?\nIt was an ugly day for stock investors during a thinly traded Black Friday session, which was susceptible to big swings on alarming news from public health officials who were assessing a new variant of the coronavirus that causes COVID-19.\nLate in the session, the World Health Organization's technical advisory group assigned the B. 1.1.529 variant of the virus the Greek letter omicron and declared it a \"variant of concern,\" as it did with the delta variant.\nFear of a new variant overshadowed the usual focus on U.S. Black Friday shopping day, which puts the focus on retailers as consumers shop for bargains.\nParticularly notable about the variant is the \"large number of mutations, some of which are concerning,\" the WHO group said in a statement. The mutations could make omicron more resistant to the current batch of vaccines.\nThe discovery of the new COVID strain was announced on Friday by South Africa's health minister Joe Phaahla. He said scientists were concerned because of its high number of mutations and the dramatic surge in infections the country had seen over the past four or five days.\n\"The pandemic and COVID variants remain one of the biggest risks to markets, and are likely to continue to inject volatility over the next year(s),\" wrote Keith Lerner, co-chief investment officer and chief market strategist at Truist Advisory Services, in a Friday note. \"It's hard to say at this point how lasting or impactful this latest variant will be for markets,\" the analyst wrote.\nThe omicron strain has been detected in Botswana and in Hong Kong in travelers who had visited South Africa.\n\"The one bull in the China shop that could truly derail the global recovery has always been a new strain of Covid-19 that swept the world and caused the reimposition of mass social retractions,\" said Jeffrey Halley, senior market analyst, at OANDA, in a note. \"All we know so far is the B. 1.1.529 is heavily mutated but markets are taking no chances.\"\n\"Just when you thought Covid was being controlled in a holiday shortened week,\" said Sam Stovall, chief investment strategist at CFRA Research, in emailed comments.\nTrading around the Thanksgiving holiday is often associated with lower trading volumes as traders typically wait until Monday to return to work. There was no U.S. economic data on the calendar for Friday.\nAfter new cases stabilized at 200 a day, South Africa reported more than 1,200 on Wednesday and 2,465 on Thursday.\nThe U.K. government is banning flights from South Africa along with five other African nations, effective Friday.\n\"Predictably, energy, travel related and financials are the leading decliners and treasuries are rallying,\" wrote Jay Hatfield, CEO and portfolio manager at Infrastructure Capital Management, in emailed comments on Friday.\n\"It makes sense to have a market significant correction given the high level of uncertainty,\" the money manager wrote.\n\"At this stage very little is known,\" Deutsche Bank strategists, led by Jim Reid, told clients in a note. \"Mutations are often less severe so we shouldn't jump to conclusions but there is clearly a lot of concern about this one. Also South Africa is one of the world leaders in sequencing so we are more likely to see this sort of news originate from there than many countries. Suffice to say at this stage no one in markets will have any idea which way this will go.\"","news_type":1},"isVote":1,"tweetType":1,"viewCount":1,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}